Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
8-12-2014 12:00 AM

Evolutionary and in silico analysis of the antiviral TRIM22 gene
Jenna Kelly, The University of Western Ontario
Supervisor: Stephen Barr, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy degree
in Microbiology and Immunology
© Jenna Kelly 2014

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Immunity Commons

Recommended Citation
Kelly, Jenna, "Evolutionary and in silico analysis of the antiviral TRIM22 gene" (2014). Electronic Thesis
and Dissertation Repository. 2327.
https://ir.lib.uwo.ca/etd/2327

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

EVOLUTIONARY AND IN SILICO ANALYSIS OF THE ANTIVIRAL TRIM22
GENE
(Thesis format: Integrated Article)

by

Jenna N. Kelly

Graduate Program in Microbiology and Immunology

A thesis submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Jenna N. Kelly 2014

Abstract
Tripartite motif protein 22 (TRIM22) is an evolutionarily ancient interferon-induced
protein that been shown to potently inhibit human immunodeficiency virus (HIV),
hepatitis B virus (HBV), and influenza A virus (IAV) replication. Altered TRIM22
expression levels have also been linked to autoimmune disease, cancer, and cellular
proliferation. Despite its important role in a number of biological processes, the factors
that influence TRIM22 expression and/or antiviral activity remain largely unknown. To
identify key functional sites in TRIM22, we performed extensive evolutionary and in
silico analyses on the TRIM22 coding region. These tools allowed us to pinpoint multiple
sites in TRIM22 that have evolved under positive selection during mammalian evolution,
including one site that coincides with the location of a common non-synonymous SNP
(nsSNP) in the human TRIM22 gene (TRIM22 rs1063303:G>C). We found that the
frequency of TRIM22 rs1063303:G>C varied considerably among different ethnic
populations and African (AFR), American (AMR), and European (EUR) populations
contained an excess of intermediate frequency TRIM22 rs1063303:G>C alleles when
compared to a neutral model of evolution. The latter is typically indicative of balancing
selection, a non-neutral selective process that maintains polymorphism in a population.
Interestingly, we also found that the TRIM22 nsSNP rs1063303:G>C had an inverse
impact on TRIM22 function. TRIM22 rs1063303:G>C increased TRIM22 expression
levels, but decreased its anti-HIV activity and altered its subcellular localization pattern.
In addition to these studies, we used a variety of in silico methods to prioritize and
delineate other functional sites in TRIM22. We showed that the majority of positively
selected sites in the C-terminal B30.2 domain of TRIM22 are located in one of four
surface-exposed variable loops that are critical for the anti-HIV effects of the closelyrelated TRIM5α protein. Moreover, we used six different in silico nsSNP prediction
programs to screen all of the nsSNPs in the TRIM22 gene and identified 14 high-risk
nsSNPs that are predicted to be highly deleterious to TRIM22 function. Finally, to
examine the TRIM22 nsSNP rs1063303:G>C in a more isolated population, we
genotyped this nsSNP in two Inuit populations (Canadian and Greenlandic Inuit). We
found that the TRIM22 rs1063303:C allele is inordinately prevalent in the Inuit compared
to non-Inuit populations and that these two populations do not contain an excess of
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intermediate frequency TRIM22 rs1063303:G>C alleles compared to a neutral model of
evolution, indicating that site TRIM22 rs1063303:G>C has not evolved under balancing
selection in the Inuit. Lastly, we found an interesting association between the TRIM22
rs1063303:C allele and serum levels of triglycerides (TG) and high-density lipoprotein
(HDL). Taken together, the results presented here identify a number of pertinent sites in
the TRIM22 protein that likely influence its biological and/or antiviral functions.

Keywords
Tripartite motif protein 22, host restriction factors, evolution, interferon, innate immune
system, single nucleotide polymorphism, in silico analysis
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Chapter 1

1

Introduction

The immune system has evolved over millennia to provide effective defense measures
against invading pathogens and promote host survival. The vertebrate immune system
can be divided into innate and adaptive arms, which together comprise both germlineencoded and acquired immune responses. The innate immune system is evolutionarily
more ancient than the adaptive immune system and constitutes the first line of defense
against infectious agents. It is also essential for initiating subsequent adaptive immune
responses, which unlike innate immune responses, are characterized by specificity and
the generation of immunological memory 1. Innate immunity is activated upon pathogen
recognition by a limited repertoire of germline-encoded pattern recognition receptors
(PRR). PRRs can be grouped into several distinct families: 1) the membrane bound tolllike receptors (TLR), 2) the cytosolic retinoic acid inducible gene (RIG-I)-like receptors
(RLR), 3) the nucleotide binding oligomerization domain (NOD)-like receptors (NLR),
and 4) DNA sensors

2,3

. PRRs recognize conserved products of microbial metabolism

called pathogen-associated molecular patterns (PAMP). PAMPs, which are not usually
present in host cells, bind to specific PRRs to activate innate immunity. For example,
specific TLR family members recognize genomic material or replication intermediates
from viruses (i.e. TLRs 3, 7, 8, and 9), while other TLRs recognize diverse microbial
products from parasites, fungi, and/or bacteria 4–8.
PRR-PAMP binding triggers a complex downstream signaling cascade that induces the
activation of multiple cytosolic transcription factors, including nuclear factor-kappa B
(NF-κB), activator protein 1 (AP-1), and interferon regulatory factors 3 (IRF-3) and 7
(IRF-7). Activation of NF-κB and AP-1 results in the upregulation of proinflammatory
cytokines [e.g. interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF-α)], whereas
activation of IRF-3 and/or IRF-7 leads to the production of type I interferons (IFN) 9.
Type I IFNs are one of the three major classes of the IFN family, which is a group of
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secreted cytokines that are essential for host antiviral defense and immune activation.
Type I IFNs are produced in direct response to viral infection and comprise multiple
subtypes of IFN-α plus IFN-β and several additional IFNs (δ, ε, κ, τ, ω) with lessdefinitive roles in antiviral immunity. The other two major classes of IFNs, type II and
type III, each contain only one subtype. IFN-γ (type II IFN) is generally produced by
activated T lymphocytes or natural killer cells in response to cytokine secretion from
infected cells or macrophages. Similar to type I IFNs, IFN-λ (type III IFN) is typically
produced in direct response to viruses; however type III IFN binds to different cognate
receptors than type I IFNs. Type III IFN receptors are found mainly on epithelial cells,
whereas type I IFN receptors are present on all cell types 10–13.
Canonical type I IFN production is essential for the host antiviral response to infection
and critical for host survival. Following synthesis and secretion, type I IFNs (IFN-α/β)
bind to the IFN-α/β receptor (IFNAR) complex on the cell surface in an autocrine and
paracrine manner, which induces signal transduction through the janus kinases/signal
transducers and activators of transcription (JAK/STAT) pathway. Specifically, IFN-α/β
binding to the IFNAR complex leads to the phosphorylation of receptor-bound tyrosine
kinases janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which in turn leads to the
phosphorylation of signal transducers and activators of transcription 1 (STAT1) and 2
(STAT2). STAT1/STAT2 phosphorylation results in STAT1/STAT2 dimerization and
recruitment of interferon regulatory factor 9 (IRF-9) to form the IFN-stimulated gene
factor 3 (ISGF3) complex. The ISGF3 complex, which acts as a transcription factor,
translocates to the nucleus where it upregulates a large number of IFN-stimulated genes
(ISG) (Fig 1.1). Many ISGs have antiviral properties, especially host restriction factors,
which directly interfere with specific stages of viral replication. Collectively, ISGs
establish a powerful cell-intrinsic antiviral state that is essential for withstanding and
controlling many pathogens 14,15.
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Figure 1.1: ISG induction by type I IFN signaling.
Type I IFNs bind to the IFNAR1/2 heterodimer complex on the surface of the cell and
activate the JAK/STAT signaling pathway. IFN-IFNAR1/2 binding triggers JAK1 and
TYK2 phosphorylation, which leads to the recruitment and phosphorylation of STAT1
and STAT2. Phosphorylated STAT1 and STAT2 form a heterodimer and bind to IRF-9,
creating the ISGF3 complex. ISGF3 translocates to the nucleus where it binds to IFNstimulated response elements (ISRE) in the promoters of multiple ISGs. This induces a
powerful antiviral state in the cell that inhibits many pathogens.
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Figure 1.1

Figure 1.1: ISG induction by type I IFN signaling.
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1.1 Host restriction factors
Host restriction factors are IFN-induced proteins that inhibit specific steps in the viral
replication lifecycle. Researchers first coined the term ‘restriction factor’ in the 1970’s
following the characterization of the mouse friend virus susceptibility 1 (Fv1) locus,
which conferred resistance to murine retroviruses

16

. Since this discovery, restriction

factors have been identified in many vertebrate species, and today the term is used to
describe host proteins that inhibit the replication of any animal virus

17,18

. Several major

characteristics distinguish restriction factors from other host proteins. Typically, host
restriction factors: 1) have antiviral activity as their main biological function, 2) are
induced by IFN signaling and/or viral infection, 3) contain evolutionary signatures of
positive selection, and 4) are antagonized by a viral protein

18,19

. Characteristics for a

number of well-known host restriction factors, including the apolipoprotein B mRNAediting enzyme catalytic polypeptide 3G (APOBEC3G), tripartite motif protein 5 alpha
(TRIM5α), bone marrow stromal antigen 2 (BST-2 or tetherin), and sterile alpha motif
and histidine/aspartic acid domain-containing protein (SAMHD1), are summarized in
Table 1.1. at the end of this section.
Type I IFNs have long been recognized as potent inhibitors of human immunodeficiency
virus (HIV) replication

20

. As such, HIV has been used for many years as a system to

identify and characterize the IFN-induced host restriction factors responsible for this
inhibition. Type I IFNs block both early and late stages of the HIV lifecycle

21–25

. Early

stages of HIV replication include HIV binding and fusion to the host cell via its CD4
receptor, uncoating of the viral core in the cell cytoplasm, reverse transcription of the
single-stranded RNA viral genome, and integration of the viral cDNA into the host cell
genome. Late stages include transcription of the integrated HIV provirus from the 5’
long-terminal repeat (LTR) promoter, viral RNA export, translation of viral proteins,
trafficking/assembly of new virions, virion budding/release, and maturation of virions
into fully infectious HIV particles (Fig 1.2). Host restriction factors, which form the
effector arm of the IFN response, target specific stages (both early and late) in the HIV
replication life cycle. However, HIV also encodes viral antagonists to counteract host
restriction factors. These antagonists are typically HIV accessory proteins, namely Vif,
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Nef, Vpu, and Vpr, which are only required for viral replication in the presence of host
restriction factors

26

. Whereas HIV type 1 (HIV-1) encodes only the latter accessory

proteins, a number of strains of simian immunodeficiency virus (SIV) and HIV type 2
(HIV-2) also encode an additional accessory protein called Vpx

27

. Stages of HIV-1

replication (and/or SIV or HIV-2 replication) targeted by the APOBEC3G, TRIM5α,
BST-2/tetherin, and SAMHD1 host restriction factors plus their viral antagonists (if
known) are shown in Fig 1.2 and outlined in further detail in the text below.

1.1.1

Inhibition of HIV replication by host restriction factors

Multiple host restriction factors that inhibit HIV replication have been identified within
the last decade, some of which have been studied extensively. One such protein is the
host restriction factor APOBEC3G, which was first identified as a HIV-1 restriction
factor in 2002

28

. APOBEC3G is targeted by the HIV-1 Vif accessory protein; however

when Vif is not present, APOBEC3G is packaged into assembling HIV-1 virions and
released into the cytoplasm of newly infected target cells. APOBEC3G is a cytidine
deaminase enzyme or an enzyme that converts deoxycytidine into deoxyuridine in a
nucleic acid sequence. When APOBEC3G is present in newly infected target cells, it
converts deoxycytidine to deoxyuridine in the nascent viral single-stranded negativesense cDNA. This results in deoxyguanine to deoxyadenine hypermutation and loss of
genetic integrity in the HIV-1 plus-strand sequence and inhibits HIV-1 replication at the
level of reverse transcription (Fig 1.2)

29–32

. When Vif is present in cells, APOBEC3G

becomes polyubiquitylated and is targeted for proteasomal degradation. Vif facilitates
this process by binding directly to both APOBEC3G and the Cul5 E3 ligase ubiquitin
complex. Interestingly, Vif antagonism is not always fully efficient and hypermutated
HIV-1 sequences are readily recovered from HIV-1 infected individuals. Moreover,
hypermutation frequency has been shown to correlate inversely with plasma viremia in
several sizable HIV-1 cohorts 33–37.
Another well-studied HIV-1 restriction factor is the TRIM5α protein. Unlike other host
restriction factors, TRIM5α typically only restricts retroviruses that have been isolated
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Figure 1.2: Stages of HIV replication targeted by host restriction factors.
Host restriction factors, such as APOBEC3G, TRIM5α, BST-2/tetherin, and SAMHD1,
target multiple stages of HIV-1 (or SIV/HIV-2) replication. Post-entry, TRIM5α targets
the assembled HIV-1 capsid protein on the viral core and facilitates its disassembly. In
the absence of Vif, the APOBEC3G protein creates deoxycytidine to deoxyuridine
mutations in the nascent viral cDNA, which inhibits HIV-1 replication at the level of
reverse transcription. SAMHD1, which is countered by Vpx (SIV/HIV-2), also inhibits
reverse transcription; however, it does so by decreasing the cellular pool of dNTPs
required for viral cDNA synthesis. BST-2/tetherin inhibits HIV-1 replication at the
budding/release stage by ‘tethering’ HIV-1 virions to the cell membrane. BST-2/tetherin
is antagonized by the HIV-1 Vpu protein.
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Figure 1.2: Stages of HIV replication targeted by host restriction factors.
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from a host species other than its own. For example, the human TRIM5α (huTRIM5α)
protein strongly inhibits N-tropic murine leukemia virus (N-MLV), but has very weak
activity against HIV-1. Similarly, rhesus monkey TRIM5α (rhTRIM5α) does not inhibit
SIVmac (SIV strain isolated from rhesus macaques that were experimentally inoculated
with SIV from asymptomatic sooty mangabey monkeys [SIVsmm]38). The majority of
studies have shown that rhTRIM5α inhibits HIV-1 by targeting the assembled HIV-1
capsid protein found on the mature viral core. Capsid is the main structural protein of
HIV-1 and forms the inner viral protein shell that surrounds the HIV-1 genome and its
core proteins in mature virions

39

. To inhibit HIV-1 replication, rhTRIM5α binds to the

incoming mature viral core and facilitates its premature disassembly. This leads to the
inhibition of reverse transcription and subsequent HIV-1 replication (Fig 1.2)

40–42

. Of

interest, rhTRIM5α, which localizes in subcellular structures called cytoplasmic bodies,
has been shown to mediate its own polyubiquitylation and proteasomal degradation
during the HIV-1 restriction process. Self-ubiquitylation of rhTRIM5α may destabilize
the HIV-1 capsid lattice and induce its disassembly. Notably, other studies have shown
that proteasome inhibitors do prevent inhibition of reverse transcription by rhTRIM5α,
but do not disrupt overall rhTRIM5α-mediated HIV-1 restriction

43–46

. Thus, it has also

been proposed that rhTRIM5α may inhibit HIV-1 replication in two or more redundant
ways, such as by blocking the nuclear translocation of the viral preintegration complex
(PIC). The viral PIC includes the viral cDNA plus both viral and host proteins and its
nuclear translocation is required for proper integration of HIV-1 into the host genome 47.
To date, there have been no HIV-1 antagonists to rhTRIM5α identified.
Tetherin or BST-2 was only recently identified as a HIV-1 restriction factor, but since
this time has been studied in great detail. BST-2/tetherin is antagonized by the HIV-1
Vpu protein and targets a later stage of viral replication than APOBEC3G or TRIM5α.
When Vpu is absent, BST-2/tetherin ‘tethers’ fully formed HIV-1 virions to the plasma
membrane of infected cells (Fig 1.2). Captured HIV-1 virions are later internalized by
endocytosis and accumulate in CD63+ endosomes, where they are likely degraded

48–53

.

BST-2/tetherin contains two membrane anchors, the N-terminal transmembrane domain
and the C-terminal glycosylphosphatidylinositol domain, which are both essential for
BST-2/tetherin-mediated virion retention and endocytosis

54–56

. Although several models

10

for BST-2/tetherin configuration have been proposed, experimental evidence strongly
supports a parallel-membrane-spanning model. This models postulates that one end of
two BST-2/tetherin monomers (either the N-terminus or C-terminus) is anchored to the
cell membrane and the other end of both monomers is anchored to the viral membrane.
BST-2/tetherin is downregulated from the cell surface when Vpu is present and likely
degraded via the proteasomal and/or lysosomal pathway. However, some studies have
shown that Vpu may simply sequester BST-2/tetherin in the cytoplasm. These methods
are unlikely to be mutually exclusive and may work together to counteract the BST2/tetherin protein. The mechanism of Vpu antagonism may also depend on the cellular
context of HIV-1 restriction 19,57.
SAMHD1, the most recently identified host restriction factor, restricts SIV/HIV-2 viral
replication in non-dividing cell types, including CD4+ T cells, dendritic cells, and
macrophages. Vpx, an accessory protein encoded by HIV-2 and certain strains of SIV,
targets SAMHD1 and induces its proteasomal degradation. In the absence of Vpx,
SAMHD1 inhibits SIV/HIV-2 replication by decreasing the intracellular pool of dNTPs
to below the level required for viral cDNA synthesis. This results in early post-entry
restriction at the level of reverse transcription (Fig 1.2)

58–61

. While HIV-1 is unable to

neutralize SAMHD1, one recent study demonstrated that a subset of Vpr proteins from
ancestral lentiviruses without Vpx are able to disrupt SAMHD1-mediated restriction.
Since Vpr is hypothesized to have originally given rise to Vpx via a gene duplication
event, the ability of Vpx to antagonize SAMHD1 may have originated in Vpr before it
was lost following Vpx acquisition. Interestingly, distinct orthologues of Vpx and Vpr
have evolved multiple ways to recognize SAMHD1. For example, certain orthologues
interact with the N-terminus of SAMHD1, while others interact with the C-terminus;
however, they all target SAMHD1 for proteasomal degradation. Thus, even though the
method of Vpx/Vpr antagonism toward SAMHD1 has remained the same, the site of
antagonism has changed back and forth throughout viral evolution 62,63.
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1.1.2

Innate immune regulation by host restriction factors

In addition to their direct antiviral effects, a growing number of host restriction factors
indirectly influence the antiviral response by regulating important innate immune
signaling pathways. For example, TRIM5α was recently shown to function as a PRR for
the HIV-1 capsid lattice. Upon capsid recognition, TRIM5α activates the transforming
growth factor beta-activated kinase 1 (TAK1), AP-1 and NF-κB signaling, and the
transcription of proinflammatory cytokines

64

. This signaling is required for TRIM5α-

mediated retroviral restriction. Thus, in addition to its direct antiviral effects, TRIM5α
also inhibits HIV-1 replication by activating innate immune signaling pathways. BST2/tetherin and SAMHD1 have also recently been implicated in the activation of innate
immune and proinflammatory signaling pathways

65,66

.

1.2 The TRIM family
The tripartite motif or TRIM family is a large group of evolutionarily ancient proteins
that are involved in multiple biological processes and have been linked to a number of
different human diseases. Many TRIM proteins are upregulated by type I and type II
IFNs and some, such as the host restriction factor TRIM5α, have antiviral properties.
TRIM proteins are particularly adept at targeting retroviruses and to date, ~20 TRIM
proteins have been shown to inhibit retrovirus replication

67–70

. Recent studies have also

identified several TRIM proteins that regulate key proteins involved in innate immune
signaling, including IRF-3, IRF-8, RIG-I, and NF-κB

71,72

. In addition to their role in

antiviral immunity, TRIM proteins have also been implicated in numerous Mendelian
inherited disorders and autoimmune diseases, cell cycle progression, development, and
several types of cancer 73–76.

1.2.1

Evolution and classification

TRIM proteins are conserved throughout the metazoan kingdom; however, the TRIM
family has expanded rapidly during vertebrate evolution. For example, the invertebrate
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Table 1.1
Table 1.1: Characteristics of well-studied host restriction factors.

Restriction factor
Fv1 (mouse)
MxA

IFN
induced?
No
Yes

MxB
IFITM1, IFITM2,
IFITM3

Yes
Yes

TRIM5α

Yes

APOBEC3G

No

SAMHD1

Yes

Viral target

Stage of life cycle inhibited

Viral antagonists 1

Retroviruses
Orthomyxoviruses
Paramyxoviruses
Hepadnaviruses
Rhabdoviruses
Alphaviruses
Bunyaviruses
Togaviruses
Picornaviruses
Retroviruses
Orthomyxoviruses
Flaviviruses
Coronavirus
Rhabdoviruses
Alphaviruses
Bunyaviruses
Filoviruses
Retroviruses
Hepadnaviruses
Retroviruses
Hepadnaviruses
Adenoviruses
Paramyxoviruses
Retrotransposons
Retroviruses
Herpesviruses

Capsid uncoating 77
Nucleocapsid transport or another early life cycle
step 79

None known
None known

Positive
selection?
Yes 78
Yes 80

Nuclear import or integration 81
Endosomal fusion or uncoating 82,83

None known
None known

ND
ND

Capsid uncoating 84

None known

Yes 85

Reverse transcription 31,33,35,77,86–90

Vif (HIV-1)
Bet (PFV)
glycol-Gag (MLV)

Yes 91

Reverse transcription 58,60,92,93

Vpx (HIV-2)
Vpr (SIV)

Yes 94
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BST-2/Tetherin

Yes

PKR

Yes

HERC5

Yes

1

Poxviruses
Retroviruses
Flaviviruses
Herpesviruses
Rhabdoviruses
Paramyxoviruses
Arenaviruses
Filoviruses
Retroviruses
Orthomyxoviruses
Filoviruses
Paramyxoviruses
Bunyaviruses
Herpesviruses
Poxviruses
Retroviruses
Orthomyxoviruses

Budding 48,51,53,54,95–98

Viral protein translation 100–102

Nuclear export, assembly 104–106

Vpu (HIV-1)
Nef (SIV)
Env (HIV-2)
VP40 (Ebola)
K5 (KSHV)
NA (IAV)
gM (Herpes)
NS1 (IAV, IBV)
NSs (RVFV)
VP35 (Ebola)

None known

Yes 99

Yes 103

Yes 106

Viral antagonists: this is not an exhaustive list, particularly for PKR. Please refer to 107 for a more comprehensive list of PKR antagonists.

Abbreviations: Myxovirus resistance (Mx) proteins A and B, Interferon induced transmembrane (IFITM) proteins 1, 2, and 3, Prototype foamy virus (PFV),
Glycosylated (glyco) Gag, Murine leukemia virus (MLV), Kaposi's sarcoma-associated herpesvirus (KSHV), Influenza A/B virus (IAV, IBV), Rift valley fever
virus (RVFV), HECT domain and RCC1-like domain-containing protein 5 (HERC5). ND: not determined.
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Drosophila melanogaster and Caenorhabditis elegans genomes contain 7 and 18 TRIM
genes, respectively. In stark contrast, the vertebrate Mus musculus genome contains 64
TRIM genes and 100 TRIM genes have now been identified in the human genome.
Notably, the TRIM family may still be expanding in humans. One study recently
identified 11 TRIM genes that are specific to humans and African apes and another 7
TRIM genes that are found only in humans. According to this study, the novel TRIM
genes were acquired through multiple segmental duplication events, the majority of
which originated from a single chromosomal locus. One Han Chinese woman with 12
extra copies of these TRIM genes was also identified, documenting TRIM copy number
variation in humans for the first time 108.
Several classification systems have been proposed for organizing the TRIM family of
proteins in humans. Initially, the TRIM family was divided into 9 distinct subgroups
according to their C-terminal domains

109

. This classification system was subsequently

modified to include 2 new subgroups of TRIMs with previously mischaracterized Cterminal domains (C-I to C-XI)

68

. Another study divided the TRIM family into two

major groups based on genomic organization, evolutionary properties, and domain
structure. This study determined that ‘Group 1’ TRIM proteins contained two B-box
(BB) domains, a variable C-terminal domain, and were found in both vertebrates and
invertebrates. In contrast, ‘Group 2’ TRIM proteins had only one BB domain, a Cterminal splA/ryanodine receptor (SPRY) domain or PRY/SPRY (B30.2) domain, and
were found only in vertebrates

110

. The most recent report, which performed a more

stringent phylogenetic analysis of the TRIM family, divided TRIM proteins into 9
distinct subgroups (A-I). ‘Group 2’ TRIM proteins were placed in one subgroup (G);
however, ‘Group 1’ TRIMs were further subdivided into 8 different phylogenetic
subgroups (A-F, H, I). Importantly, this study consolidated data from previous reports
and compared the phylogenetic and domain-based classification systems for the TRIM
family (Fig 1.3) 111.
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Figure 1.3: Subgroup classification of the TRIM family.
Subgroup classifications (A-I) are based on the most recent phylogenetic analysis of the
TRIM family 111. Previous C-terminal domain-based TRIM classifications (C-I to C-XI)
are shown in parentheses

68

. TRIM proteins contain an N-terminal RING domain (blue

square), one or two BB domains (dark/light pink circles), and a CC domain (orange
rectangle). In addition, TRIM proteins contain one or more of 10 different C-terminal
motifs (MATH, COS, FN3, PRY/SPRY, FIL [filamin], NHL, ARF, PHD, BR, and/or
TM). Group 2 TRIM proteins (subgroup G) are labeled and encased in a red box. Other
subgroups (A-E, H, I) are considered Group 1 TRIMs 110.
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Figure 1.3

Figure 1.3: Subgroup classification of the TRIM family.
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1.2.2

The RBCC motif

Members of the TRIM family are defined by their N-terminal TRIM or RBCC motif,
which is comprised of a ‘Really Interesting New Gene’ (RING) domain, one or two BB
domains, and a predicted coiled-coil (CC) region. The entire RBCC motif is present in
most TRIM proteins; however, in TRIM proteins that lack one of these domains, the
other domains are conserved in both order and spacing

68,112

. The C-terminal domain of

TRIM family members is variable and contains any of 10 distinct motifs alone or in
combination. The majority of TRIM proteins have a C-terminal SPRY or PRY/SPRY
domain (also called a B30.2 domain). Other possible C-terminal domains include ARF
(ADP ribosylation factor-like), the COS (C-terminal subgroup one signature) box, PHD
(plant homeodomain), MATH (merpin and tumor-necrosis factor receptor-associated
factor homology), FN3 (fibronectin type 3), and/or FIL (filamin-type immunoglobulin)
(Fig 1.3) 112,113.
The first domain in the RBCC motif, the RING domain, is characterized by a canonical
sequence that consists of a number of conserved cysteine and histidine residues. These
residues form a specialized zinc finger and coordinate two zinc atoms in a cross-braced
arrangement

114,115

. Studies have shown that RING finger proteins interact directly with

ubiquitylation enzymes and often function as E3 ubiquitin ligases 116–119. Consistent with
these studies, many RING-containing TRIM proteins have been shown to possess E3
ubiquitin ligase activity

113,120,121

. In many (but not all) cases, this E3 ubiquitin ligase

activity is required for TRIM-mediated antiviral activity. Previous studies have also
shown that RING-mediated E3 ligase activity is necessary for activation of antiviral
signaling by TRIMs 1, TRIM5, TRIM13, TRIM25, TRIM32, and TRIM62 64,122–124.
Ubiquitylation is a three-step process that involves ubiquitin-activating (E1), ubiquitinconjugating (E2), and ubiquitin-ligating (E3) enzymes. Ubiquitylation begins when the
E1-activating enzyme activates ubiquitin and transfers it to an E2-conjugating enzyme.
Following transfer, an E3 ligating enzyme facilitates ubiquitin attachment to the target
substrate protein, which occurs via the formation of an isopeptide bond between the Cterminal glycine residue of ubiquitin and an internal lysine (Lys) residue of the target
protein (Fig 1.4). There are two main families of E3 ubiquitin ligases: RING and HECT
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(homologous to the E6-AP carboxyl terminus). Unlike HECT-containing E3 ligase
proteins, RING E3 ligases bind directly to both the E2 conjugating enzyme and the target
protein and this increased proximity facilitates the direct transfer of ubiquitin from the E2
enzyme to the target protein

23,29

. TRIM proteins represent the largest group of RING-

containing E3 ubiquitin ligases and multiple TRIM family members were recently shown
to interact with the UBE2D and UBE2E (ubiquitin conjugating enzymes 2/E2 class D and
class E) classes of E2 conjugating enzymes; however, other combinations of TRIM-E2
proteins have also been identified 64,113,120,121,126.
Substrate proteins can be modified by a single ubiquitin moiety (monoubiquitylation) or
can be tagged with a chain of ubiquitin (polyubiquitylation). Ubiquitin chains are linked
together via the formation of an isopeptide bond between the C-terminal glycine residue
of one ubiquitin and one of seven internal lysine residues of a second ubiquitin moiety.
Notably, ubiquitin chains linked through distinct Lys residues have different cellular
functions. Lys48 ubiquitin chains mark proteins for degradation by the 26S proteasome,
whereas Lys63, other Lys-based ubiquitin chains, and monoubiquitylation often serve
non-proteolytic functions. Depending on the substrate proteins and enzymes involved,
these modifications can serve as signals for diverse cellular processes, including DNA
repair, transcription, signal transduction, and/or intracellular trafficking

127

. Thus far,

most well-characterized TRIM proteins have been shown to facilitate either Lys48 or
Lys63 polyubiquitylation. Many TRIM proteins can also undergo self-ubiquitylation,
including TRIM5α (both huTRIM5α and rhTRIM5α proteins), which induces its own
proteasomal degradation and rapid turnover. Several groups have proposed that selfubiquitylation of rhTRIM5α indirectly leads to the proteasomal degradation of HIV-1
virions. While the precise mechanism of TRIM5α-mediated restriction is still not fully
understood, some studies have shown that HIV-1 restriction is dependent on TRIM5α’s
E3 ubiquitin ligase activity 43,45,46,128–131.
In addition to their function as E3 ubiquitin ligases, several TRIM proteins have been
shown to function as E3 ligases for other ubiquitin-like proteins, such as SUMO (small
ubiquitin-like modifier) and ISG15 (interferon stimulated gene 3) 132–134. Ubiquitin-like
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Figure 1.4: The RING E3 ligase-mediated ubiquitylation pathway.
Ubiquitin is activated by the E1 activating enzyme to form a thioester linkage with the
active-site cysteine of E1. Activated E1-bound ubiquitin is transferred to the active-site
cysteine of the E2 conjugating enzyme. E2 transfer also requires the formation of a
thioester linkage. E2-bound ubiquitin then interacts with a RING E3 ligase enzyme, but
does not directly transfer ubiquitin to the E3. Instead, the RING E3 ligase binds to both
the appropriate protein substrate and the E2. The increased proximity between the E2bound ubiquitin and the protein substrate facilitates the transfer of ubiquitin to a Lys
residue on the substrate. The substrate can undergo monoubiquitylation (addition of one
ubiquitin moiety) at one or more Lys residues or polyubiquitylation (addition of a chain
of ubiquitin moieties linked together via internal Lys residues). Chains that are linked
together by the Lys48 residue of ubiquitin typically target substrates for 26S proteasomal
degradation.
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Figure 1.4
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21

proteins are activated and conjugated to target proteins using a distinct set of enzymes;
however, the overall process is analogous to ubiquitylation

135

. Notably, unlike other

SUMO E3 ligase proteins, the SUMO E3 ligase activity of TRIM proteins is dependent
on both RING and BB domains

132

. Some TRIM family members have been shown to

undergo SUMO modification themselves (self-sumoylation) and several TRIM proteins
contain SUMO-interacting motifs (SIMs). SIMs bind to other proteins that have been
modified with SUMO. Interestingly, two SIMs in huTRIM5α and rhTRIM5α play an
important role in N-MLV and HIV-1 restriction 136–139.
Following the RING finger domain, TRIM proteins contain one or two BB domains.
Similar to the RING domain, BB domains are zinc binding motifs with a number of
conserved cysteine and histidine residues; however, unlike the RING domain, BBs are
found exclusively in the TRIM family. There are two types of BBs, BB1 and BB2, that
share similar but distinct consensus motifs. When both BB are present in TRIMs, BB1
always precedes BB2. If only one BB is present it is always BB2

68,113,120

. Structural

studies of several human TRIM proteins have revealed that TRIM BBs have a similar
ternary structure as the RING finger domain

140–142

. Studies on the BB2 domains of

human TRIM63 (MuRF1) and TRIM5α identified two unusual conserved clusters of
hydrophobic residues on the surface of the domain. Two hydrophobic clusters that are
flanked by a number of charged residues were identified on the surface of the BB2
domain of TRIM5α. A number of these residues (e.g. W115, L116, and R119) were
required for major TRIM5α functions, including TRIM5α turnover, higher order selfassociation, formation of cytoplasmic bodies, HIV-1 capsid binding, and/or HIV-1
restriction

143

. TRIM63 had a similar cluster of solvent-exposed hydrophobic residues

located at the surface of its BB2 domain, which form a dimer interface and mediate
TRIM63 self-association 142.
The final component of the RBCC motif is the predicted CC region. The CC domain
contains many predicted hyper-secondary structures and intertwined α-helices, which
mediate homomeric and heteromeric interactions among TRIM proteins and other
binding partners. A large number of TRIM proteins have been shown to self-associate
through the CC domain

112

. The CC domain also promotes the formation of higher-
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molecular-weight complexes that among other functions, define specific subcellular
structures. For example, the CC domain of TRIM19 (also referred to as promyelocytic
leukemia protein [PML]) is essential for the proper assembly and maintenance of
macromolecular called nuclear bodies (NB). Moreover, the CC domain of TRIM5α
facilitates TRIM5α trimerization. Mutations in CC that disrupt TRIM5α trimerization
impair TRIM5α-mediated HIV-1 restriction

144–147

. Interestingly, it has been proposed

that the pleiotropic effects of TRIM proteins may be due to the ability of the CC to
facilitate diverse homomeric and heteromeric interactions 120,148.

1.2.3

The SPRY and PRY/SPRY (B30.2) domains

The SPRY and PRY/SPRY (B30.2) domains are the most common C-termini found in
TRIM family proteins. The evolutionarily ancient SPRY domain (~140 amino acids) is
present alone or fused to a related domain called the PRY domain (~60 amino acids),
which always precedes the SPRY domain. Unlike the SPRY-only domain, the fused
PRY/SPRY domain is only found in vertebrates and PRY/SPRY-containing proteins
(including TRIMs) have expanded rapidly during vertebrate evolution. The reasons for
this expansion are still unclear; however, it has been proposed that the PRY/SPRY
domain has been selected and maintained in vertebrates as a component of immune
defense

68,149

. Indeed, the PRY/SPRY domain in TRIM proteins is often critical for

TRIM-mediated virus inhibition. For example, rhTRIM5α interacts with the HIV-1
capsid protein via its PRY/SPRY domain and both PRY and SPRY portions of the
domain are necessary for this interaction. Furthermore, the PRY/SPRY domain in the
TRIM25 protein, which activates the RIG-I signaling cascade, is both necessary and
sufficient for its interaction with RIG-I. These PRY/SPRY-mediated protein-protein
interactions are required for both rhTRIM5α and TRIM25 to execute their antiviral
functions 40,122,150–153.
The SPRY and PRY/SPRY domain superfamily is among one of the largest families of
protein interaction modules in humans. In addition to the TRIM family, the SPRY and
PRY/SPRY domains are found in several other protein families, including a number of

23

families that contain proteins involved in ubiquitylation processes. As mentioned in the
previous section, the TRIM family also contains a sizeable number of proteins that are
involved in ubiquitylation. Thus, although SPRY and PRY/SPRY-containing proteins
have diverse biological functions, it has been proposed in the literature that they may
function primarily as target substrate recognition modules for E3 ubiquitin ligases

154,155

.

This is consistent with experimental evidence for some members of the TRIM family,
such as TRIM27, which interacts with the NOD2 (nucleotide-binding oligomerization
domain-containing protein 2) protein through its PRY/SPRY domain and subsequently
facilitates NOD2 polyubiquitylation and degradation using its RING domain

156

.

However, in the majority of cases, the mechanistic details and/or interacting substrate
proteins required for TRIM-mediated biological activities are unknown.
Several SPRY and PRY/SPRY domain structures have now been resolved, including a
limited number of structures in complex with their binding partners. These studies have
revealed that the SPRY and PRY/SPRY domain structures are extremely versatile and
can interact with diverse ligands 157,158. The core fold of the PRY/SPRY domain is a bent
β-sandwich comprised of two antiparallel β sheets. The majority of conserved residues
are located in the hydrophobic core between the antiparallel β sheets, whereas loops of
variable length and sequence protrude from the core β-sandwich. In many PRY/SPRYcontaining proteins, these variable loops form protein binding surfaces that determine
substrate binding specificity

154,155,159–162

. For example, four variable (v) loops in the

recently solved structure of the rhTRIM5α PRY/SPRY domain comprise the HIV-1
capsid binding site. The binding surface is dominated by one variable loop (v1) that is
highly flexible and interacts weakly with multiple capsid epitopes. Interestingly, the
authors of this study suggests that capsid recognition by rhTRIM5α may function in a
similar manner as IgM-mediated antigen recognition 163.

1.1.3

Antiviral activity

Most TRIM proteins are upregulated by type I IFNs and multiple TRIMs have been
shown to possess antiviral activity. As mentioned previously, TRIM5α restricts the
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replication of diverse retroviruses, including HIV-1 and N-MLV. A comprehensive
screen for antiretroviral activity of 55 human and mouse TRIMs revealed that 19
additional TRIM proteins inhibit the entry or release of HIV-1, MLV, and/or avian
leucosis virus. Interestingly, unlike TRIM5α, most of the additional TRIM proteins
inhibited late stages of the viral life cycle

69

. Multiple TRIM proteins have also been

shown to have antiviral activity against hepatitis B virus (HBV). These TRIM proteins
have been shown to significantly reduce the HBV transcription in HepG2 cells

164,165

.

Some TRIM proteins, such as TRIM19/PML, have been implicated in the inhibition of
additional viruses, including herpes simplex virus, human cytomegalovirus, vesicular
stomatitis virus, and influenza A virus (IAV) 166. Recently, TRIM56 was shown to inhibit
the replication of bovine viral diarrhea virus in vitro and mouse-specific TRIM79α was
identified as a potent inhibitor of tick-borne encephalitis virus

167,168

. In addition,

TRIM21 was previously shown to act as an intracellular IgG receptor that neutralizes
antibody-coated virus in the cytoplasm by targeting it for degradation by the 26S
proteasome

169

. These studies suggest that TRIM family proteins restrict evolutionarily

diverse viruses and target a variety of stages in the viral replication life cycle.

1.2 The TRIM22 protein
TRIM22 is an evolutionarily ancient IFN-induced antiviral protein that inhibits HIV-1,
HBV, IAV, and encephalomyocarditis virus (EMCV) replication. Similar to other host
restriction factors, the major biological activity of TRIM22 is its antiviral activity;
However, altered TRIM22 expression levels have also been associated with multiple
sclerosis, several cancers, and a number of autoimmune diseases. While TRIM22 is
clearly an important and dynamic protein, the key factors that influence its expression
and antiviral activity remain largely unknown

170

. An overview of what is currently

known about TRIM22 evolution, structure, and function is provided below.
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1.2.1

Origins and evolution

Human TRIM22 is located on chromosome 11 within a cluster of closely-related TRIM
genes that also includes TRIM5, TRIM6, and TRIM34

171,172

. The origins of the entire

TRIM5/6/22/34 gene cluster can be traced back to the Cretaceous period, or more
specifically, to approximately 90-180 million years ago (Fig 1.5). Studies have shown
that TRIM5/6/22/34 is absent in Metatherian (marsupial) mammals (e.g. opossum and
chicken), but present in all major Eutherian (placental) groups (e.g. cow, dog, and
human)

172

. As such, the TRIM5/6/22/34 gene cluster must have emerged after the

divergence of Metatherian and Eutherian mammals, but before the separation of major
Eutherian groups. Of interest, several groups have proposed that TRIM5/6/22/34 likely
arose through tandem gene duplication, as TRIM5, TRIM6, TRIM22, and TRIM34 are
close human paralogs, and because major gene re-arrangements have been observed in
this chromosomal region

108,172,173

. Gene duplication plays an important role in evolution

and a number of TRIM genes have been shown to undergo gene duplication in both
primates and teleost fish 108,174.
Within the TRIM5/6/22/34 gene cluster, TRIM22 and TRIM5 have an interesting and
dynamic evolutionary relationship. In some Eutherian groups, such as cow, there are
multiple copies of the TRIM5 gene but no TRIM22 gene. However, in other Eutherian
groups, such as dog, the TRIM22 gene is present but the TRIM5 gene is not

172

. In

addition, TRIM22 and TRIM5 have evolved in a mutually exclusive manner, whereby
positive selection has acted on either TRIM22 or TRIM5 (but not both) in different
primate lineages. This striking anti-correlative pattern of evolution is thought to occur
due to tight genetic linkage between the two genes

172

. Both TRIM22 and TRIM5 are

classified as Subgroup G (also Group 2) TRIM genes according to the most recent
phylogenetic-based classification system (TRIM6 and TRIM34 are also Subgroup G,
Group 2 TRIM genes) (Fig 1.3) 110,111.
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Figure 1.5: TRIM22 evolution, genomic organization, and protein structure.
An approximate timeline of Metatherian and Eutherian mammalian evolution is shown
on the top panel. The estimated time (~90-180 million years ago) that TRIM22 (and the
rest of the TRIM5/6/22/34 gene cluster) emerged in Eutherian mammals is indicated by
two arrows. The middle panel shows the genomic organization of the TRIM5/6/22/34
gene cluster on human chromosome 11. The bottom panel illustrates the TRIM22 protein
domains (RING, BB2, CC, and PRY/SPRY or B30.2) and the approximate location of its
E3 ligase activity and nuclear localization signal (NLS).
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Figure 1.5: TRIM22 evolution, genomic organization, and protein structure.
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1.2.2

Protein structure

Similar to other Subgroup G (and Group 2) members, the TRIM22 protein is comprised
of an N-terminal RBCC motif that includes RING, BB2, and CC domains and a Cterminal B30.2 domain (Figs. 1.3 and 1.5). The RING domain of TRIM22 has been
shown to possess both E3 ubiquitin and E3 SUMO ligase activity

132,175

. TRIM22’s E3

ubiquitin ligase activity is dependent on two catalytic cysteine (Cys) residues (i.e. Cys15
and Cys18) in its RING domain. These Cys residues help stabilize the zinc finger motif
and facilitate the transfer of ubiquitin to the appropriate substrate protein 113,117. TRIM22
also mediates its own ubiquitylation and 26S proteasomal degradation when combined
with the E2 conjugating enzyme UbcH5B (also referred to as UBC2D2)

175

. TRIM22

inhibits viral replication by both E3 ubiquitin ligase dependent and independent
mechanisms. For example, TRIM22’s E3 ubiquitin ligase activity is required for
TRIM22-mediated inhibition of HBV, IAV, and EMCV

164,176,177

. However, HIV-1

inhibition occurs in both the presence and absence of TRIM22’s E3 ubiquitin ligase
activity 178,179.
The second domain in the TRIM22 protein is the BB2 domain. Similar to the RING
domain, the BB2 domain contains a zinc finger motif; however, the BB2 domain only
coordinates one zinc ion (the RING domain coordinates two zinc ions)

180

. While the

function of TRIM22’s BB2 domain is still unclear, BB2 mutations in other TRIM
proteins have been shown to affect viral recognition or inhibition. For example, in the
TRIM5α protein, the RING and BB2 domains work together to promote TRIM5α
dimerization, which is important for higher-order self-association of rhTRIM5α on the
HIV-1 capsid lattice and subsequent HIV-1 restriction

181

. It is unknown whether the

TRIM22 BB2 domain is required for higher-order self-association; however, the BB2
does play a role in TRIM22’s nuclear localization

182

. The BB2 domain of TRIM22 is

followed by the predicted CC region, which contains many putative hyper-secondary
structures and α-helices

183

. In TRIM5α, the CC region promotes TRIM5α trimerization

and may be involved in TRIM5α cytoplasmic body formation. Similar to dimerization,
TRIM5α trimerization drives its interaction with the HIV-1 capsid lattice

146,181

. The CC

region also promotes higher-order self-association in a number of additional TRIM
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proteins. While TRIM22 has been shown to undergo trimerization, the biological and
antiviral significance of TRIM22 trimerization is unknown 112.
The TRIM22 protein contains a C-terminal B30.2 (PRY/SPRY) domain. Although the
structure of this domain has not been resolved for TRIM22, several domain-deletion
studies have shown that it is integral for many TRIM22 functions. For example, one
study showed that B30.2 mutants of TRIM22 were no longer able to inhibit HBV
replication and localized exclusively to the cytoplasm in HepG2 cells

164

. Several

additional studies have also reported the TRIM22’s B30.2 domain is necessary for its
nuclear localization and the formation of nuclear bodies (NB), including a study that
showed that amino acids 491-494 are critical for nuclear localization and amino acids
493-494 are critical for NB formation

184,185

. TRIM22’s B30.2 domain may also be

required for EMCV restriction, self-ubiquitylation, and/or the ubiquitylation of other
substrate proteins. One study that investigated TRIM22-mediated EMCV restriction
showed that a C-terminal TRIM22 mutant lacking both CC and B30.2 domains was
unable to inhibit EMCV replication or facilitate ubiquitylation of target proteins even
though its RING domain was still intact and bound to the ubiquitylated E2 enzyme

176

.

An N-terminal TRIM22 mutant lacking both RING and BB2 domains lost the ability to
undergo self-ubiquitylation, suggesting that the B30.2 domain of TRIM22 may be
ubiquitylated by its own RING finger domain

176

. While the role of TRIM22’s B30.2

domain in HIV-1 restriction is still unclear, rhTRIM5α’s B30.2 domain is required for
HIV-1 restriction

146

. Moreover, several hyper-variable regions (v1-v4) in the B30.2

domain of rhTRIM5α form the binding surface for HIV-1 capsid and confer virus
specificity for TRIM5α-mediated restriction of retroviruses

186

. The B30.2 domain of

TRIM22 also contains these hyper-variable regions (v1-v4); however, it is unknown
whether they play a role in its antiviral activity or specificity.

1.2.3

Induction and expression

Several reports have demonstrated that TRIM22 is basally expressed in multiple human
tissues and is highly upregulated in response to type I and type II IFN (Table 1.2)
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Table 1.2
Table 1.2: Factors that alter TRIM22 protein expression levels.

Change

Cell type and/or Tissue 1

Cytokines
IFN-α

Increase

IFN-β
IFNIL-1-β
IL-2
IL-15
Progesterone
TNF-α

Increase
Increase
Increase
Increase
Increase
Increase
Increase

Primary MDM; CEM, Jurkat, THP-1, H9, HepG2, U937 U-937-4, Daudi,
and HeLa cells
HOS, Daudi, and HeLa cells
HeLa, HepG2, and MCF7 cells
Coronary artery endothelium
CD4+, CD8+, NK cells
CD4+, CD8+, NK cells
ABC28 and T47D cells
Coronary artery endothelium

Antigens/Infection
EBV infection
EBV LMP-1
HBV infection
HCV infection
HIV-1 infection
HIV-1 Tat
HPV infection
KSHV infection
KSHV LANA

Increase
Increase
Increase
Increase
Increase
Increase
Decrease
Increase
Increase

BL41-EBV cells
DG75 cells
Liver tissue
Liver tissue
Immature DCs, Primary MDMs
Immature DCs
Human keratinocytes
KSHV lesion
BJAB cells
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LPS
Rubella infection

Increase
Increase

Primary MDMs
ECV304 cells

Activation/Differentiation/Cell
cycle
1α,25-dihydroxyvitamine D33
Anti-CD2
Anti-CD2/CD28
Anti-CD2/CD28/CD3
All-trans retinoic acid
p53
p73
Pioglitazone
UV-irradiation

Increase
Increase
Decrease
Decrease
Increase
Increase
Increase
Increase
Increase

Primary MDMs
Primary T cells
Primary T cells
CD4+, CD8+, NK cells
Primary MDMs; HL60 and NB4 cells
K562 and U-937-4 cells
U-937-4 cells
Primary MDMs
MCF-7 cells

Disease
Systemic Lupus Erythematosus
Wilms Tumor
Neuroblastoma
Breast Cancer

Increase
Decrease
Decrease
Decrease

CD4+ T cells from SLE patient
Primary Wilms Tumor
Primary Neuroblastoma
Primary Breast cancer and 10 Breast cancer cell lines

1

Please refer to

170

for comprehensive list of all references

Abbreviations: Monocyte-derived macrophages (MDM), Dendritic cells (DC), Epstein-Barr virus (EBV), Human papillomavirus (HPV), Kaposi’s sarcomaassociated herpesvirus (KSHV)
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164,172,178,179,187–193

. TRIM22 expression is also induced by several viral antigens (e.g.

Epstein-Barr virus [EBV], HIV-1, HBV, Kaposi’s sarcoma-associated herpes virus
[KSHV], and Rubella), cytokines, and hormones. Studies have shown that TRIM22
contains two IFN-stimulated response elements (ISRE-1, ISRE-2) and one IFN-γ
activation site (GAS) in its 5’ promoter region. Notably, ISRE-1 and GAS are not
required for IFN-γ induction of TRIM22. Instead, induction of TRIM22 by IFN-γ
requires ISRE-2 plus six upstream nucleotides (referred to as the 5’ extended ISRE or
eISRE)

190

. This induction is dependent on the chromatin remodeling enzyme brahma-

related gene 1, which recruits IFN regulatory factor 1 (IRF-1) to the eISRE, and histone
deacetylase activity, which prevents the proteasomal degradation of IRF-1

192,194

. JAK,

phosphatidylcholine-phospholipase C, and protein kinase C are also required for
induction of TRIM22 by IFN-γ. p300 enhances IFN-γ induced expression of TRIM22
and is also required for the recruitment of RNA polymerase II to the 5’ TRIM22
promoter. IRF-1 binding to eISRE appears to also be required for IFN-α induced and
basal TRIM22 expression 195.

1.2.4

Sub-cellular localization

Conflicting reports have been published on the sub-cellular localization of TRIM22.
Some reports show that TRIM22 localizes predominantly in the cytoplasm or in the
nucleus, whereas others show that TRIM22 localizes in both the cytoplasm and the
nucleus

112,164,175,182,184,196–198

. These studies also report different TRIM22 localization

patterns (i.e. diffuse, speckled, and/or aggregated). Although the reasons for these
inconsistencies are unclear, several possible explanations have been given in the
literature. These include whether TRIM22 was expressed endogenously (e.g. IFN
treatment of cells) or exogenously (e.g. overexpression of TRIM22), the method of
fixation, and the epitope tag. Other potential explanations include cell-type specific
factors or induction by different cellular signals. Consistent with the latter, TRIM22
localizes in NBs in progesterone-treated, but not IFN-γ-treated, MCF7 and HeLa cell
lines 197.
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Several determinants of TRIM22 sub-cellular localization have been identified. The
TRIM22 protein contains a bipartite nuclear localization signal (NLS) in the Spacer 2
domain (SP2), which was previously shown to be necessary, but not sufficient, for
nuclear localization

197

. Although the B30.2 domain does not contain a known NLS,

multiple groups have shown that it is required for nuclear localization

164,184,196,197

. One

group in particular showed that the amino acids 491-494 are essential for TRIM22
nuclear localization and that the amino acids 493-494 are critical for the formation of
TRIM22 NBs in MCF7 cells

197

. Another group reported that the amino acids 395, 396,

and 400 are required for the cytoplasmic localization of TRIM22 in COS-7 (African
green monkey) cells

196

. However, this group did not investigate how these amino acids

influence TRIM22 localization in human cells. Notably, some studies that observed
cytoplasmic TRIM22 localization used a shorter form of TRIM22 (442 instead of 498
amino acids) that is translated from a 1329 mRNA coding sequence. As such, in these
studies the lack of amino acids 491-494 likely contribute to the cytoplasmic localization
of TRIM22.
In many cell types, TRIM22 localizes in punctate NBs, which have been shown to
partially co-localize with Cajal bodies (CB)

197

. CBs are distinct nuclear organelles that

are involved in RNA processing and modification, assembly/modification of splicing
machinery, and cell cycle progression

199

. TRIM22 interacts with p80-coilin, which is a

major component of CBs, in stably-transfected MCF7 cells and progesterone-treated
ABC28 cells

197

. Similar to CBs, TRIM22 localization may change throughout the cell

cycle. One report showed that during G0/G1 TRIM22 localizes in NBs, in S-phase it
localizes diffusely in the nucleus, and in mitosis it assumes a diffuse pattern in the
nucleus and cytoplasm (exogenous TRIM22 expression in HeLa cells)

197

. However, a

second study reported that TRIM22 co-localizes with the centrosome independently of
the cell cycle (exogenous TRIM22 expression in U2OS cells as well as endogenous
TRIM22 expression in peripheral blood mononuclear cells)

198

. Notably, these two

localization patterns may not be mutually exclusive because TRIM22 did not localize
exclusively to centrosomes. These data suggest that multiple factors influence the subcellular localization of TRIM22, indicating that TRIM22 may have several biological
roles.
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1.2.5

Antiviral function

Human TRIM22 was first identified in 1995 during a search for IFN-induced genes in
Daudi cells. Following sequence analysis, which revealed that TRIM22 was highly
homologous to the mouse Rpt-1 gene, exogenous TRIM22 expression was shown to
downregulate transcription from the HIV-1 LTR

187,200

. Although this experiment was

performed using a luciferase reporter gene instead of the entire HIV-1 genome, it was
first to report an antiviral (and anti-HIV-1) function for TRIM22. In 2006, another
independent study showed that TRIM22 was highly up-regulated in primary monocytederived macrophages (MDM) in response to HIV-1 infection, IFN-α treatment, or
stimulation with lipopolysaccharide (LPS). In addition, they showed that exogenous
TRIM22 expression inhibited HIV-1 infection by 50-90% in 293T cells and primary
MDMs

189

. In 2008, Barr and colleagues showed that TRIM22 was a key mediator of

type I IFN-induced inhibition of HIV-1 replication

178

. Two different methods of HIV-1

inhibition were observed. In HOS and HeLa cell lines, TRIM22 expression inhibited
HIV-1 particle production by preventing the trafficking of the Gag polyprotein to the
plasma membrane. This effect was dependent on the E3 ligase activity of TRIM22.
Because TRIM22 was also shown to interact with Gag it was thought that TRIM22mediated post-translational modification of Gag may be responsible for altered Gag
trafficking. However, to date, TRIM22 has never been shown to modify Gag posttranslationally. Unlike in HOS and HeLa cells, in U2OS and 143B cells, TRIM22
inhibited the accumulation of intracellular Gag protein. Although the mechanism of
restriction was not identified in these cell lines, several potential explanations were
suggested, including inhibition of LTR-driven transcription or degradation of the Gag
RNA and/or polyprotein

178

. Notably, these experiments provided the first mechanistic

data for restriction of HIV-1 replication by TRIM22.
It has since been confirmed that TRIM22 can restrict HIV-1 transcription

179

. In 2011,

TRIM22 was identified as the sole factor expressed in clones of U937 cells that were
non-permissive to HIV-1 replication, but absent in permissive U937 clones. Using a
luciferase reporter plasmid, the authors tested LTR-driven transcription in the non-
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permissive and permissive clones. LTR transcription levels in non-permissive clones
were decreased 7-10 fold compared to permissive clones; however, non-permissive
transcription levels were increased when shRNA was used to knockdown TRIM22.
Moreover, when TRIM22 was expressed in permissive clones transcription levels
decreased to those observed in non-permissive clones. Further examination of these
clones revealed that TRIM22 inhibited basal LTR-driven HIV-1 transcription and that
these effects were independent of NF-κB binding sites in the LTR, Tat-mediated LTR
transactivation, and TRIM22 E3 ligase activity 179.
In addition to these in vitro studies, there is also in vivo evidence to support a role for
TRIM22 as an anti-HIV-1 effector. A 2011 study demonstrated that increased TRIM22
expression was associated with significantly lower viral loads and significantly higher
CD4+ T-cell counts in HIV-1 positive individuals in the primary phase of infection

201

.

Recently, a follow-up study showed that TRIM22 expression was also associated with
significantly lower viral loads in HIV-1 positive individuals in the chronic phase of
infection

202

. These data suggest that TRIM22 expression contributes to HIV-1 disease

progression in infected individuals.
TRIM22’s antiviral activity is not limited to HIV-1. Exogenous expression of TRIM22
has also been shown to inhibit the replication of EMCV, IAV, and HBV. For EMCV
restriction, TRIM22 was shown to interact with the 3C viral protease and mediate its
ubiquitylation and subsequent degradation

176

. The 3C protease has a number of

important roles, including processing the viral polyprotein, and is essential for successful
EMCV replication176. A similar mechanism of restriction was reported for IAV
inhibition. Specifically, TRIM22 was shown to interact with IAV’s viral nucleoprotein
(NP), which plays a critical structural function and is required for IAV replication.
Following TRIM22-NP interaction, TRIM22’s E3 ubiquitin ligase activity facilitates
ubiquitylation and subsequent proteasomal degradation of NP

177

. Several studies have

recently shown that TRIM22 may be an important antiviral factor in the liver. In 2009,
one study demonstrated that TRIM22 expression inhibited HBV gene expression and
replication in cultured cells and mice

164

. Further experiments revealed that TRIM22

inhibited the activity of the HBV core promoter (CP), which plays a key role in HBV

36

replication. HBV CP inhibition was dependent on TRIM22’s B30.2 domain and its E3
ligase activity, even though a ubiquitylation target was not identified

164

. Interestingly,

TRIM22 expression is also significantly upregulated during clearance of HBV and
hepatitis C virus (HCV) in chimpanzees

203,204

. In human HCV infection, TRIM22 is

significantly upregulated in the cirrhotic liver of HCV positive individuals and
individuals with mild chronic HCV with no fibrosis 205.

1.2.6

Other functions

Several reports have implicated TRIM22 in other biological processes, including cell
cycle regulation and cell proliferation/differentiation. One study identified a functional
p53 response element in intron 1 of the TRIM22 gene and demonstrated that upon p53
binding this element activates TRIM22 expression. Moreover, the same study showed
that overexpression of TRIM22 in U937 cells led to decreased clonogenic growth and
that endogenous TRIM22 was upregulated during induced differentiation in NB4 cells
188

. A later study investigating TRIM22 expression during hematopoietic differentiation

showed that TRIM22 is highly expressed in CD34+ bone marrow progenitor cells, but
declines in mature populations. Notably, although TRIM22 expression was inversely
correlated with differentiation in both lineages, its expression pattern differed during
erythroid versus granulocytic differentiation. Decreased TRIM22 expression was more
pronounced and lasting during erythroid differentiation and undetectable in nucleated
erythroid populations 193.
TRIM22 has also been linked to other human diseases, including certain cancers and
autoimmune diseases. Two studies have shown that decreased TRIM22 expression is
associated with increased progression, relapse, and mortality in cases of Wilms tumor
206,207

. In addition, a recent study reported that TRIM22 expression is significantly

decreased in both a panel of 10 breast cancer cell lines and breast tumors compared to
three non-malignant cell lines and normal breast tissue. Interestingly, TRIM22 protein
levels correlated with p53 protein levels in the normal breast tissue, but not in breast
cancer tissue. Additional experiments showed that TRIM22 expression was no longer
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p53-inducible in breast cancer cells, suggesting that a defect in p53-mediated TRIM22
regulation was responsible for TRIM22 downregulation in breast cancer

208

. Two gene

profiling studies have also implicated TRIM22 in the pathogenesis of systemic lupus
erythematosus (SLE). The first study showed that TRIM22 was overexpressed in the
CD4+ T cells of individuals with active SLE compared to individuals with non-active
SLE. The second study also reported that TRIM22 was upregulated in SLE-positive
CD4+ T cells and that, along with a number of other IFN-induced genes, TRIM22 was
significantly hypomethylated in SLE cells compared to healthy controls 209,210.

1.3 Rationale and Experimental Approach
Genetic variation in immune genes plays an integral role in host susceptibility to and
progression of infection and disease. Much of this variation is due to single nucleotide
polymorphisms (SNPs), which are defined as single base changes in a DNA sequence.
While many SNPs are phenotypically neutral, non-synonymous or amino acid altering
SNPs (nsSNP) often have deleterious effects on protein structure and/or function

211–218

.

Previous studies have shown that nsSNPs do not appear randomly in the genome, but
emerge based on genomic location and selective pressures. Since innate immune genes
are located at the interface of the microbial environment, they tend to be exposed to a
wide range of selective pressures. As such, innate immune genes often contain genetic
signatures of positive (directional) and/or balancing selection, whereas most other host
genes are dominated by negative (purifying) selection 219–221.
Multiple host restriction factors, including APOBEC3G, TRIM5α, BST-2/tetherin, and
SAMHD1, have evolved under positive and/or balancing selection

18

. Host restriction

factors often interact directly with viral antagonists and/or other viral proteins and as a
result, they tend to be subjected to intense pathogenic pressures. In order to effectively
adapt to an ever-changing pathogenic environment, host restriction factors must evolve
new advantageous mutations and/or maintain genetic flexibility to counteract emerging
pathogenic threats. Since new beneficial mutations and/or sites of genetic diversity are
typically located at critical functional sites, performing evolutionary analyses on host
restriction factors can be a powerful way to delineate integral sites in these proteins. It

38

follows that a number of studies on host restriction factors have used an evolutionary
approach to identify essential residues in these proteins

62,85,91,99,106,222

. In addition, other

studies have used in silico nsSNP prediction programs to identify functionally and/or
clinically relevant polymorphisms in innate immune genes

19–24

. Further, in silico

methods have also been used to identify important functional regions in these genes (e.g.
post-translational modifications) and support evolutionary analyses

229–232

. One of the

major advantages of performing in silico analyses is that it allows for the systematic
analysis and prioritization of specific functional sites. This is becoming increasingly
important given the tremendous number of SNPs in the human genome and the vast
amount of genetic data that is generated on a daily basis. Collectively, evolutionary and
in silico analyses provide valuable insight into protein function and are powerful tools
that can help identify key structural and/or functional sites in a protein.
Given the important role played by TRIM22 in multiple biological processes, including
the host antiviral response, and the paucity of information about key functional sites in
the TRIM22 protein, we conducted an extensive evolutionary and in silico analysis to
identify critical amino acid residues that mediate TRIM22 function. This approach has
previously been used to pinpoint specific amino acid residues that are essential for the
activities of other host restriction factors, including the APOBEC3G, TRIM5α, BST2/tetherin, and SAMHD1 proteins. We hypothesized that evolutionary forces have been
acting on TRIM22 and have selected for specific amino acids that impact TRIM22
function. To address this hypothesis, we characterized the evolutionary forces acting on
TRIM22 and used a number of in silico methods to delineate and prioritize potential
functional sites in human TRIM22 that may be relevant to its overall antiviral and/or
biological functions. We then investigated how various TRIM22 nsSNPs may affect
human infection and disease and identified a functional nsSNP (rs1063303:G>C) that
influences two diverse TRIM22-mediated biological activities.
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Chapter 2

2

Ancient and recent adaptive evolution in the antiviral
TRIM22 gene: identification of a single nucleotide
polymorphism that impacts TRIM22 function 1

TRIM22 is a novel IFN-induced protein that potently inhibits the replication of
evolutionarily diverse viruses, including HIV-1, HBV, and IAV. Altered TRIM22
expression is also associated with diseases such as multiple sclerosis, cancer, and
autoimmunity. To date, the factors that influence TRIM22 expression and antiviral
activity are largely unknown. Here, we used an evolutionary approach to identify
potential genetic determinants of TRIM22 function. Evolutionary analysis using 29
mammalian TRIM22 sequences revealed that TRIM22 evolution has been shaped by
ancient and variable selective forces. Positive selection has operated on a number of
TRIM22 sites, many of which cluster together in putative protein-protein interaction
motifs. Interestingly, we found that the second most prevalent nsSNP in the human
TRIM22 gene (rs1063303:G>C) is located at one of these positively selected sites. In
addition, the frequency of this nsSNP varied up to 10-fold between different ethnic
populations. We found that nsSNP rs1063303:G>C had an inverse functional impact,
whereby it increased TRIM22 expression and decreased TRIM22 antiviral activity.
Taken together, our data describes the extensive genetic variation in TRIM22 and
identifies nsSNP rs1063303:G>C as a highly prevalent nsSNP that impacts TRIM22
function.

1

The material contained in this chapter was published in: Kelly, J.N., Woods, M.W., Xhiku, S., and Barr,
S.D. Ancient and recent adaptive evolution in the antiviral TRIM22 gene: identification of a single
nucleotide polymorphism that impacts TRIM22 function. Hum Mutat. (2014).
Copyright 2014.
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2.1 Introduction
The TRIM family is a large group of proteins involved in diverse cellular processes.
TRIM proteins are increasingly becoming recognized as key regulators of the innate
immune response and a number of TRIM proteins have been shown to possess antiviral
activity 1–6. According to a recent evolutionary study, TRIM proteins can be divided into
two main groups based on genomic organization, evolutionary properties, and domain
structure. Group 1 TRIM proteins (G1) are present in both invertebrate and vertebrate
species and have variable C-terminal domains, while Group 2 TRIM proteins (G2) are
only found in vertebrates and have a C-terminal B30.2 domain 7. All TRIM proteins (G1
and G2) have a conserved N-terminal RBCC motif, which consists of a RING domain,
one or two BB domains, and a predicted CC region. The RING domain often has E3
ligase activity, allowing some TRIMs to modify other proteins (including viral proteins)
with ubiquitin or ubiquitin-like molecules 8–10.
In the human genome, four G2 TRIM genes cluster together on chromosome 11: TRIM6,
TRIM34, TRIM5, and TRIM22 (Online Mendelian Inheritance in Man #606559).
Evolutionary analysis of this gene cluster has shown that TRIM6 and TRIM34 have
evolved under purifying selection in primates, and that TRIM5 and TRIM22 have a
dynamic evolutionary relationship in primates that includes episodes of gene expansion
and gene loss

11,12

. It was previously shown that TRIM5 and TRIM22 sequences have

undergone positive selection in primates, with primate lineages showing positive
selection in either TRIM5 or TRIM22, but not both

12–15

. Moreover, the TRIM5 and

TRIM22 genes of Haplorhini primates have evolved species-specific differences in
transcriptional regulation, mediated by transposable element sequences in their noncoding regions

16

. Both TRIM5 and TRIM22 encode proteins with antiviral activity

against retroviruses. TRIM5α inhibits HIV-1 replication in non-human primate cells;
however, this activity is weak to absent in human cells

17–19

. Conversely, TRIM22

inhibits HIV-1 replication in several human cell lines and primary MDMs

20–23

. The

TRIM22 protein also inhibits the replication of EMCV, HBV, and IAV 24–26.
Genetic conflict between host and viral genomes can lead to the rapid accumulation of
amino acid replacement changes (dN) relative to synonymous changes (dS). This
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phenomenon of positive selection (i.e. dN/dS >1) is one hallmark of the evolutionary
‘battle’ that occurs between host antiviral factors and their pathogen antagonists

27,28

.

Although positive selection is not typically observed in other host genes, multiple
antiviral factors contain genetic signatures of positive selection

29,30

. For example, well-

known host restriction factors, including APOBEC3G, BST2/tetherin, and TRIM5α all
contain positively selected sites that play key roles in their antiviral activities 13–15.
A previous evolutionary study of TRIM22 in primates spanning ~33 million years of
primate divergence identified a strong signature of positive selection for TRIM22 in
hominoids and old world monkeys (OWM)

12

. The positions of amino acid residues

found to be under positive selection were located predominantly in the β2-β3 surface
loop of B30.2 domain. In the present study, we analyzed TRIM22 sequences from
evolutionarily diverse mammals spanning ~100 million years and used an evolutionguided functional approach to identify residues that may dictate TRIM22-mediated
antiviral activity. Using three paired evolutionary models, we identified residues in
several TRIM22 domains that are predicted to be under strong positive selection in
mammals. We demonstrated that the human TRIM22 gene exhibits remarkable genetic
diversity and characterized one highly prevalent nsSNP (rs1063303:G>C) that is located
at a site evolving under strong positive selection. Notably, we showed that nsSNP
rs1063303:G>C has an inverse functional impact on TRIM22, whereby it increased
TRIM22 expression levels and decreased TRIM22 antiviral activity. Our findings in this
study indicate that genetic variation in the TRIM22 gene is both prevalent and ancient,
and that positively selected sites in TRIM22 may influence its antiviral activity.

2.2 Materials and methods
2.2.1

Sequence analysis

TRIM22 sequences were aligned in COBALT and a phylogenetic tree was generated
using EvolView software

31,32

. Positive selection was evaluated using the Selecton

program, as previously described

33,34

. Briefly, sequences were analyzed using three

paired models, two nested (M8a and M8; M7 and M8) and one non-nested (M8a and
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MEC). The models that allowed positive selection to occur (M8 and MEC) fit the data
better than models that did not allow positive selection to occur (M8a and M7). The nonsynonymous (Ka) to synonymous (Ks) ratio (i.e. Ka/Ks) was also calculated for each
codon using Selection. Codons with a Ka/Ks ratio >1.5 exhibited high probabilities of
having evolved under positive selection and were highlighted in Fig 2.1b. Primate
TRIM22 sequences in Fig 2.2c were also aligned in COBALT. Frequency data for the
rs1063303:G>C nsSNP was extracted from the 1000 Genomes database and includes
individuals from the following regions: African (AFN) population includes Nigeria,
Kenya, The Gambia, Sierra Leone, Americans of African ancestry in southwestern
United States, African Caribbean in Barbados; American (AMR) population includes
Puerto Rico, Colombia, Peru, Mexican ancestry from Los Angeles, United States;
European (EUR) population includes Italy, United Kingdom, Finland, Spain, Northern
and Western European ancestry from Utah, United States; Asian (ASN) population
includes China, Vietnam, and Japan 35.

2.2.2

Cells, plasmids, and transfections

Cells were maintained at 37°C with 5% CO2 in standard DMEM growth medium
(Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS, 100
U/ml penicillin, and 100 µg/ml streptomycin). 293T and HeLa cell lines were obtained
from the ATCC. HOS-CD4+ cell line was obtained from NIH AIDS Reagents. The
empty vector plasmid (pGL3) was purchased from Promega and the pR9 plasmid
encoding replication-competent HIV-1 was kindly provided by Dr. F. Bushman
(University of Pennsylvania, USA). The coding region of the wild type TRIM22 gene
(GenBank Accession NM_006074.4) was subcloned into p3xFLAG-CMV-10 (Sigma)
using HindIII and XbaI restriction sites to generate pWT-T22. The flag-tagged nsSNP
rs1063303:G>C plasmid (pSNP-T22) was created using PCR mutagenesis. pSNP-T22
contains C in place of the ancestral allele G at nucleotide position 725 of the TRIM22
coding region (GenBank Accession NM_006074). The following primers were used to
amplify pWT-T22 and generate PCR fragment 1: “Forward WT” (5’ ACG TAA GCT
TAT GGA TTT CTC AGT AAA GG 3’) and “Reverse SNP” (5’ GAC GAT CCC GTC
AAC CTC CGC TGG AGA 3’). Similarly, PCR fragment 2 was generated using the
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primers: “Forward SNP” (5’ TCT CCA GCG GAG GTT GAC GGG ATC GTC 3’) and
“Reverse WT” (5’ ACG TTC TAG ATC AGG AGC TCG GTG GGC ACA CAG 3’).
Following amplification, a 1:25 dilution of PCR fragment 1 and PCR fragment 2 was
added with “Forward WT” and “Reverse WT” primers together in a PCR reaction. The
amplified TRIM22 coding region containing the nsSNP was subcloned into p3xFLAGCMV-10 (Sigma) using HindIII and XbaI to generate pSNP-T22. The entire coding
region of pSNP-T22 was sequenced and no other PCR-introduced variations were
detected. 293T and HeLa cells were seeded in 12-well or 6-well plates and transfected
using Lipofectamine 2000 (Invitrogen) with 2 µg or 5 µg of plasmid DNA (pEV, pWTT22, or pSNP-T22), respectively. As a control for transfection efficiency, a plasmid
encoding enhanced green fluorescent protein (peGFP) (Clontech) was included in the
transfections at a concentration of one tenth the total amount of transfected DNA. The
percent GFP+ cells were measured using standard flow cytometry. Unless otherwise
stated, all co-transfections of pR9 with pEV, pWT-T22, and pSNP-T22 were performed
at a ratio of 10:1.

2.2.3

RNA isolation and real-time PCR

Total RNA was extracted from cells using the R&A-BLUE Total RNA Extraction kit
(Frogga Bio). To ensure that no detectable genomic or plasmid DNA was carried over
during the RNA purification, 0.1µg of each RNA sample was subjected to PCR (35
cycles) and real-time PCR using primers within the TRIM22 coding region or primers
specific to the TRIM22 3’ untranslated region. 1µg of DNase-treated RNA was then
reverse transcribed to cDNA using the M-MLV reverse transcriptase and Oligo(dT)
primers (Invitrogen). Prior to real-time PCR, cDNA samples were diluted 1:10 with
water. Each PCR reaction consisted of 10µl of SYBR Green Master Mix, 2µl of the
appropriate primers (1µl of 10µM forward primer (5’ CAT CTG CCT GGA GCT CCT
GAC 3’) and 1µl of 10µM reverse primer (5’ AGA TGA TCA CTG ACT CCT TGA
TCT TTG C 3’), 1µl of diluted cDNA, and water to a total volume of 20µl. Real-time
PCR was run on the Rotor-Gene 6000 real-time PCR machine (Corbett Life Science)
under the following cycling conditions: 10 min at 95°C and 40 cycles of 10 sec at 95°C,
15 sec at 60°C, and 20 sec at 72°C. The Rotor-Gene 6000 series software (version 1.7)
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was used to determine the CT for each PCR reaction. All samples were amplified in
triplicate with no template controls and the mean was used for further analysis.

2.2.4

Western Blotting

Cells were pelleted by centrifugation (350 x g for 10 minutes), washed twice with PBS,
and lysed in 1X RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1x
Complete Protease Inhibitor (Roche), 1% Triton X-100, 0.1% SDS). Virus released into
the supernatant was clarified by centrifugation, pelleted by centrifugation (21,000 x g for
2 hours) over a cushion of 20% sucrose and lysed with 1X RIPA buffer. Protein was
separated on a 12% SDS-PAGE gel and then transferred to a FluorTransW membrane
(Pall) by semi-dry transfer. Following transfer, the membrane was blocked for 1 hour in
LI-COR Blocking Buffer (LI-COR Biosciences) and incubated overnight with primary
antibody at 4°C (1:1000 dilution with LI-COR Blocking Buffer). Detection was carried
out using an IRDye-labeled secondary antibody (1:20,000 dilution with LI-COR
Blocking Buffer for 30 minutes) and the LI-COR Odyssey Detection System (LI-COR
Biosciences).

2.2.5

Confocal immunofluorescence microscopy

Cells were seeded in 12-well plates on 18mm coverslips. 24 hours post-transfection, cells
were washed with PF buffer (1x PBS + 1% FBS), fixed (1x PBS + 5% formaldehyde +
2% sucrose for 10 minutes), and permeabilized (1x PBS, 5% NP-40, 10% sucrose for 10
minutes). Cells were incubated with primary antibodies for 1 hour (1:1000 dilution of
mouse anti-Flag antibody in PF buffer), washed thoroughly with PF buffer, and then
incubated with secondary antibodies for 1 hour (1:1000 dilution of AlexaFluor 546 antimouse antibody in PF buffer). Coverslips containing the cells were mounted on glass
slides with Vectashield mounting media (Vector laboratories) and slides were examined
using a Zeiss LSM 510 confocal fluorescence microscope. DAPI staining was used to
visualize the nuclei (blue). Images shown represent optical slices taken through the center
of cells from a series of z-stack images with a 63x Plan-Apochromat oil immersion
objective lens (Numerical Aperture = 1.4).
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2.2.6

Neutrality tests

Tajima’s D and Fu’s FS neutrality tests were performed to distinguish between neutrally
evolving sequences under mutation-drift equilibrium and sequences evolving under nonneutral processes such as balancing selection

36–38

. These two tests are based on the

principle that a recent population expansion associated with a non-neutral process will
detect a shift in the allele frequency spectrum compared to a neutral Wright-Fisher
model. A negative Tajima’s D signifies an excess of low frequency variants relative to
expectation, indicating population size expansion (e.g. after a bottleneck or selective
sweep) and/or purifying selection. A positive Tajima’s D signifies low levels of both low
and high frequency (i.e. an excess of intermediate frequency) variants, indicating a
decrease in population size and/or balancing selection. A negative value of Fu’s FS is
evidence for an excess number of rare alleles, as would be expected from a recent
population expansion or from genetic hitchhiking. A positive value of FS is evidence for a
deficiency of alleles, as would be expected from a recent population bottleneck or from
overdominant selection. The FS statistic was considered significant at the 5% level if its P
value was below 0.02

38

. The analyses were performed using the software Arlequin

39

3.5.1.3 . Simulated P values were generated using 10,000 simulations under a model of
selective neutrality.

2.2.7

Statistical analysis

Unless stated otherwise, statistical analyses were performed using GraphPad Prism
(Version 6.0). P values of less than 0.05 were considered statistically significant.

2.3 Results
2.3.1

Positive selection in multiple TRIM22 domains among
mammals

To better understand the evolution of TRIM22, and to examine how selective pressures
have shaped its antiviral properties, we obtained the TRIM22 coding sequence from 29
evolutionarily diverse mammalian species (Table 2.1). We aligned these sequences and
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Table 2.1
Table 2.1: Mammalian TRIM22 coding sequences used for Selecton analysis.

Common name
Human
Chimpanzee
Bonobo
Gorilla
Sumatran Orangutan
Bornean Orangutan
Island Siamang
White-Cheeked Gibbon
African Green
Patas
Sooty Mangabey
Baboon
Rhesus Macaque
Kikuyu Colobus
Red-Shanked Douc
Bolivian Squirrel
Common Squirrel
White-Faced Saki
Dusky Titi
Common Marmoset

Scientific name
Homo sapiens
Pan troglodytes
Pan paniscus
Gorilla gorilla
Pongo abelii
Pongo pygmaeus
Hylobates syndactylus
Nomascus leucogenys
Cercopithecus aethiops
Erythrocebus patas
Cercocebus atys
Papio anubis
Macaca mulatta
Colobus guereza kikuyuensis
Pygathrix nemaeus
Saimiri boliviensis
Saimiri sciureus sciureus
Pithecia pithecia pithecia
Callicebus moloch
Callithrix jacchus

Type 1
HOM
HOM
HOM
HOM
HOM
HOM
HOM
HOM
OWM
OWM
OWM
OWM
OWM
OWM
OWM
NWM
NWM
NWM
NWM
NWM

NCBI Reference
NP_006065.2
NP_001106867.1
XP_003819095.1
XP_004050610.1
NP_001153280.1
EU124707
EU124708
NP_001267028.1
EU124709
EU124696
EU124695
NP_001162333.1
NP_001106830.1
EU124712
EU124710
XM_003923356.1
EU124716
EU124715
EU124692
XM_002754905.2

Verified 2
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
Yes
Yes
Yes
No
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Pygmy Marmoset
Bolivian Red Howler
Southern White Rhinoceros
Cat
Pacific Walrus
Giant Panda
Dog
Florida Manatee
African Elephant
1
2

Callithrix pygmaea
Alouatta sara
Ceratotherium simum simum
Felis catus
Odobenus rosmarus divergens
Ailuropoda melanoleuca
Canis lupus familiaris
Trichechus manatus latirostris
Loxodonta Africana

NWM
NWM
OM
OM
OM
OM
OM
OM
OM

EU124714
EU124713
XM_004418316.1
XM_003992898.1
XM_004407583.1
XM_002926071.1
XM_542402.4
XM_004389072.1
NW_003573536.1

Mammals are classified as hominoids (HOM), old world monkeys (OWM), new world monkeys (NWM) or other mammals (OM).
Sequences were independently verified in 12

Yes
Yes
No
No
No
No
No
No
No
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generated a phylogenetic tree, representing ~100 million years of evolution (Fig 2.1a).
Our primate phylogeny was consistent with previously published studies and only
orthologous non-primate sequences were included in our analysis (Table 2.1)

12

. Using

this dataset, we employed the software program Selecton to evaluate TRIM22 evolution
among mammals. Selecton uses several standard evolutionary models, including two
nested paired models (M8a and M8; M7 and M8) and one non-nested paired model (M8a
and MEC)

33,34

. We compared the nested pairs using the likelihood ratio test and found

that in both cases, the model that allowed sites to evolve under positive selection (M8) fit
the data significantly better than the models that did not (M8a and M7) (Table 2.2). The
non-nested MEC model differs from the nested model in that it accounts for differences
in amino acid replacement rates. A position with radical amino acid replacements will
obtain a higher Ka value than a position with more moderate replacements. Akaike
Information Content (AICc) scores are compared between the MEC and the M8a models.
The lower the AICc score, the better the fit of the model to the data, and hence the model
is considered more justified

33

. Comparison of the AICc scores of the MEC and M8a

models were indicative of positive selection (M8a: 25211.8, MEC: 25079.2) and that the
data was more congruent with the model that allowed for positive selection (MEC) than
the one that did not (M8a) (Table 2.2).
The Selecton analysis identified several codons with high probabilities of having evolved
under positive selection (Fig 2.2). Eleven of the 28 codons predicted to be evolving under
positive selection were located in the B30.2 domain (Fig 2.1b Table 2.3). Six of these
eleven codons (K324, R327, T330, K332, S334, C337) clustered together in the one
region, whereas the other five (S377, S395, G471, L488, V489) were more dispersed.
The codon numbering uses the translation initiation codon as codon 1. Interestingly,
many of the positively selected codons corresponded in location and spacing to
previously identified positively selected codons in the TRIM5α protein (K324, P325,
G330, R332, R335, Q337, F339, V340, K389, Q471, G483) (Fig 2.1c)

15

. In TRIM5α,

most positively selected codons are located in one of four variable regions (v1-v4) in the
B30.2 domain. These variable regions are also found in a number of other TRIM
proteins, including TRIM22

15,19

. The v1 region of TRIM5α (or the ‘antiviral patch’
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Figure 2.1: Mapping positively selected sites in the TRIM22 protein.
(a) Phylogenetic tree showing the evolutionary relationship among 29 mammalian
species for the TRIM22 protein. Tree was created using COBALT and EvolView
software. Numbers shown represent arbitrary distances from each branch point on the
tree. Hominoids (HOM) are highlighted in red, old world monkeys (OWM) in purple,
new world monkeys (NWM) in blue, and additional mammals in green. (b) Bayesian
analysis of mammalian TRIM22 coding sequences. Ka/Ks values for each codon are
plotted on y-axis. Ka/Ks ratio >1 indicates positive selection, Ka/Ks ratio <1 indicates
purifying selection, and Ka/Ks ratio of 1 indicates neutral selection. Asterisks show
approximate location of codons under strong positive selection. TRIM22 domains are
shown above the graph, along with the approximate location of functional motifs
(C15/18: two cysteine residues required for E3 ligase activity; C97, H100: zinc finger
motif in the BB2 domain; predicted CC region; NLS). The ‘antiviral patch’ refers to
several residues previously shown to be a major specificity determinant for TRIM5αmediated anti-HIV activity. (c) Comparative model showing the putative B30.2 3D
structures for both TRIM5α and TRIM22. The blue and red colored regions represent
structurally conserved regions (blue) or regions with no correspondence in structural
proximities (red) after structural alignment. The QH value is a metric for structural
homology (an adaptation of the Q value that measures structural conservation). Q=1
implies that two structures are identical. When Q has a low score (0.1-0.3), structures are
not aligned well (i.e. only a small fraction of the Cα atoms superimpose). Colored balls
correspond to residues (van der Waals radii) predicted to evolve under strong positive
selection (colored yellow for TRIM5α and green for TRIM22). (d) Molecular model of
TRIM22’s B30.2 domain. The colored regions in the image on the left show the four
variable regions (v1: red, v2: blue, v3: magenta, and v4: green). The image on the right
shows only the variable regions (v1-v4) plus the location of sites predicted to evolve
under strong positive selection (yellow). Molecular models were created with Visual
Molecular Dynamics (VMD) software (v1.9.1) support. VMD is developed with NIH
support by the Theoretical and Computational Biophysics group at the Beckman Institute,
University of Illinois at Urbana-Champaign.
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Figure 2.1

Figure 2.1: Mapping positively selected sites in the TRIM22 protein.
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Table 2.2
Table 2.2: Models of evolution applied to TRIM22 coding sequences.

Nested
M8a, M8
M7, M8
Non-nested
M8a, MEC
1

Log-likelihood
-12601.9, -12599.1
-12608.1, -12599.1
Log-likelihood
-12601.9, -12534.6

2(Ln1-Ln0)
5.6
18
AICc Score∆ 1
25211.8, 25079.2

Degrees of Freedom
1
2
Parameters
4, 5

Χ2
<0.001
<0.001

AICc Score∆ = -2*logL+2p*(N/N-p-1), where L is the likelihood of the model given the data, p is the
number of free parameters, and N is the sequence length. The lower the AICC score, the better the fit of the
model to the data, and hence the model is considered more justified.
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Figure 2.2: Selecton analysis of mammalian TRIM22 coding sequences.
Selecton results for 29 mammalian TRIM22 coding sequences using the MEC model.
Positively selected sites are colored orange or yellow (Ka/Ks > 1), whereas sites
undergoing purifying selection are colored shades of purple (Ka/Ks <1). Sites colored
white have a Ka/Ks ratio = 1.
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Figure 2.2

Figure 2.2: Selecton analysis of mammalian TRIM22 coding sequences.

72

Table 2.3
Table 2.3: Positive selection in TRIM22 protein domains.

Domain (AA 1)
RING (1-59)
SP1 (60-96)
BB2 (97-129)
CC (130-233)
SP2 (234-296)
B30.2 (297-498)
1

Percent PS 2
1.00
0.60
0.40
0.60
0.80
2.21

Ka/Ks 3
1.86
1.97
2.30
1.83
1.90
1.90

Positively selected codons
D2, F3, S4, S50, S54
T61, N76, V96
Q105, I106
A171, V192, T220
L241, R242, K257, R279
K324, R327, T330, K332, S334,
C337, S377, S395, G471, L488, V489

AA: Amino acids included in each domain
Percent PS: Percent of positively selected sites in each domain compared to the total number of sites
3
Ka/Ks: Number of non-synonymous substitutions per non-synonymous site (Ka) to the number
of synonymous substitutions per synonymous site (Ks)

2

73

region) was previously shown to be a major determinant for species-specific HIV-1
restriction in primates

18

. Mutations in other variable regions (v2-v4) of TRIM5α have

also been shown to alter HIV-1, SIV, and N-MLV restriction 40–44. Remarkably, all of the
positively selected codons in TRIM22’s B30.2 domain (except G471) were located in one
of its v1-v4 regions. Six positively selected codons were found in the v1 region, two in
the v2 region, and two in the v4 region. Unlike TRIM5α, there were no positively
selected codons in TRIM22’s v3 region (Fig 2.1d).
Outside of the B30.2 domain, we also found evidence for positively selected codons in
each of TRIM22’s other domains (Table 2.3). Many of these codons clustered together
around putative functional motifs in the TRIM22 protein. For example, three positively
selected codons (V96, Q105, I106) surrounded a zinc finger motif in the BB2 domain
(Fig 2.1b, Table 2.3). Zinc finger motifs are critical for proper domain folding and often
contribute to protein-protein interactions

45

. We also identified four positively selected

codons (L241, R242, K257, R279) that flanked the nuclear localization signal (NLS) in
TRIM22’s SP2 domain (Fig 2.1b, Table 2.3). Along with amino acids 491-494 in the
B30.2 domain, TRIM22’s NLS was previously shown to be required for its nuclear
localization 46,47. Notably, we also identified two positively selected codons (L488, V489)
in the B30.2 domain that are located directly upstream of amino acids 491-494 (Fig 2.1b
Table 2.3).

2.3.2

Genetic Variation in the Human TRIM22 Gene

Since TRIM22 is an integral component of the host antiviral response, and since it has
been linked to a number of diseases, we also had an interest in its evolutionary pattern
among humans. To examine genetic variation in the human TRIM22 gene, we compiled a
list of known nsSNPs in the TRIM22 coding region using the National Center for
Biotechnology Information (NCBI) dbSNP database. To date, 64 nsSNPs and 2 indels
have been identified in the exons of human TRIM22, most of which are found in its
B30.2 domain. The majority of these nsSNPs result in missense variations; however,
several generate truncated versions of the TRIM22 protein (nonsense and frameshift
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variations). To identify nsSNPs that may play important roles in the activity of human
TRIM22, we used a program called Sorting Intolerant From Tolerant (SIFT) to predict
their functional effects

48

. SIFT analysis predicted that 23 nsSNPs were deleterious to

TRIM22 function and 33 nsSNPs were tolerated. Paradoxically, two of the potentially
deleterious nsSNPs (rs192306924:C>A, rs1063303:G>C) were located at amino acid
sites evolving under strong positive selection in mammals (Table 2.2). Due to its high
prevalence in the human population, we selected nsSNP rs1063303:G>C for further
analysis and characterization.
The guanine (G) to cytosine (C) nucleotide change in nsSNP rs1063303:G>C results in
an arginine (R) to threonine (T) amino acid change at position 242 in the TRIM22 protein
(Fig 2.3a). To determine its prevalence in the human population, we obtained frequency
data from four different ethnic populations using the 1000 Genomes database

35

.

Interestingly, we observed large differences in the frequency of nsSNP rs1063303:G>C
among various ethnic groups. For example, 31% of European (EUR) individuals were
homozygous for the nsSNP (C/C) genotype; however, only 3% of Asian (ASN)
individuals were homozygous for C/C. African (AFN) and American (AMR) populations
had intermediate nsSNP frequencies, with 15% and 19% of individuals who were
homozygous for the C/C genotype, respectively (Fig 2.3b). An alignment of amino acid
site 242 in mammals revealed that the ancestral allele (G) was highly conserved in
hominoids (HOM) and Old World monkeys (OWM), but variable in New World
monkeys (NWM) and other mammals (Fig 2.3c). The reason for these frequency
differences among humans for nsSNP rs1063303:G>C is unknown.
Tests for Selective Neutrality
A recent genome-wide scan of two ethnic populations identified TRIM22 as one of 60
‘extreme’ genes undergoing balancing selection in humans

49

. To distinguish between a

neutrally evolving site under mutation-drift equilibrium and a site evolving under nonneutral processes such as balancing selection, we performed both the Tajima’s D and
Fu’s FS tests for neutrality on the TRIM22 rs1063303 variant. These two tests are based
on the principle that a recent population expansion associated with a non-neutral process
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Figure 2.3: Genetic variation at amino acid site 242 in the TRIM22 protein.
(a) Schematic showing the approximate location of nsSNP rs1063303:G>C in the human
TRIM22 protein. Inset shows the nucleotide (red) and amino acid changes for nsSNP
rs1063303:G>C. C15/18: two cysteine residues required for E3 ligase activity; C97,
H100: zinc finger motif in the BB2 domain; predicted CC region; NLS. The ‘antiviral
patch’ refers to several residues previously shown to be a major specificity determinant
for TRIM5α-mediated anti-HIV activity

18

. (b) Genotype frequency data for nsSNP

rs1063303:G>C in African (AFR) (n= 246), American (AMR) (n= 181), Asian (ASN)
(n= 286), and European (EUR) (n= 379) 1000 Genomes populations

35

. For each

population, the percentage of wild type homozygotes (GG), heterozygotes (GC), and
nsSNP homozygotes (CC) are colored green, red, or blue, respectively. (c) Sequence
alignment of nsSNP rs1063303:G>C in HOM and OWM (left) as well as NWM and
additional mammals (right). Amino acid changes at site 242 (location of nsSNP
rs1063303:G>C in human TRIM22) are denoted by an asterisk and highlighted in bold.
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Figure 2.3

Figure 2.3: Genetic variation at amino acid site 242 in the TRIM22 protein.
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will detect a shift in the allele frequency spectrum compared to a neutral Wright-Fisher
model. As shown in Table 2.4, Tajima’s D values were positive for all populations,
indicating an excess of intermediate frequency nucleotide site variants compared to the
expectation under a neutral model of evolution. These deviations from neutrality were
significant (P <0.05) for the AFR, AMR and EUR populations, but not for the ASN
population. Similarly, the results of Fu’s FS test also showed largely positive values for
AFR, AMR and EUR populations, indicating an excess of intermediate haplotypes over
that expected under neutrality. None of the FS coefficients were considered significant at
the 5% level (P <0.02); however, the FS coefficients for AFR, AMR and EUR
populations approached significance.

2.3.3 Functional Analysis of the rs1063303:G>C Polymorphism
To investigate whether nsSNP rs1063303:G>C was deleterious to TRIM22 function, we
transfected human cells with an empty vector control plasmid (pEV), a plasmid encoding
flag-tagged wild type TRIM22 (pWT-T22), or a plasmid encoding flag-tagged TRIM22
with the R242T variation (pSNP-T22). Total RNA was isolated 24 hours posttransfection, reverse-transcribed into cDNA and subjected to quantitative polymerase
chain reaction (qPCR). Surprisingly, cells transfected with pSNP-T22 exhibited an
average 40-fold increase in TRIM22 mRNA compared to cells transfected with pWT-T22
(p= 0.0001, unpaired Student’s t test) (Fig 2.4a). Whole cell lysates from similarly
transfected cells were subjected to Western blot analysis using anti-flag to analyze
TRIM22 levels. Densitometric analysis of Western blots after normalization to β-actin
levels and transfection efficiency revealed that TRIM22 protein levels were 10.3 fold
higher in cells transfected with pSNP-T22 compared to cells transfected with pWT-T22
(Fig 2.4b). We also examined the effect of nsSNP rs1063303:G>C on the sub-cellular
localization of TRIM22 using confocal microscopy. Consistent with previous reports,
WT-T22 protein localized predominantly in the nucleus and formed punctate bodies
25,50,51

(Fig 2.4c). In contrast, SNP-T22 protein localized diffusely in both the cytoplasm

and the nucleus.
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Table 2.4
Table 2.4: Results of Tajima’s D and Fu’s FS neutrality tests.

Population
African (AFR)
Asian (ASN)
American (AMR)
European (EUR)

Tajima’s D
2.56
0.82
2.49
2.79

p-value
0.028
0.251
0.031
0.017

Fu’s FS
2.06
0.29
1.83
2.51

p-value
0.050
0.439
0.065
0.028
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Figure 2.4: nsSNP rs1063303:G>C alters TRIM22 expression and antiviral activity.
(a) Total RNA was harvested from HeLa cells transfected with empty vector control
plasmid (pEV), plasmid expressing wild type TRIM22 (pWT-T22) (rs1063303:G), or
TRIM22 plasmid containing nsSNP rs1063303:G>C (pSNP-T22). RNA was reverse
transcribed into cDNA and quantified using qPCR. Data shown as the fold change
relative to wild type TRIM22 mRNA levels after normalization to β-actin levels. P=
0.0001 unpaired Student’s t test. (b) HeLa or HOS cells were transfected with equivalent
amounts of one of the following plasmids: pEV, flag-tagged pWT-T22, or flag-tagged
pSNP-T22. TRIM22 protein was detected via Western blotting using an anti-flag
antibody. β-actin was used as a loading control. (c) Confocal immunofluorescence
microscopy of HeLa cells transiently transfected with pEV, pWT-T22 or pSNP-T22.
HeLa cells were fixed 24 hours post-transfection and TRIM22 localization was detected
using an anti-flag antibody (green). Images shown represent optical slices taken through
the center of cells from a series of z-stack images with a 63x Plan-Apochromat oil
immersion objective lens (Numerical Aperture = 1.4). DAPI staining was used to
visualize the nuclei (blue). Scale bars = 10 µm. (d) Lysates from HeLa cells coexpressing the full-length replication-competent HIV-1 plasmid (pR9) and increasing
concentrations of either pWT-T22 or pSNP-T22 were resolved by SDS-PAGE and
subjected to Western blotting using anti-p24CA or anti-β-actin (β-actin was used as a
loading control. Data shown are representative of at least three independent experiments.
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Figure 2.4
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Figure 2.4: nsSNP rs1063303:G>C alters TRIM22 expression and antiviral activity.
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Previous studies have demonstrated that TRIM22 can inhibit HIV-1 particle production
in human cells

20–23

. To assess the impact of nsSNP rs1063303:G>C on TRIM22’s

antiviral activity, human osteosarcoma (HOS) cells or HeLa cells were co-transfected
with a plasmid encoding replication-competent proviral HIV-1 (pR9) and either pWTT22 or pSNP-T22. HIV-1 Gag is expressed as the Pr55Gag polyprotein, which includes
the matrix (p17MA), capsid (p24CA) and nucleocapsid (p7NC) proteins. Pr55Gag is
proteolytically cleaved into MA, CA and NC proteins during the assembly/budding
process. Intracellular Gag protein levels were measured by quantitative Western blotting
using anti-p24CA. Cells expressing increasing concentrations of WT-T22 exhibited
decreasing levels of intracellular HIV-1 Gag protein expression. Cells expressing
increasing concentrations of SNP-T22 did not exhibit a substantial reduction in
intracellular Gag protein production (Fig 2.4d). Collectively, these data show that the
rs1063303:G>C variant had an inverse functional impact where it increased TRIM22
expression and decreased the antiviral activity of TRIM22.

2.4 Discussion
Recent studies on host restriction factors have used an evolutionary approach to identify
amino acid residues that are required for their antiviral activity. These studies exploit the
evolutionary ‘arms race’ that occurs between host restriction factors and viruses as they
compete to gain an evolutionary advantage over each other. As a result of this
evolutionary ‘battle’, many host restriction factors contain genetic signatures of positive
selection, particularly at amino acid sites that interact with viral antagonists

13–15

. Here,

we used a similar evolutionary approach to analyze TRIM22 sequences spanning >100
million years of evolution. In addition to the positively selected residues previously
identified in the coiled-coil and B30.2 domains

12

, we identified positively selected

residues in several other domains of TRIM22. We also showed that the human TRIM22
gene contains multiple nsSNPs with the potential to alter TRIM22 function and identified
a highly prevalent nsSNP in TRIM22 that alters its expression and antiviral activity
against HIV-1 replication.
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Positively selected residues are often located near protein binding sites and tend to be
solvent-exposed. In addition, these residues typically occur in clusters with other
positively selected residues

52

. Although the tertiary structure of TRIM22 has not yet

been resolved, its primary amino acid sequence contains a number of putative protein
binding motifs. For example, RING domains with E3 ligase activity bind E2 conjugating
enzymes via their zinc finger motifs to mediate ubiquitin transfer to a substrate protein 45.
TRIM22 contains a zinc finger motif in its RING domain that facilitates E3 ligase activity
in combination with the E2 enzyme UbcH5b 9. TRIM22 also contains a second zinc
finger motif in its BB2 domain, a bipartite nuclear localization signal in its Spacer 2
domain, and a short sequence in its B30.2 domain that is required for its nuclear
localization (amino acids 491-494)

46,47

. Remarkably, 13 of the 28 positively selected

residues that we identified in TRIM22 are located within 15 amino acids of one of these
motifs (Figure 2.1c). Most are not located directly within the motifs, but instead cluster
around them in groups of three or four. Although in TRIM22 none of these motifs have
been explicitly shown to interact with other proteins, this type of evolutionary pattern
suggests that they may indeed function as protein binding sites.
We identified a number of positively selected residues in the B30.2 domain of TRIM22
that correspond in location and spacing to positively selected residues in TRIM5α. In
addition, similar to TRIM5α, we showed that the majority of these residues are located in
one of four variable regions (v1-v4). In rhesus monkey TRIM5α, v1-v4 form flexible
loops that map to the structurally divergent face of the protein 53. Multiple residues within
TRIM5α v1-v4 regions are critical for virus restriction, including several positively
selected sites. For example, residues 324 and 332 in the v1 region and residues 385 and
389 in the v2 region are required for TRIM5α-mediated inhibition of HIV-1 and/or SIV
in hominoids 18,41,42. Moreover, in the v3 region, residues 409 and 410 are required for NMLV restriction by human TRIM5α

43

. Unlike TRIM5α, there are no residues evolving

under positive selection in the v3 region of TRIM22. Thus, it is possible that this region
of TRIM22 is not subject to strong evolutionary pressures (e.g. from viral antagonists).
Consistent with this, TRIM22 does not inhibit N-MLV replication in human cells

23

.

Similar to TRIM5α, TRIM22 has been shown to interact with the HIV-1 Gag and/or
capsid protein

23,54,55

. Because the v1-v4 regions of rhesus monkey TRIM5α form an
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extensive HIV-1 capsid binding interface, it is possible that these regions are also
important for TRIM22 and HIV-1 Gag/capsid binding. It will be interesting to learn
whether the v1, v2, and v4 regions of TRIM22 are targeted by an HIV-1 antagonist,
thereby placing evolutionary pressure on TRIM22 to, for example, maintain its
interaction with the HIV-1 Gag protein.
Genes that evolve under positive selection during interspecies evolution also tend to be
highly polymorphic in humans

56

. We demonstrate here that the human TRIM22 gene

contains multiple nsSNPs and that many of these nsSNPs are predicted to be deleterious
to

protein

function.

We

characterized

one

potentially

deleterious

nsSNP

(rs1063303:G>C) that is highly prevalent in the human population and show that it is
located at an amino acid site in TRIM22 that has undergone strong positive selection in
mammals. Of interest, the frequency of nsSNP rs1063303:G>C varies considerably
among different ethnic populations. Ethnic differences in nsSNP frequencies have been
reported for many genes, including several nsSNPs in toll-like receptor genes and a
number nsSNPs associated with autoimmune disease

57,58

. It is possible that the

differences in nsSNP rs1063303:G>C frequency are due to differential prevalence of
certain diseases in different geographic locations. For example, one nsSNP in the βglobin gene is highly prevalent in regions that are endemic for malaria, but not in nonendemic regions. This nsSNP produces an abnormal version of the β-globin protein
called hemoglobin S (HbS), which causes sickle-cell disease in homozygotes (HbSS), but
affords protection from malaria in heterozygotes (HbAS)

59

. As such, the ‘deleterious’

HbS allele is maintained at higher than expected frequencies in certain populations. This
type of evolution, whereby polymorphism is maintained in a population because it
confers a selective advantage, is referred to as balancing selection 30.
Several host restriction factors have been shown to undergo balancing selection in
primates, including human TRIM5α and primate OAS1 60–62. Moreover, a recent genomewide scan of two ethnic populations identified TRIM22 as one of 60 ‘extreme’ genes
undergoing balancing selection in humans 49. Given its high frequency in certain human
populations and history of positive selection in mammals, it is possible that nsSNP
rs1063303 confers some selective advantage in heterozygotes and is maintained by
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balancing selection in these populations. For example, the nsSNP allele may be more
advantageous against a virus other than HIV-1 that is particularly prevalent in certain
geographic locations. The overall positive values resulting from the Tajima’s D and Fu’s
FS tests suggest that there is an excess of intermediate frequency of the TRIM22
rs1063303 alleles, which can imply a decrease in population size and/or balancing
selection. Together, our analyses reveal a complex and multifaceted scenario for the
evolution of nsSNP rs1063303 and the TRIM22 gene.
Other retroviral restriction factors, such as APOBEC3G and TRIM5α, contain nsSNPs
that alter their antiviral activity against HIV-1. For example, the H186R variant in
APOBEC3G is strongly associated with CD4+ T-cell decline and accelerated disease
progression in African Americans. Interestingly, this association is not present in
Caucasian individuals or Europeans

63–65

. A number of TRIM5α nsSNPs, including

H43Y, R136Q, and G249D, also correlate with notable differences in HIV-1 acquisition
and disease progression

66,67

. We showed here that a TRIM22 clone containing the

ancestral allele rs1063303:G potently inhibited particle production of full-length
replication-competent HIV-1; whereas a TRIM22 clone containing the derived allele
rs1063303:C drastically increased the amount of TRIM22 mRNA and protein in human
cells, altered its sub-cellular localization, and failed to inhibit HIV-1 particle production.
This finding contrasts a previous study by Ghezzi and colleagues

68

who showed that a

TRIM22 clone containing the derived allele rs1063303:C inhibited expression of
luciferase from a reporter construct containing luciferase under control from the HIV-1
long terminal repeat (LTR) promoter. A likely reason for this difference could be
attributed to differences between the two systems where we used full-length HIV-1 and
they used only the HIV-1 LTR, implying that other HIV-1 proteins (e.g. antagonists) may
affect the antiviral activity of TRIM22. In addition, Ghezzi and colleagues 68 showed that
SNP rs1063303 alone was not associated with disease progression, however a TRIM22
haplotype involving specific SNP alleles of rs1063303 and rs7935564 was found more
frequently in advanced progressors than in long-term non-progressors. Together, these
findings highlight the importance of function-altering TRIM22 SNPs and haplotypes,
warranting further investigation into their clinical significance.
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It remains unclear how TRIM22 rs1063303:G>C increases TRIM22 mRNA and protein
levels. Non-synonymous SNPs in the gene coding region are typically expected to alter
protein function, expression, conformation or stability. It is possible that the amino acid
change associated with rs1063303 may affect TRIM22 protein stability or its ability to
undergo self-ubiquitination and proteasomal degradation. TRIM22 has been shown to
inhibit expression from the promoters of HIV-1 and hepatitis B virus 20,22,25. The different
TRIM22 SNP rs1063303 variants may exhibit reduced or enhanced TRIM22 activity,
thereby affecting gene expression from TRIM22 target promoters such as the HIV-1 LTR
and/or the promoter controlling expression of TRIM22 itself. Other explanations for the
observed difference in TRIM22 RNA and protein levels include, among others, structural
changes in the RNA transcript that can in turn influence splicing, stability or translational
regulation. Further studies are required to determine precisely how TRIM22
rs1063303:G>C affects TRIM22 mRNA and protein levels.
Interestingly, TRIM22 mRNA expression levels have previously been shown to influence
HIV infection in vivo. In the Centre for the AIDS Programme of Research in South
Africa (CAPRISA) study cohort, expression of TRIM22 mRNA was positively correlated
with CD4+ T-cell count and negatively correlated with viral load

69

. Conversely, a study

in the Swiss HIV study cohort found that expression of TRIM22 mRNA was positively
correlated with HIV-1 RNA levels at the viral set point

70

. Given the differences in

nsSNP rs1063303 frequency among different ethnic populations, it is interesting to note
that the CAPRISA cohort is comprised entirely of black African females, whereas the
Swiss cohort is comprised entirely of Caucasian individuals. It is tempting to speculate
that the high prevalence of nsSNP rs1063303:G>C in Caucasians is at least partially
responsible for the increased viral load in these individuals. Further studies that include
populations from different geographic regions are needed to determine if and how nsSNP
rs1063303 influences HIV-1 infection in these different groups and if other SNPs are
involved.
Previous studies on host restriction factors have shown that they are rapidly evolving
genes that must remain genetically ‘flexible’ to adapt to changing pathogenic landscapes.
Although their flexibility is integral to host survival, it can also be detrimental to protein
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function. Our study characterizes the effects of nsSNP rs1063303:G>C on TRIM22
protein function and provides insight into the ancient and extensive genetic variation
within the TRIM22 gene.
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Chapter 3

3

In silico analysis of functional single nucleotide
polymorphisms in the human TRIM22 gene 2

TRIM22 is an evolutionarily ancient protein that plays an integral role in the host innate
immune response to viruses. The antiviral TRIM22 protein has been shown to inhibit the
replication of a number of viruses, including HIV-1, HBV and IAV. TRIM22 expression
has also been associated with multiple sclerosis, cancer, and autoimmune disease. In this
study, multiple in silico computational methods were used to identify nsSNPs that are
deleterious to TRIM22 structure and/or function. A sequence homology-based approach
was adopted for screening nsSNPs in TRIM22, including six different in silico prediction
algorithms and evolutionary conservation data from the ConSurf web server. In total, 14
high-risk deleterious nsSNPs were identified in TRIM22, most of which are located in a
protein-protein interaction module called the B30.2 domain. Additionally, 9 of the top
high-risk deleterious nsSNPs altered the putative structure of TRIM22’s B30.2 domain,
particularly in the surface-exposed v2 and v3 regions. These same regions are critical for
retroviral restriction by the closely-related TRIM5α protein. A number of putative
structural and functional residues, including several sites that undergo post-translational
modification (PTM), were also identified in TRIM22. This study is the first extensive in
silico analysis of the highly polymorphic TRIM22 gene and will be a valuable resource
for future targeted mechanistic and population-based studies.

2

The material contained in this chapter was published in: Kelly, JN and Barr, SD. In silico analysis of
functional single nucleotide polymorphisms in the human TRIM22 gene. PLoS One. 9 (7): e101436 (2014).
Copyright 2014. Open-Access License
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3.1 Introduction
SNPs, defined as single base changes in a DNA sequence, are responsible for the
majority of genetic variation in the human population. Although many SNPs are
phenotypically neutral, nsSNPs often have deleterious effects on protein structure or
function. nsSNPs are located in protein coding regions and generate an amino acid
substitution in their corresponding protein product. As such, nsSNPs can alter the
structure, stability, and/or function of proteins, and are often associated with human
disease. Indeed, previous studies have shown that approximately 50% of the mutations
involved in inherited genetic disorders are due to nsSNPs

1–3

. Recently, a number of

genetic studies have focused on nsSNPs in innate immune genes. These studies have
identified multiple nsSNPs that influence susceptibility to infection, as well as the
development of inflammatory disorders and autoimmune diseases

4–9

. Nonetheless,

because innate immune genes are often highly polymorphic, many nsSNPs in these genes
remain uncharacterized.
Members of the TRIM protein family are involved in a wide range of biological
processes related to innate immunity

10–12

. TRIM proteins are defined by their RBCC

motif, which consists of a RING domain, one or two BB domains, and a predicted CC
region. Most TRIM proteins also contain a protein-protein interaction module called a
B30.2 domain at their C-terminus

13–15

. Many TRIM proteins are induced by IFN

signaling and several possess antiviral activity, in particular against the Retroviridae
family of viruses. Recent studies have implicated TRIM proteins in the regulation of
pathogen-recognition and important immune signaling pathways, a finding that has
sparked considerable interest in understanding how TRIM family proteins contribute to
the innate immune response 16–21.
One well-studied member of the TRIM family, TRIM5α, is required for the speciesspecific block against HIV-1 replication in primate cells

22–24

. Recently, TRIM5α was

also shown to promote innate immune signaling and to function as an innate immune
sensor for the retrovirus capsid lattice in vitro. Previous studies have established that
TRIM5α binds to the HIV-1 capsid protein in the mature viral core via four variable
regions (v1-v4) in its B30.2 domain

25,26

. The v1 or ‘antiviral patch’ region was
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previously shown to be the major determinant for species-specific HIV-1 restriction by
TRIM5α. Mutations in the other variable regions (v2-v4) have also been shown to
interfere with TRIM5α-mediated restriction of HIV-1, SIV, and/or N-MLV

22,26–29

.

Notably, analogous variable regions are found in several other B30.2-containing TRIM
proteins 30–32.
Human TRIM5 is located on chromosome 11 within a cluster of four closely-related
TRIM genes that also includes TRIM6, TRIM22, and TRIM34. TRIM5 and TRIM22 have
an ancient and dynamic evolutionary relationship, whereby both genes have evolved
under positive selection for millions of years in a mutually exclusive manner 33. Similar
to TRIM5α, TRIM22 has also been shown to inhibit HIV-1 replication in a number of
human cell lines and primary monocyte-derived macrophages

34–37

. TRIM22 expression

levels have also been shown to influence HIV-1 infection in vivo

38–40

. Interestingly,

nsSNPs in TRIM5α, including H43Y, R136Q, and G249D, significantly alter HIV-1
acquisition and disease progression in humans

41–44

. Despite TRIM22’s highly

polymorphic nature, it is unknown how nsSNPs affect its biological and/or antiviral
functions. Here, multiple in silico computational methods were used to identify nsSNPs
in the TRIM22 gene that are predicted to be highly deleterious to TRIM22 structure
and/or function. A total of 14 high-risk deleterious nsSNPs were identified, including 9
that altered the putative structure of TRIM22’s B30.2 domain. A number of sites
predicted to undergo PTM (ubiquitylation, sumoylation, phosphorylation) were also
identified. This is the first extensive in silico analysis of the TRIM22 gene and will
establish a strong foundation for future structure-function and population-based studies.

3.2 Materials and methods
3.2.1

Retrieval of nsSNP data

Polymorphism data for the TRIM22 gene was retrieved from the following databases:
UniProt (http://www.uniprot.org), NCBI dbSNP (https://www.ncbi.nlm.nih.gov/SNP/),
1000 Genomes (http://www.1000genomes.org/), and the Ensembl genome browser
(http://www.ensembl.org/index.html) 45–47.
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3.2.2

In silico nsSNP analysis

Functional effects of nsSNPs were predicted using the following in silico algorithms:
Polymorphism Phenotyping v 2 (PolyPhen-2) (http://genetics.bwh.harvard.edu/pp2)
Sorting Intolerant From Tolerant (SIFT) (http://sift.jcvi.org/)
(http://snpanalyzer.uthsc.edu/)

50

49

48

,

, nsSNP Analyzer

, Predictor of Human Deleterious Single Nucleotide

Polymorphisms (PhD-SNP) (http://snps.biofold.org/phd-snp/phd-snp.html)

51

, SNPs and

Gene Ontology v 3 (SNPs&GO) (http://snps-and-go.biocomp.unibo.it/snps-and-go/)

52

,

and PMut (mmb2.pcb.ub.es:8080/PMut) 53. nsSNPs predicted to be deleterious by at least
4 in silico algorithms were categorized as high-risk nsSNPs and were selected for further
analysis.

3.2.3

Phylogenetic analysis

Evolutionary conservation of amino acid residues in TRIM22 was determined using the
ConSurf web server (consurf.tau.ac.il/)

54

. In ConSurf, 14 TRIM22 homologues were

aligned and position-specific conservation scores were calculated using an empirical
Bayesian algorithm (Conservation Scores: 1-4 Variable, 5-6 Intermediate, and 7-9
Conserved). Putative functional and structural residues were also predicted using
ConSurf by combining evolutionary conservation scores with solvent accessibility
predictions (Fig 3.1). Highly conserved amino acids that were located at high-risk nsSNP
sites were selected for further analysis.

3.2.4

Comparative molecular modeling

3D-Jigsaw (v 2.0) was used to generate 3D structural models for the B30.2 domain of
wild type TRIM22 (UniProtKB Q8IYM9) and the 9 high-risk nsSNPs. For each model,
only the B30.2 domain sequence was submitted. 3D-Jigsaw searches multiple sequence
databases (e.g. PFAM and PDB) and builds structures based on homologues of known
structure

55

. Models were viewed using the Swiss-PdbViewer (v 4.1)

56

. Tm-Align was

used to calculate Tm-scores and root mean square deviation (RMSD) 57. The total energy
after minimization (TEM) was calculated via the L-BFGF method using the NOMADRef Gromacs server (http://lorentz.immstr.pasteur.fr/nomad-ref.php) 58.
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3.2.5

Prediction of post-translational modification sites

Putative ubiquitylation sites were predicted using the UbPred (www.ubpred.org) and
BDM-PUB (bdmpub.biocuckoo.org) programs 2. For UbPred, lysine residues with a
score of ≥ 0.62 were considered ubiquitylated. For BDM-PUB, the balanced cut-off
option was selected. Putative sumoylation sites were predicted using the SUMOplot
(http://www.abgent.com/sumoplot) and SUMOsp v 2.0 (http://sumosp.biocuckoo.org/)
programs

59

. For SUMOplot, only high probability motifs with a score > 0.5 were

considered sumoylated. Medium level threshold with a 2.64 cut-off value was selected
for SUMOsp 2.0 analysis. Putative phosphorylation sites were predicted using GPS 2.1
(http://gps.biocuckoo.org/) and NetPhos 2.0 (http://www.cbs.dtu.dk/services/NetPhos/)
60,61

. For GPS 2.1 analysis, high level threshold with cut-off values ranging from 0.776-

11 were selected. For NetPhos 2.0, serine, threonine, and tyrosine residues with a score of
> 0.5 were considered phosphorylated. Sumo-interacting motifs (SIM) were identified
manually and compared to experimentally verified SIMs in the scientific literature 62,63.

3.2.6

Protein stability analysis

I-Mutant version 2.0, an online support vector machine tool based on the ProTherm
database, was used to evaluate nsSNP-induced changes in protein stability

64

. nsSNP

protein-coding sequences were submitted to I-Mutant 2.0 for 2 high-risk nsSNPs that
coincide with putative PTM sites, 5 low-risk nsSNPs that coincide with putative PTM
sites, and 12 additional high-risk nsSNPs that do not coincide with predicted PTM sites.
I-Mutant 2.0 estimates the free energy change value (DDG) by calculating the unfolding
Gibbs free energy value (∆G) for the wild type protein and subtracting it from that of the
mutant protein (DDG or ∆∆G = ∆G mutant – ∆G wild type). It also predicts the sign
(increase or decrease) of the free energy change value (DDG), along with a reliability
index for the results (RI: 0-10, where 0 is the lowest reliability and 10 is the highest
reliability). A DDG < 0 corresponds to a decrease in protein stability, whereas a DDG > 0
corresponds to an increase in protein stability. However, according to the ternary
classification system (SVM3), a large decrease in protein stability corresponds to a DDG
< -0.5 and a large increase in protein stability corresponds to a DDG > 0.5. In contrast,
DDG values that fall between -0.5 and 0.5 correspond to relatively neutral protein
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stability

64,65

. The pH was set to 7 and the temperature was set to 25°C for all

submissions.

3.3 Results and Discussion
3.3.1

SNP dataset

SNP data for the TRIM22 gene was retrieved from the NCBI dbSNP database, the
Ensembl genome browser, and the UniProt database

45–47

. According to these databases,

the TRIM22 gene contains a total of 64 nsSNPs plus 8 SNPs in its 5’ UTR and 32 SNPs
in its 3’ UTR. Of the 64 nsSNPs, 10 generate truncated versions of the TRIM22 protein
(nonsense and frameshift mutations), whereas 54 introduce single amino acid changes
(missense mutations) into TRIM22 (Table 3.1). To determine whether a given missense
mutation affected TRIM22 function, we subjected the latter 54 nsSNPs to multiple in
silico SNP prediction algorithms. The results, which are summarized in Table 3.2,
identified a number of nsSNPs with a high probability of being deleterious to TRIM22
structure and/or function.

3.3.2

In silico nsSNP analysis

Our analyses included the following six in silico SNP prediction algorithms: Polyphen-2,
SIFT, nsSNP Analyzer, PhD-SNP, PMUT, and SNPs&GO

48–52,66

. According to our

Polyphen-2 results, 13 nsSNPs (23%) are damaging to TRIM22 function, whereas 33
nsSNPs (59%) are benign. An additional 10 nsSNPs (18%) are predicted to be ‘possibly
damaging’ by Polyphen-2 (Table 3.2). Our SIFT analysis predicted that 19 nsSNPs (34%)
are deleterious to TRIM22 function and 37 nsSNPs (66%) are tolerated. On the contrary,
the nsSNP Analyzer predicted that 21 nsSNPs (38%) cause disease and 35 nsSNPs (62%)
are neutral (Table 3.2). Both PhD-SNP and PMUT predicted that 25 (45%) nsSNPs are
pathological and 31 (55%) nsSNPs are neutral (Table 3.2). SNPs&GO analysis, which
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Table 3.1
Table 3.1 In silico prediction results for nsSNPs in TRIM22.

nsSNP ID
rs368531868
rs200816458
rs372487646
rs375540431
rs11541920
rs192306924
rs201847190
rs182619286
rs199625192
rs200668710
rs141180305
rs370446835
rs373103298
rs371543745
rs187628129
rs368058642
rs200924168
rs375795798
rs7935564
rs201531661

Mutation 1
D2E
V7A
E10D
I43M
V47E
T61N
L68R
R69Q
H73R
E83K
E90K
D95A
H99Y
L104F
Q105K
E135K
R150K
I152K
D155N
K185Q

Polyphen-2
Benign
Benign
Benign
Benign
Benign
Benign
Probably damaging
Possibly damaging
Probably damaging
Benign
Benign
Possibly damaging
Benign
Probably damaging
Benign
Possibly damaging
Benign
Benign
Benign
Benign

SIFT
Tolerated
Tolerated
Deleterious
Tolerated
Tolerated
Deleterious
Deleterious
Tolerated
Deleterious
Tolerated
Tolerated
Tolerated
Tolerated
Deleterious
Tolerated
Tolerated
Tolerated
Tolerated
Deleterious
Tolerated

nsSNP Analyzer
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Disease
Neutral
Disease
Neutral
Neutral
Neutral
Neutral
Disease
Neutral
Disease
Neutral
Neutral
Disease
Neutral

PhD-SNP
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Disease
Disease
Disease
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Disease
Neutral
Disease
Neutral
Neutral

PMUT
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Pathological
Pathological
Neutral
Pathological
Pathological
Neutral
Neutral
Pathological
Pathological
Neutral
Pathological
Neutral
Pathological

SNPs&Go
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Disease
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Disease
Neutral
Neutral
Neutral
Neutral

# Del 2
0
0
1
0
0
1
5
2.5
5
0
1
1.5
0
3
1
4.5
0
2
2
1

102

rs368924880
rs2291843
rs374292901
rs201523218
rs1063303
rs61735273
rs370736499
rs143605305
rs112606816
rs181298463
rs73404240
rs368682946
rs12364019
rs372042006
rs75023388
rs201494620
rs368220166
rs199987600
rs371728648
rs200243523
rs191847788
rs375595000
rs369734227
rs150095329
rs370495523
rs200915295
rs187416296

N196S
T232A
I234N
R239Q
R242T
S244L
I253T
V255I
L264M
R279Q
T294K
A315V
R321K
R327C
R327H
T330I
K332N
A341T
G346S
V359I
K364N
P403T
I410V
T415I
L432W
F435C
R442C

Benign
Benign
Probably damaging
Benign
Benign
Probably damaging
Benign
Benign
Possibly damaging
Benign
Benign
Benign
Possibly damaging
Benign
Benign
Benign
Benign
Benign
Probably damaging
Possibly damaging
Possibly damaging
Probably damaging
Possibly damaging
Benign
Probably damaging
Benign
Probably damaging

Tolerated
Tolerated
Deleterious
Tolerated
Tolerated
Deleterious
Tolerated
Tolerated
Tolerated
Tolerated
Tolerated
Tolerated
Deleterious
Tolerated
Tolerated
Tolerated
Tolerated
Tolerated
Deleterious
Tolerated
Deleterious
Deleterious
Tolerated
Tolerated
Deleterious
Deleterious
Tolerated

Neutral
Neutral
Disease
Neutral
Disease
Disease
Neutral
Neutral
Neutral
Neutral
Disease
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Neutral
Disease

Neutral
Neutral
Disease
Disease
Neutral
Disease
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Disease
Neutral
Disease
Disease
Neutral
Disease
Disease
Disease
Disease
Neutral
Neutral
Neutral
Disease
Disease

Neutral
Neutral
Pathological
Pathological
Pathological
Neutral
Neutral
Neutral
Neutral
Pathological
Pathological
Neutral
Neutral
Pathological
Pathological
Neutral
Neutral
Neutral
Pathological
Neutral
Neutral
Pathological
Neutral
Neutral
Pathological
Neutral
Pathological

Neutral
Neutral
Neutral
Neutral
Neutral
Disease
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Disease
Disease
Disease
Neutral
Neutral
Neutral
Neutral
Disease

0
0
5
2
2
5
0
0
0.5
1
2
0
1.5
2
1
1
1
0
5
3.5
4.5
6
1.5
1
4
2
5
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rs370420711
rs377529439
rs371028900
rs371139090
rs138529937
rs368256788
rs267603016
rs200638791
rs61735327
rs200148337
1
2

A451V
F456I
T460I
G471E
C472S
R473H
P480S
P484S
M491I
C494F

Possibly damaging
Probably damaging
Probably damaging
Benign
Probably damaging
Benign
Probably damaging
Possibly damaging
Benign
Probably damaging

Deleterious
Deleterious
Deleterious
Tolerated
Tolerated
Tolerated
Deleterious
Deleterious
Tolerated
Deleterious

Neutral
Disease
Disease
Neutral
Neutral
Neutral
Disease
Neutral
Disease
Disease

Disease
Disease
Disease
Disease
Neutral
Disease
Disease
Disease
Disease
Disease

Pathological
Neutral
Pathological
Neutral
Pathological
Neutral
Pathological
Pathological
Pathological
Pathological

Neutral
Disease
Disease
Neutral
Neutral
Neutral
Disease
Disease
Neutral
Disease

3.5
5
6
1
2
1
6
4.5
3
6

Mutation: Wild type residue/amino acid position/nsSNP residue.
# Del: Total number of deleterious predictions; A score of 0.5 was assigned to amino acids that were predicted to be ‘possibly damaging’ by Polyphen-2.
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Table 3.2
Table 3.2 Summary of in silico prediction results for all nsSNPs in TRIM22.

Prediction
Deleterious
PD 2
Benign
Disease
Neutral
1
2

Total number of nsSNPs (%) 1
Polyphen-2 SIFT
nsSNP
Analyzer
13 (23)
19 (34) 10 (18)
33 (59)
37 (66) 21 (38)
35 (62)

PhD-SNP

PMUT

SNPs&GO

25 (45)
31 (55)

25 (45)
31 (55)

11 (20)
45 (80)

Percentage of total nsSNPs (56) are shown in parentheses for each prediction program.
PD: nsSNPs predicted to be ‘possibly deleterious’ by Polyphen-2
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includes information from the Gene Ontology annotation, predicted that 11 nsSNPs
(20%) cause disease and 45 nsSNPs (80%) are neutral (Table 3.2). Interestingly, we
found that the majority of potentially deleterious nsSNPs were located in the B30.2
domain, including 3 nsSNPs that were predicted to be damaging by all six SNP
prediction algorithms (P403T, T460I, and C494F). Because each algorithm uses different
parameters to evaluate the nsSNPs, nsSNPs with more positive results are more likely to
be truly deleterious. Here, we classified nsSNPs as high-risk if they were predicted to be
deleterious by four or more SNP prediction algorithms. 14 nsSNPs met this criteria and
were selected for further analysis (Table 3.3).

3.3.3

Conservation Profile of High-Risk nsSNPs

Amino acids that are involved in important biological processes, such as those located in
enzymatic sites or required for protein-protein interactions, tend to be more conserved
than other residues. As such, nsSNPs that are located at highly conserved amino acid
positions tend to be more deleterious than nsSNPs that are located at non-conversed sites
3,67

. To further investigate the potential effects of the 14 high-risk nsSNPs in Table 3.3,

we calculated the degree of evolutionary conservation at all amino acid sites in the
TRIM22 protein using the ConSurf web server. ConSurf employs an empirical Bayesian
method to determine evolutionary conservation and identify putative structural and
functional residues 54. For the purpose of this study, we focused on amino acid sites that
coincide in location with the 14 high-risk nsSNPs; however, ConSurf also identified a
number of other residues that may be functionally relevant (Fig 3.1).
ConSurf analysis revealed that residues L68, H73, E135, I234, S244, G346, K364, P403,
L432, R442, F456, T460, and C494 are highly conserved (Conservation Score of 7-9). In
addition, ConSurf predicted that T460 was an important structural residue (highly
conserved and buried) and that L68, K364, and P403 were important functional residues
(highly conserved and exposed) (Table 3.4). To identify putative structural and functional
sites, ConSurf combines evolutionary conservation data with solvent accessibility
predictions. Highly conserved residues are predicted to be either structural or functional
based on their location relative to the protein surface or protein core 68. Remarkably, two
of the three high-risk nsSNPs that were predicted to be deleterious by all six SNP
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Table 3.3
Table 3.3: TRIM22 nsSNPs predicted to be functionally significant by four or more
SNP prediction algorithms.

nsSNP ID
rs201847190
rs199625192
rs368058642
rs374292901
rs61735273
rs371728648
rs191847788
rs375595000
rs370495523
rs187416296
rs377529439
rs371028900
rs200638791
rs200148337
1

Mutation
L68R
H73R
E135K
I234N
S244L
G346S
K364N
P403T
L432W
R442C
F456I
T460I
P484S
C494F

# Del: number of deleterious predictions.

Domain
Spacer 1
Spacer 1
Coiled-coil
Spacer 2
Spacer 2
B30.2
B30.2
B30.2
B30.2
B30.2
B30.2
B30.2
B30.2
B30.2

MAF
N/A
0.0005
0.0001
0.0001
0.0354
0.0001
0.0005
0.0001
0.0001
0.0041
0.0001
0.0003
0.0008
N/A

# Del 1
5
5
4.5
5
5
5
4.5
6
4
5
5
6
4.5
6
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Figure 3.1: ConSurf analysis of amino acid residues in the TRIM22 protein.
Schematic showing ConSurf results for the human TRIM22 protein. Amino acids were
ranked on a conservation scale of 1-9 and are highlighted as follows: blue residues (1-4)
are variable, white residues (5) are average, and purple residues (6-9) are conserved.
Residues predicted to be exposed to the surface of the protein are indicated via an orange
letter ‘e’, while residues predicted to be buried are indicated via a green letter ‘b’.
Putative structural residues are demarcated with a blue letter ‘s’ (highly conserved and
buried), whereas putative functional residues are demarcated with a red letter ‘f’ (highly
conserved and exposed).
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Figure 3.1: ConSurf analysis of amino acid residues in the TRIM22 protein.
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Table 3.4
Table 3.4 Conservation profile of amino acids in TRIM22 that coincide with the
location of high-risk nsSNPs.

nsSNP ID
rs201847190
rs199625192
rs368058642
rs374292901
rs61735273
rs371728648
rs191847788
rs375595000
rs370495523
rs187416296
rs377529439
rs371028900
rs200638791
rs200148337
1

Amino Acid
L68
H73
E135
I234
S244
G346
K364
P403
L432
R442
F456
T460
P484
C494

CS 1
8
7
7
7
8
8
9
8
8
7
8
9
6
8

ConSurf prediction
Highly conserved and exposed (f 2)
Exposed
Exposed
Buried
Buried
Buried
Highly conserved and exposed (f 2)
Highly conserved and exposed (f 2)
Buried
Exposed
Buried
Highly conserved and buried (s 3)
Exposed
Buried

CS: Conservation score (1-4= variable, 5-6= intermediate, 7-9= conserved).
f: predicted functional residue
3
s: predicted structural residue
2
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prediction algorithms (P403T and T460I) were also identified as important structural or
functional residues by ConSurf (Table 3.1, Table 3.3). Taken together, our data strongly
suggest that the nsSNPs P403T and T460I are deleterious to TRIM22 structure and/or
function.

3.3.4

Comparative Modeling of High-Risk nsSNPs

To examine whether P403T and T460I altered the 3D structure of TRIM22’s B30.2
domain, we individually substituted each nsSNP into the wild type TRIM22 sequence
and submitted the sequences to 3D-Jigsaw for structural analysis. We also submitted
sequences for the remaining 7 high-risk nsSNPs in the B30.2 domain (i.e. G346S,
K364N, L432W, R442C, F456I, P484S, and C494F) since our in silico and ConSurf
results indicated that these nsSNPs were also highly likely to be deleterious. Theoretical
structural models were generated for each nsSNP using the 3D-Jigsaw program, which
constructs 3D models for proteins based on homologues of known structure 55. We then
used Swiss-PdbViewer to compare each nsSNP model to the predicted 3D-Jigsaw model
of wild type TRIM22 56. All of the nsSNPs altered the putative 3D structure of wild type
TRIM22’s B30.2 domain. G346S, P403T, L432W, F456I, and C494F introduced an
alpha helix into the v2 region, whereas the other 4 nsSNPs introduced beta strands into
the v2 region (Fig 3.2). With the exception of P484S, which introduced an alpha helix
into the v3 region, all of the nsSNP models contained elongated and/or additional beta
strands in the v3 region. Only G346S and F456I altered the v1 region (both introduced an
alpha helix); however, all 9 nsSNPs altered the length and/or number of beta strands in
non-variable regions of the B30.2 domain. Notably, P484S was the only nsSNP model
that contained fewer beta strands than wild type TRIM22 in certain regions (Fig 3.2). The
majority of nsSNP models contained a greater number of beta strands than wild type
TRIM22, resulting in overall net increase in beta strand formation.
To extend our structural analysis, we used Tm-Align to calculate the Tm-score and root
mean square deviation (RMSD) for each nsSNP model. Tm-score is used to assess
topological similarity between wild type and mutant models, whereas RMSD is used to
measure average distance between the α-carbon backbones of wild type and mutant
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Figure 3.2: Structural models for wild type TRIM22 and high-risk nsSNPs in the
B30.2 domain.
Putative structural models for the B30.2 domains of wild type TRIM22 and the 9 highrisk nsSNPs located in the B30.2 domain. Variable regions (v1-v4) are highlighted as
follows: v1 blue, v2 orange, v3 magenta, and v4 green. Non-variable regions are shown
in white and mutated amino acids are shown in yellow. Left image: Enlarged reference
image that illustrates the color and location of each variable region and the color of
mutated amino acids (image shown is the v1-v4 regions of wild type TRIM22 and the
P403 amino acid). Each of the 9 nsSNP images (small images on the right) show the
putative 3D structure of wild type TRIM22’s B30.2 domain on the left and the putative
3D structure of TRIM22’s B30.2 domain with the mutated amino acid (nsSNP) on the
right. The location of the amino acid in question is shown (yellow) on both wild type and
nsSNP structures. All models were generated using the 3D-JigSaw protein comparative
modeling server and SPDBV (v4.1).
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Figure 3.2

Figure 3.2: Structural models for wild type TRIM22 and high-risk nsSNPs in the B30.2 domain.
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models 57,69. A higher RMSD typically indicates greater deviation between wild type and
mutant structures. The Tm-score and RMSD for each nsSNP model is listed in Table 3.4.
The maximum RMSD was 3.04 (R442C), followed by 3.03 (F456I), 3.00 (L432W), 2.96
(G346S), and 2.80 (P484S). RMSD for nsSNPs K364N, P403T, T460I, and C494F
ranged from 1.58 to 1.99 Å. These results indicate that 9 high-risk nsSNPs markedly alter
the putative structure of TRIM22’s B30.2 domain, in particular the surface-exposed v2
and v3 regions, and that they likely induce severe structural changes in the TRIM22
protein.
Importantly, these nsSNPs may decrease flexibility in the v2 and v3 regions of TRIM22.
The v2/v3 regions of wild type TRIM22 are predicted to form relaxed loop segments,
similar to the loops in the recently solved 3D structure of rhesus monkey TRIM5α’s
B30.2 domain

26

. In contrast, the v2 and v3 regions of the nsSNP models contain more

rigid secondary structures, such as alpha helices or beta strands (Fig 3.2). Since loop
flexibility in rhesus monkey TRIM5α is thought to facilitate restriction of divergent
retroviruses and to increase resistance to mutations in the HIV-1 capsid protein, it is
possible that these nsSNPs may impair the antiviral activity and/or breadth of TRIM22.
Further experiments, such as the resolution of wild type TRIM22’s tertiary structure, are
required to address these possibilities.

3.3.5

Prediction of Post-Translational Modification Sites in TRIM22

To investigate how nsSNPs may influence the post-translational modification (PTM) of
TRIM22, we used a variety of in silico prediction tools to identify putative PTM sites in
the TRIM22 protein. PTMs are involved in many biological processes, including a
number of canonical innate immune pathways, and are essential for the regulation of
protein structure and function

59,70–72

. To analyze residues in TRIM22 that may undergo

ubiquitylation or sumoylation, we used the UbPred, BDM-PUB, SUMO-plot, and
SUMOsp 2.0 programs. The GPS 2.1 and NetPhos 2.0 servers were used to predict
serine, threonine, and tyrosine phosphorylation sites in the TRIM22 protein 2,60,61,73.
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Table 3.5
Table 3.5: RMSD (Å) and TM-score for the 9 high-risk nsSNPs in the B30.2 domain
of TRIM22.

nsSNP ID
rs371728648
rs191847788
rs375595000
rs370495523
rs187416296
rs377529439
rs371028900
rs200638791
rs200148337

Mutation
G346S
K364N
P403T
L432W
R442C
F456I
T460I
P484S
C494F

RMSD and Tm-scores were calculated using Tm-Align.

RMSD (Å)
2.96
1.72
1.99
3.00
3.04
3.03
1.76
2.80
1.58

TM-Score
0.75184
0.93911
0.85389
0.70821
0.68305
0.73743
0.94873
0.75981
0.95645
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UbPred predicted that 6 lysine residues in TRIM22 undergo ubiquitylation. In contrast,
BDM-PUB predicted that 19 lysine residues undergo ubiquitylation. Both UbPred and
BDM-PUB predicted that residues K63, K160, and K173 undergo ubiquitylation (Table
3.5). According to ConSurf, these 3 lysine residues are highly conserved and exposed to
the protein surface. ConSurf also predicted that K173 was a functional residue (Fig 3.1).
SUMOplot predicted that 4 lysine residues in TRIM22 undergo sumoylation, whereas
SUMOsp 2.0 predicted that 2 lysine residues undergo sumoylation. Both programs
predicted that K153 undergoes sumoylation (Table 3.5). Similar to K173, ConSurf
showed that K153 is highly conserved and exposed to the protein surface. ConSurf also
predicted that K153 was a functional residue (Fig 3.1).
In addition to putative sumoylation sites, we also identified 7 potential sumo-interacting
motifs (SIM) (Fig 3.3a). SIMs are short hydrophobic motifs that interact non-covalently
with other sumoylated proteins. The best characterized SIMs have the consensus
sequence V/I/L-x-V/I/L-V/I/L or V/I/L-V/I/L-x-V/I/L 63. Notably, 5 of the putative SIMs
are highly conserved in multiple TRIM22 orthologues and 3 are also present in the
human and rhesus monkey TRIM5α proteins (Fig 3.3b). In addition, 2 TRIM5α SIMs
(ILGV and VIGL) were previously shown to be required for TRIM5α-mediated antiviral
activity. SIM mutations in the rhesus monkey TRIM5α protein abolished HIV-1
restriction and disrupted TRIM5α trafficking to SUMO-1 nuclear bodies. Moreover, SIM
mutations in the human TRIM5α protein abrogated N-MLV restriction by preventing
TRIM5α binding to the sumoylated N-MLV capsid protein 62,74. More studies are needed
to determine the role that SIMs play in TRIM22-mediated antiviral activity.
To identify putative phosphorylation sites in TRIM22, we used GPS 2.1 and NetPhos 2.0
servers. The GPS 2.1 server predicted that there were 31 serine-specific phosphorylation
sites, 13 threonine-specific sites, and 11 tyrosine-specific sites in the TRIM22 protein.
Conversely, NetPhos 2.0 predicted that there were 19 serine-specific phosphorylation
sites, 4 threonine-specific sites, and 2 tyrosine-specific sites (Table 3.6). 16 serine
residues, 3 threonine residues, and 2 tyrosine residues were predicted to be
phosphorylated by both GPS 2.1 and NetPhos 2.0 servers. Many of these putative
phosphorylation sites are highly conserved among multiple TRIM22 orthologues and
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Table 3.6
Table 3.6 Putative ubiquitylation and sumoylation sites in the TRIM22 protein.

Ubiquitylation
UbPred
93 (7e)*
160 (7e)*
173 (9e)*
204 (6e)
257 (1e)
430 (6e)

BDM-PUB
6 (3e)
44 (1e)
85 (2e)
93 (7e)*
103 (6e)
109 (9e)
160 (7e)*
173 (9e)*
265 (6e)
266 (9e)
268 (2e)
272 (6e)
273 (9e)
275 (7e)
324 (1e)
332 (2e)#
374 (1e)
380 (3e)
382 (1e)

Sumoylation
SUMOplot
6 (3e)
153 (9e)*
185 (4e)
265 (6e)

SUMOsp 2.0
85 (2e)
153 (9e)*

Conservation scores are shown in parentheses following amino acid site; Putative functional residues are
indicated with bold text, whereas putative structural residues are indicated with italicized text (ConSurf
results Fig 3.1); Residues predicted to undergo ubiquitylation or sumoylation by both programs are
indicated with an asterisk; Residues predicted to undergo ubiquitylation or sumoylation that also coincide
with the location of nsSNPs are indicated with a hashtag.
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Figure 3.3: Putative sumo-interacting motifs (SIM) in TRIM22.
(a) List of putative SIMs in the TRIM22 protein, including the sequence and domain
location for each SIM (amino acids are indicated in parentheses); Red and blue amino
acids are predicted functional and structural residues, respectively (ConSurf analysis Fig
3.1); Asterisk: SIMs that are conserved in all mammalian TRIM22 orthologues except
elephant; Double asterisk: SIMs that are not found in TRIM5α, but are replaced by a
different SIM (e.g. VLTL, IVPL). (b) Alignment of mammalian TRIM22, human
TRIM5α, and rhesus monkey TRIM5α amino acid sequences (amino acids 350-444 of
the B30.2 domain are shown). Conserved SIMs are highlighted in magenta and other
SIMs are highlighted in light blue. Conserved amino acids are indicated with an asterisk.
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Figure 3.3

Figure 3.3: Putative sumo-interacting motifs (SIM) in TRIM22.
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Table 3.7
Table 3.7 Putative phosphorylation sites in the TRIM22 protein.

GPS 2.1
Serine
4 (1e)
27 (9e)
46 (7e)*
54 (3e)*
87 (4e)*
122 (9e)
231 (4e)
235 (9e)
244 (8b)*#
245 (8b)*
259 (9e)*
261 (2e)*
269 (1e)*
271 (8e)*
276 (5e)*
284 (5e)*
309 (8e)
312 (6e)
317 (9b)
373 (8b)*
376 (2e)*
377 (1e)
383 (3e)*
384 (9e)*
391 (3e)
424 (7e)
425 (6e)*
426 (4e)*
455 (9b)
497 (9e)
498 (7e)

Threonine
23 (7e)
61 (1b)#
170 (1e)
220 (1e)
232 (1e)#
263 (3e)*
294 (7e)#
311 (2b)
325 (1e)*
330 (1e)*#
433 (7b)
460 (9b)#
492 (6e)

Tyrosine
175 (1b)
298 (1e)
299 (6b)
355 (5b)
356 (8b)*
394 (1b)
398 (7b)
418 (8b)
467 (8b)
479 (5b)*
481 (8e)

NetPhos 2.0
Serine
46 (7e)*
50 (1e)
54 (3e)*
87 (4e)*
244 (8b)*#
245 (8b)*
259 (9e)*
261 (2e)*
269 (1e)*
271 (8e)*
276 (5e)*
284 (5e)*
373 (8b)*
383 (3e)*
384 (9e)*
399 (7b)
425 (6e)*
426 (4e)*
475 (8e)

Threonine
130 (7b)
263 (3e)*
325 (1e)*
330 (1e)*#

Tyrosine
356 (8b)*
479 (5b)*

Conservation scores are shown in parentheses following amino acid site; Putative functional residues are
indicated with bold text, whereas putative structural residues are indicated with italicized text (ConSurf
results Fig 3.1); Residues predicted to undergo phosphorylation by both programs are indicated with an
asterisk; Residues predicted to undergo phosphorylation that also coincide with the location of nsSNPs are
indicated with a hashtag.
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several were predicted to be important structural or functional residues by ConSurf
(Table 3.6, Fig 3.1). Although TRIM22 phosphorylation has never been demonstrated
experimentally, our results suggest that it may undergo phosphorylation at a number of
sites. Of interest, other TRIM proteins have been shown to undergo phosphorylation,
including the antiviral TRIM19 and TRIM21 proteins 75–79.
Several putative PTMs coincide in location with nsSNPs in the TRIM22 gene (T61, T232,
S244, T294, T330, K332, and T460). S244 and T460 are particularly interesting because
both sites are highly conserved among TRIM22 orthologues and S244L and T460I were
predicted to be deleterious by 5 and 6 in silico algorithms, respectively (Table 3.2, Table
3.3). In addition, T460 was predicted to be a critical structural residue by ConSurf.
Although the consequences of TRIM22 phosphorylation are currently unknown, the
mutation of phosphorylation sites in other proteins has been shown to profoundly alter
protein function by, for example, altering protein stability, localization, or protein-protein
interactions. To this end, we used I-Mutant to predict whether S244L and T460I altered
the stability of the TRIM22 protein. I-Mutant is a support vector machine-based tool that
predicts changes in protein stability following single site mutations by estimating free
energy changes as well as the direction of the change (increase or decrease)

64

. Both

S244L and T460I were predicted to be less stable than the wild type protein, with free
energy change values of -0.83 and -1.38, respectively (Table 3.7). The I-Mutant results
for the 12 high-risk nsSNPs that do not coincide with putative PTM sites, plus the results
for the 5 low-risk nsSNPs that do coincide with putative PTM sites, are also shown in
Table 3.7.
It is possible that the phosphorylation of TRIM22 at sites S244 and/or T460 is required
for some integral TRIM22 function and that the nsSNPs S244L and T460I impair this
function; however, these nsSNPs may also impair protein stability, which would likely
amplify any detrimental of PTM impairment. Many additional high-risk nsSNPs, plus
several low-risk nsSNPs located at putative PTM sites, also decreased TRIM22 protein
stability (Table 3.7). A number of studies have shown that decreased protein stability
leads to increased protein misfolding, aggregation, and degradation. Accordingly,
decreased stability typically results in decreased net function 80–83. Future in-depth studies
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are required to investigate the effects of these nsSNPs on the structure and function of
TRIM22’s B30.2 domain. Pertinent TRIM22 sites that are predicted to be highly
deleterious and/or undergo PTMs are depicted in Figure 3.4.

3.4 Conclusions
Our results demonstrate that multiple nsSNPs in the antiviral TRIM22 gene may be
deleterious to TRIM22 structure and/or function. Most of these high-risk nsSNPs are
located at highly conserved amino acid sites in a protein-protein interaction module
called the B30.2 domain. In this study, we show that 9 of the top high-risk nsSNPs
disrupt the putative structure of TRIM22’s B30.2 domain, particularly the surfaceexposed v2 and v3 regions. In the closely-related TRIM5α protein, these same regions
were previously shown to play a key role in retroviral restriction. In addition to these
findings, we also identify several TRIM22 sites that may undergo post-translational
modification, including sites that coincide with the location of high-risk nsSNPs. This
study is the first systematic and extensive in silico analysis of functional SNPs in the
TRIM22 gene.
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Table 3.8
Table 3.8: I-Mutant results for selected nsSNPs in the TRIM22 protein.

nsSNP ID
rs192306924
rs201847190
rs199625192
rs368058642
rs2291843
rs374292901
rs61735273
rs73404240
rs201494620
rs368220166
rs371728648
rs191847788
rs375595000
rs370495523
rs187416296
rs377529439
rs371028900
rs200638791
rs200148337

Mutation
T61N
L68R
H73R
E135K
T232A
I234N
S244L
T294K
T330I
K332N
G346S
K364N
P403T
L432W
R442C
F456I
T460I
P484S
C494F

# Del. Pred.
1
5
5
4.5
0
5
5
2
1
1
5
4.5
6
4
5
5
6
4.5
6

DDG
0.56
-1.02
0.23
-1.00
-0.53
-0.80
-0.83
-0.63
-2.14
-0.42
-0.27
-1.09
-2.64
0.08
-1.23
-1.59
-1.38
-2.97
-0.21

Sign of DDG
Decrease (1)
Decrease (7)*
Decrease (3)
Decrease (9)*
Decrease (5)
Decrease (1)
Decrease (2)
Decrease (5)
Decrease (7)*
Decrease (2)
Decrease (7)
Decrease (4)
Decrease (8)
Decrease (6)
Decrease (6)*
Decrease (8)*
Decrease (5)*
Decrease (9)*
Decrease (4)

PTM
Yes
No
No
No
Yes
No
Yes
Yes
Yes
Yes
No
No
No
No
No
No
Yes
No
No

ConSurf
1b
8e
7e
7e (9b)
1e
7b (9e)
8b
7e
1e
2e
8b
9e
8e
8b
7e
8b (9b)
9b
6e (9b)
8b
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Figure 3.4: Putative functional sites in the TRIM22 protein.
Schematic depicting the approximate location of the top predicted PTM sites
(ubiquitylation, sumoylation, and phosphorylation), the 14 high-risk nsSNPs in TRIM22,
the 3 sumo-interacting motifs (SIMs), and the 2 high-risk nsSNP sites (S244L and T460I)
predicted to undergo phosphorylation in the wild type TRIM22 protein. Several sites of
known functional importance are marked on the TRIM22 protein (top image), including
the C15/C18 residues (required for TRIM22 E3 ligase activity), the C97/H100 residues
(part of the zinc-binding motif in BB2), and the nuclear localization signal (NLS)

84–86

.

The ‘antiviral patch’ region, which was previously shown to be integral for the antiviral
activity of TRIM5α, is shown in the B30.2 domain, as well as the approximate location of
each variable region (v1-v4, bright blue areas)

29,33

. Amino acids 491-494 were

previously shown to be required for the nuclear localization of TRIM22 87. RING, B-box
2 (BB2), coiled-coil (CC), and B30.2 (PRY/SPRY) domains are listed.
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Figure 3.4

Figure 3.4 Putative functional sites in the TRIM22 protein.
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Chapter 4

4

The TRIM22 nsSNP rs1063303:G>C is not evolving
under balancing selection in the Inuit and is associated
with low serum TG and high serum HDL levels in the
Canadian Inuit

TRIM22 is an IFN-induced antiviral protein that plays a key role in the host antiviral
response and inhibits the replication of diverse viruses, such as HIV-1, HBV, and IAV.
Altered TRIM22 expression has also been linked to cancer, autoimmune disease, and
cellular proliferation/differentiation. We previously identified a nsSNP in the TRIM22
gene (rs1063303:G>C) that had an inverse impact on TRIM22 function. The TRIM22
rs1063303:C allele increased TRIM22 expression, but decreased its anti-HIV activity.
Interestingly, we found that the frequency of rs1063303:G>C varied markedly among
ethnic populations and that the AFR, AMR, and EUR cohorts from the 1000 Genomes
project contained an excess of intermediate frequency TRIM22 rs1063303:G>C alleles.
The latter is typically indicative of balancing selection, a non-neutral selective force that
maintains polymorphism in a population. In this study, we determined the frequency of
the TRIM22 nsSNP rs1063303:G>C in two different Inuit populations and one non-Inuit
population and calculated the selective forces acting on this site. Interestingly, we found
that the TRIM22 rs1063303:C allele is significantly more prevalent in Inuit compared to
non-Inuit populations and that unlike AFR, AMR, and EUR cohorts, the Inuit do not
contain an excess of intermediate frequency TRIM22 rs1063303:G>C alleles, indicating
that TRIM22 rs1063303:G>C has not evolved under balancing selection in these Inuit
populations. Surprisingly, we also found that TRIM22 rs1063303:G>C was associated
with significantly lower serum triglycerides (TG) levels and significantly higher highdensity lipoprotein (HDL) levels in the Canadian Inuit population. TRIM22’s effect on
TG and HDL is unprecedented in the TRIM protein family and may represent an exciting
new research avenue for TRIM22 and other TRIM proteins.
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4.1 Introduction
Infection and inflammation induce the acute-phase response (APR), an early, complex
host reaction to injurious stimuli, that leads to specific changes in lipid and lipoprotein
metabolism 1. During the APR in humans and other primates, serum triglyceride (TG)
levels are markedly increased, a phenomenon that is largely due to increased levels of
circulating very-low-density lipoprotein (VLDL). Conversely, both serum low-density
lipoprotein (LDL) and serum high-density lipoprotein (HDL) levels, along with serum
total cholesterol levels, are decreased (Appendix A). These changes are mediated by a
number of proinflammatory cytokines, including TNF, IL-1, IL-2, IL-6, and IFN

2–8

.

Accordingly, SNPs in these cytokines and the genes they induce have been associated
with altered levels of serum lipoproteins, a modified APR to infection, and multiple
inflammatory and metabolic disorders 9–15.
Interestingly, in addition to their well-documented role in lipid transport, an increasing
body of evidence suggests that lipoproteins participate in host defense as agents of the
innate immune response. For example, lipoproteins bind to and neutralize a variety of
DNA and RNA viruses, such as Vesicular stomatitis virus (VSV), Rubella virus, HIV,
SIV, Herpes simplex virus, Vaccinia virus, Japanese encephalitis virus, Poliovirus, and
Epstein-Barr virus

16–21

. Moreover, during the IFN response to viral infection a soluble

antiviral form of the LDL receptor is produced that inhibits the replication of VSV and
rhinovirus

22–24

. Multiple lipoproteins also bind to and neutralize the bacterial cell wall

components lipopolysaccharide (LPS) and lipoteichoic acid (LTA)

25–29

. Thus, the APR

and its cytokine-induced lipoprotein changes are initially beneficial to the host because
they help resolve infection and inflammation; however, they can also promote disease
pathogenesis if they are prolonged (e.g. during chronic infection, metabolic syndrome,
inflammatory disorders, diabetes, obesity, or heart failure) 11–13,30–38.
TRIM family proteins have been implicated in a wide range of biological processes,
including the innate immune response to viral infection. Multiple TRIM proteins are
upregulated by type I and type II IFNs and recent studies have identified a number of
TRIMs that can: 1) restrict viral replication directly by targeting specific viral proteins
(e.g. TRIM5α inhibits HIV replication by targeting the HIV capsid protein), and/or 2)
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restrict viral replication indirectly by augmenting innate immune signaling pathways (e.g.
TRIM5α activates the TAK1 kinase complex, which induces downstream NF-κB and
AP-1 signaling and the transcription of inflammatory cytokines)

39–44

. TRIM proteins

contain a conserved N-terminal RBCC motif, which consists of RING, BB, and CC
domains, and a variable C-terminal domain

45

. The RING domain typically confers E3

ligase activity and this activity is often critical for TRIM protein function. Multiple
TRIMs have been shown to function as E3 ubiquitin and/or E3 sumo ligases and can
post-translationally modify specific host/viral proteins with ubiquitin and/or sumo
moieties

46,47

. Most TRIM proteins contain a C-terminal B30.2 domain, which is a

flexible, highly plastic structure that typically functions as a protein-protein interaction
module 48,49.
The TRIM22 protein is a B30.2-containing member of the TRIM family that plays an
integral role in the host antiviral response. TRIM22 is upregulated by type I and type II
IFNs, several proinflammatory cytokines, and a number of different viral infections

50

.

Studies have shown that TRIM22 inhibits the replication of multiple viruses, including
HIV-1, HBV, and IAV

51–54

. TRIM22 has also been linked to cancer, autoimmune

disease, and cellular proliferation/differentiation

55–63

. We previously identified a

common nsSNP in the TRIM22 gene (rs1063303:G>C) that had an inverse impact on
TRIM22 function

64

. rs1063303:G>C increased TRIM22 expression, but decreased its

anti-HIV activity and altered its sub-cellular localization pattern. Interestingly, the
frequency of rs1063303:G>C varied markedly among different ethnic groups (1000
Genomes AFN, AMR, ASN, and EUR populations) and we found an excess of
intermediate frequency rs1063303:G>C alleles in AFN, AMR, and EUR cohorts. An
excess of intermediate frequency alleles is often indicative of balancing selection, an
evolutionary process whereby polymorphism is maintained in a population because it
confers some selective advantage 65.
Although it is rare in other host genes, balancing selection has been described in many
immune genes and may be beneficial when, for example, different alleles are effective
against distinct pathogens

66

. Selecting for multiple alleles at a single site (maintaining

heterozygosity) may also make it more difficult for pathogens to evolve suitable escape
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mutants against immune genes

67

. Here, we genotyped TRIM22 nsSNP rs1063303:G>C

in two distinct Inuit populations (Canadian and Greenlandic Inuit) as well as one nonInuit population (Canadian population of European descent). In contrast to some ethnic
groups (including the AFR, AMR, and EUR cohorts mentioned above), the Inuit have
been geographically isolated for many years. As such, they have likely evolved against
unique selective pressures and distinct pathogenic landscapes

68,69

. We determined the

frequency of a functionally important TRIM22 nsSNP (rs1063303:G>C) in these Inuit
populations and examined the selective forces acting on this site. Of interest, we found
that rs1063303:G>C is significantly more prevalent in the Inuit compared to non-Inuit
populations, and that unlike AFR, AMR, and EUR cohorts, there is not an excess of
intermediate frequency rs1063303:G>C alleles in the two Inuit populations, suggesting
that this site has not evolved under balancing selection in these groups. We also found an
unexpected, but striking, association between the TRIM22 nsSNP rs1063303:G>C and
serum levels of TG and HDL. The TRIM22 rs1063303:C allele was associated with
significantly lower serum TG levels and significantly higher serum HDL levels in the
Canadian Inuit population. The effect of TRIM22 on serum TG and HDL levels is
unprecedented in the TRIM family.

4.2 Materials and methods
4.2.1

Study subjects

Study subjects included Inuit individuals from Canada (Kivalliq region, Nunavut) and
Greenland (Nuuk, Sisimiut, Qasigiannguit, and four villages in Uummannaq region), as
well as Canadians of European descent (European Caucasian population). 42 subjects in
the Canadian Inuit population self-reported as being of European background and were
included in the analysis as a regional Caucasian control group 70. All study subjects had
previously been participants in one of the following population studies: 1) the Keewatin
Health Assessment Study

71

; 2) the Greenland Population Study 72; and 3) the Study of

Health Assessment and Risk in Ethnic Groups 73. The details of these studies have been
described previously

71–73

. Signed informed consent was obtained from all participants
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and the studies were approved by the Universities of Manitoba and Toronto, and from
Western University.

4.2.2

Clinical characteristics and biochemical analyses

Body weight, height, and plasma lipoprotein analyses [fasting plasma concentrations of
total cholesterol (TChol), TG, HDL-cholesterol, LDL-cholesterol, and apolipoproteins
(Apo) A-I and B] were determined as previously described 71–73.

4.2.3

Genotype analyses

Detection of nsSNP rs1063303:G>C was carried out using a custom designed TaqMan
genotyping assay (Applied Biosystems, Foster City, CA). The nsSNP genotyping was
performed using an allelic discrimination assay with the 7900HT Fast Real-time PCR
system and read using automated software (SDS 2.3 Applied Biosystems, Foster City,
CA). PCR reactions were run in 5 µL volumes using an amplification protocol of 95°C
for 10 minutes, followed by 50 cycles of 95°C for 15 sec, then 60°C for 1.3 minutes.

4.2.4

Neutrality tests

Tajima’s D and Fu’s FS neutrality tests were performed to detect signals of selection at
site rs1063303:G>C in the Canadian Inuit, Greenlandic Inuit, and European Caucasian
populations. These tests differentiate between neutrally evolving sites under mutationdrift equilibrium and sites evolving under non-neutral processes such as balancing
selection. Negative Tajima’s D and/or Fu’s FS values are evidence of an excess of low
frequency variants relative to expectation, whereas positive Tajima’s D and/or Fu’s FS
values are indicative of an excess of intermediate frequency variants. A P value of less
than 0.02 was considered significant for the FS statistic

74–76

. Statistical significance was

assessed by coalescent simulations using Arlequin software (v 3.5.1.3) with 10,000
iterations 77.

4.2.5

Statistical analyses

Statistical analyses were performed using the SAS version 9.2 software (SAS Institute,
Cary, NC). A χ2 test was used to examine deviation in genotype frequency from the

139

Hardy-Weinberg equilibrium. ANOVA was used to determine sources of variation for
study subjects’ levels of TChol, TG, HDL-cholesterol, LDL-cholesterol, Apo-AI, and
Apo-B. TRIM22 rs1063303:G>C was used as the independent class variable, while sex
and body mass index (BMI) were entered as covariates. P values less than 0.05 were
considered statistically significant.

4.3 Results
4.3.1

Baseline phenotypic characteristics of study subjects

Baseline phenotypic characteristics for the Canadian Inuit, Greenlandic Inuit, and
European Caucasian populations whose TRIM22 rs1063303:G>C genotype and serum
lipoprotein levels were determined are summarized in Table 4.1, including the baseline
levels of total cholesterol (TChol), TG, HDL-cholesterol, LDL-cholesterol, Apo-AI, and
Apo-B. Mean age, body mass index (BMI), and percentage of female study subjects are
also shown in Table 4.1.

4.3.2

TRIM22 rs1063303:G>C genotype and allele frequencies

TRIM22 rs1063303:G>C genotype and allele frequencies were calculated for the three
populations (Canadian Inuit, Greenlandic Inuit, and European Caucasian) and are shown
in Table 4.2. There were 21 G/G homozygotes (0.091), 62 heterozygotes (0.267), and 147
C/C homozygotes (0.634) in the Canadian Inuit population. Similarly, there were 20 G/G
homozygotes (0.078), 104 heterozygotes (0.408), and 131 C/C homozygotes (0.514) in
the Greenlandic Inuit population. Thus, rs1063303:C was the major allele in both the
Canadian and Greenlandic Inuit populations, which had allele frequencies of 0.84 and
0.72, respectively. In contrast, the rs1063303:C allele was much less prevalent in the
European Caucasian population as well as in a small subset of European Caucasian
individuals within the Canadian Inuit (Table 4.2). Similar low rs1063303:C allele
frequencies were reported previously for the European Caucasian population from the
1000 Genomes project (EUR) 64. Moreover, rs1063303:C was even less prevalent in
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Table 4.1
Table 4.1 Baseline phenotypic characteristics (mean ± SD) of Canadian Inuit,
Greenland Inuit, and European Caucasian populations.

Canadian Inuit
Number
232
Percent female (%)
50.4
Age (years)
38.1 ± 14.8
2
BMI (kg/m )
26.9 ± 4.84
Total cholesterol (mmol/L) 5.06 ± 1.01
Triglycerides (mmol/L)
1.17 ± 0.77
HDL cholesterol (mmol/L) 1.37 ± 0.39
LDL cholesterol (mmol/L) 3.16 ± 0.92
Apo-AI (g/L)
N/A
Apo-B (g/L)
N/A

Greenland Inuit
254
62.9
48.6 ± 13.3
27.1 ± 5.18
6.35 ± 1.03
1.14 ± 0.68
1.67 ± 0.47
4.15 ± 1.04
1.81 ± 0.30
0.99 ± 0.24

European Caucasian
67
59.7
57.7 ± 18.1
27.6 ± 5.26
5.29 ± 0.86
1.20 ± 0.40
1.21 ± 0.33
3.73 ± 0.79
1.41 ± 0.25
1.07 ± 0.21
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Table 4.2
Table 4.2 Genotype frequencies for TRIM22 rs1063303:G>C in the Canadian Inuit,
Greenlandic Inuit, and European Caucasian populations.

Population
Canadian Inuit
Inuit
Caucasian
Greenland Inuit
European Caucasian
European (1000 Genomes*)
African (1000 Genomes*)
American (1000 Genomes*)
Asian (1000 Genomes*)

n
232
188
44
255
67
193
133
84
66

G/G
0.091
0.053
0.273
0.078
0.397
0.228
0.329
0.365
0.745

G/C
0.267
0.208
0.523
0.408
0.397
0.507
0.541
0.464
0.231

C/C
0.634
0.734
0.205
0.514
0.206
0.265
0.130
0.171
0.024

* 1000 Genomes populations: European (EUR) cohort includes British individuals from Scotland and
England, Iberian individuals from Spain, Finnish individuals and Italian individuals; African (AFR) cohort
includes Yoruba individuals from Nigeria, Luhya individuals from Kenya, and African Americans from the
southwestern United States; American (AMR) cohort includes Colombian individuals, Puerto Rican
individuals, and Mexican Americans from Los Angeles, United States; Asian (ASN) cohort includes
Japanese individuals, Han Chinese individuals from Beijing, and Southern Han Chinese.
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AFR, AMR, and ASN populations from the 1000 Genomes project

64

. Genotype

frequencies determined for the Canadian Inuit, Greenlandic Inuit, and European
Caucasian populations did not show significant deviation from expectations based on
Hardy-Weinberg equilibrium (P > 0.05).

4.3.3

TRIM22 rs1063303:G>C is not evolving under balancing
selection in the Canadian or Greenlandic Inuit

Since the Inuit have lived in isolation for many years, we hypothesized that within the
Inuit, TRIM22 rs1063303 may contain a unique evolutionary signature. We previously
identified an excess of intermediate frequency rs1063303:C alleles in the AFR, AMR,
and EUR, but not ASN, cohorts from the 1000 Genomes project. This excess differed
significantly from what was expected under a neutral model of evolution (P < 0.05)

64

.

We performed the Tajima’s D and Fu’s FS neutrality tests to establish whether TRIM22
rs1063303:G>C has evolved under neutral or non-neutral processes in the Inuit. As
shown in Table 4.3, the Tajima’s D values for both the Canadian and Greenlandic Inuit
populations did not differ significantly (P > 0.05) from what was expected under a
neutral model of evolution, suggesting that rs1063303:G>C has not evolved under
balancing selection in these populations. While the Tajima’s D value was higher in the
European Caucasian population (1.61) compared to the Canadian and Greenlandic Inuit
populations (1.20 and 1.29), it did not reach statistical significance. Within the Canadian
Inuit, a smaller Tajima’s D value (0.60) was achieved when the small subset of European
Caucasian individuals was removed from the population. Similarly, the results of Fu’s FS
test also showed non-significant values for the Canadian Inuit, Greenlandic Inuit, and
European Caucasian populations (Table 4.3).

4.3.4

Association between TRIM22 rs1063303:G>C and plasma
lipoproteins in the Canadian Inuit

We previously demonstrated that the TRIM22 rs1063303:C allele is associated with a
significant increase in TRIM22 expression levels and a significant reduction in antiviral
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Table 4.3
Table 4.3: Results of Tajima’s D and Fu’s Fs neutrality tests.

Population
Canadian Inuit
Inuit
Caucasian
Greenland Inuit
European Caucasian

Tajima’s D
1.20
0.60
1.11
1.29
1.61

p-value
0.179
0.272
0.19
0.150
0.114

Fu’s Fs
1.83
1.05
1.17
1.96
1.78

p-value
0.126
0.294
0.167
0.111
0.092
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activity

64

. Since TRIM22 has been implicated in a plethora of diverse biological roles,

we hypothesized that a significant increase in TRIM22 expression due to the TRIM22
rs1063303:C allele may contribute to other biological functions. We took advantage of
the extensive clinical data associated with the Canadian and Greenlandic Inuit
populations used in this study to determine if the TRIM22 rs1063303:C allele was
associated with a particular clinical phenotype. ANOVA was used to determine sources
of variation for various serum lipoproteins, including TChol, TG, HDL, LDL, Apo-AI,
and Apo-B, in Canadian Inuit, Greenlandic Inuit, and European Caucasian populations.
The ANOVA results for the three populations are summarized in Table 4.4. Significant
associations were found in the Canadian Inuit population between the TRIM22
rs1063303:C allele and serum levels of both TG (P < 0.0008) and HDL (P < 0.05). TG
and HDL associations were not found in the Greenlandic Inuit or the European Caucasian
populations. Sex was found to significantly associate with HDL in all populations (P <
0.005), while BMI was significantly associated with most lipoproteins in all three
populations. Sex was also significantly associated with Apo-AI (P < 0.05) and LDL (P <
0.05) in the Greenlandic Inuit population (Table 4.4).
TRIM22 rs1063303:G>C genotypes and their corresponding TG and HDL levels are
shown in Table 4.5 for the Canadian Inuit population. A significant association between
the presence of the rs1063303:C allele and decreased serum TG levels was detected, with
C/C homozygotes having lower serum TG levels than heterozygotes and heterozygotes
having lower serum TG levels than G/G homozygotes. This pattern suggests that the
rs1063303:C allele shows incomplete dominance. A similar significant association was
found between the rs1063303:C allele and elevated levels of plasma HDL (Table 4.5).

4.4 Discussion
Here, we showed that the TRIM22 nsSNP rs1063303:G>C is inordinately prevalent in
two Inuit populations (Canadian and Greenlandic) and that the rs1063303:C allele is
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Table 4.4
Table 4.4: ANOVA results

Table 4.4: Summary of ANOVA results showing determinants of serum lipoproteins in the Canadian Inuit, Greenlandic Inuit,
and European Caucasian populations.
Source of Variation
Canadian Inuit
Sex
BMI
TRIM22 rs1063303:C
Greenlandic Inuit
Sex
BMI
TRIM22 rs1063303:C
European Caucasian
Sex
BMI
TRIM22 rs1063303:C

df

F

TChol
P

TG
F

HDL
P

F

LDL
P

F

F

P

Apo-A1
P

1
1
2

0.76 n.s.
0.51 n.s.
23.42 <0.0001 0.07
3.89 0.0454 26.48 <0.0001 8.34 0.0043 0.75
2.21 n.s.
7.31 0.0008 3.49 0.0323 1.43

1
1
2

0.07 n.s.
0.04 n.s.
36.37 <0.0001 11.93 0.0006 4.96 0.0268
4.95 0.0271 51.94 <0.0001 2.97 n.s.
0.08 n.s.
10.42 0.0014
0.65 n.s.
0.07 n.s.
0.18 n.s.
0.69 n.s.
0.24 n.s.

1
1
2

0.47 n.s.
0.27 n.s.
8.76
5.11 0.0112 71.42 <0.0001 6.54
0.89 n.s.
0.54 n.s.
2.90

0.0043
0.0012
n.s.

0.95
1.22
1.79

n.s.
n.s.
n.s.

n.s.
n.s.
n.s.

F

Apo-B
P

1.19 n.s.
0.16 n.s.
19.29 <0.0001 6.78 0.0031
0.67 n.s.
0.33 n.s.

0.17 n.s.
10.21 0.0005
0.34 n.s.

P value indicates probability of a greater between-group F value using ANOVA; n.s. indicates not significant (i.e. P > 0.05)

0.44 n.s.
9.26 0.0026
0.13 n.s.
1.09 n.s.
2.32 n.s.
0.71 n.s.
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Table 4.5
Table 4.5: Significant associations between the TRIM22 rs1063303:G>C genotype
and plasma lipoproteins in the Canadian Inuit.

Genotype
G/G
G/C
C/C

TG (LSM ± SEM) (mmol/L)
1.72 ± 0.09
1.15 ± 0.08
1.07 ± 0.06

* LSM: least squares means, SEM: standard error of the mean

HDL (LSM ± SEM) (mmol/L)
1.18 ± 0.08
1.34 ± 0.05
1.41 ± 0.03
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associated with significantly lower levels of serum TG and significantly higher levels of
serum HDL in the Canadian Inuit. Unlike in several non-Inuit populations (i.e. AFR,
AMR, and EUR cohorts from the 1000 Genomes project

64

), the two Inuit populations

(Canadian and Greenlandic Inuit) did not contain a significant excess of intermediate
frequency TRIM22 rs1063303:G>C alleles when compared to a neutral evolutionary
model. The latter, which is not indicative of balancing selection, suggests that this site
(TRIM22 rs1063303:G>C) has evolved in response to distinct evolutionary pressures in
the Canadian and Greenlandic Inuit.
One possible explanation for this disparate evolutionary footprint in the Inuit is lack of
exposure to certain pathogens. We previously showed that TRIM22 rs1063303:G>C is
located at site in TRIM22 that has been subject to strong positive selection during the
evolution of mammals. Moreover, certain human populations (AFR, AMR, and EUR)
contained an excess of intermediate frequency TRIM22 rs1063303:G>C alleles, which
indicates a decrease in population size and/or balancing selection

64

. In innate immune

genes, amino acid sites that are subject to positive and/or balancing selection are often
functionally relevant, typically because they are located at the host-pathogen interface
where they are exposed to diverse pathogenic pressures

66

. Indeed, we demonstrated in

our previous study that TRIM22 rs1063303:G>C increased the expression of TRIM22,
but disrupted its ability to restrict HIV-1 replication 64. While the reason for this effect is
currently unclear, these results combined with the fact that this site has evolved under
multiple non-neutral evolutionary forces, strongly suggests that its evolution has been
driven by HIV-1 and/or other pathogens. Canadian and Greenlandic Inuit populations,
who have lived in isolation for many years with little exposure to ‘modern’ infectious
diseases, may not have been subjected to the same pathogenic pressures at this site as
other populations.
Despite advances in other non-Inuit populations, relatively few innate immune nsSNPs
have been documented in the Inuit. Notably, there is evidence that the Inuit (and other
indigenous populations) suffer disproportionately from infectious diseases and have a
much higher rate of infection when compared to their non-indigenous counterparts

68

.

While several socio-economic factors certainly contribute to this increased prevalence,
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differences in their immune response may also play a role. Interestingly, the Inuit have
been shown to possess a unique distribution of human leukocyte antigen (HLA) alleles
when compared to non-Inuit populations

78–81

. Because specific HLA alleles have been

linked with susceptibility to a number of viral infections, it has been suggested that the
Inuit’s unique distribution of HLA alleles may make them more vulnerable to certain
infections

82–85

. Since TRIM22 and other important antiviral genes, such as TRIM5α,

APOBEC3G, BST-2/tetherin, and SAMHD1, are located at the host-pathogen interface
where they often interact directly with viral pathogens, it is possible that the Inuit also
contain a unique distribution of alleles in these genes and that this affects their antiviral
response. It would be interesting to clone several of these antiviral genes from the Inuit
population and test their antiviral activity against the spectrum of viruses known to be
inhibited by these proteins. One could also compare various innate immune responses
among the Inuit and other non-Inuit populations.
Surprisingly, we found an association between TRIM22 rs1063303:G>C and the serum
levels of specific lipoproteins. In the Canadian Inuit population, the rs1063303:C allele
was associated with significantly lower serum TG levels and significantly higher serum
HDL levels. These TG and HDL associations were not found in the Greenlandic Inuit or
the European Caucasian populations. The effect of TRIM22 on serum lipoprotein levels
is unprecedented in the TRIM protein family. The molecular details underlying this effect
are currently unexplored and may be explained by a number of diverse factors given the
wide ranging functions of TRIM22. It is possible, for example, that TRIM22 modulates
serum lipoprotein levels indirectly by influencing innate immune and/or inflammatory
signaling pathways. Recent studies have implicated multiple TRIM proteins in the
regulation of key innate signaling pathways, particularly pathways that control NF-κB
signaling, the IFN response, and cytokine production following PRR activation

40,42,44

.

PRRs, which include the membrane-bound TLRs and cytoplasmic receptors such as
RLRs, are activated by diverse microbial products termed PAMPs. TRIM proteins have
been shown to regulate NF-κB activation, either positively or negatively, by targeting
various stages of the NF-κB signaling pathway. For example, TRIM19/PML sequesters
NF-κB in PML nuclear bodies to prevent it from activating downstream transcription,
whereas TRIM30α and TRIM27 repress NF-κB signaling by targeting TAB2/TAB3 or
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IKK family members, respectively

86–88

. TRIM23, which is essential for viral-induced

NF-κB activation, enhances downstream antiviral signaling by modifying NEMO with
ubiquitin

89

. Although it remains unclear whether endogenous levels of TRIM22 can

regulate NF-κB signaling, one recent study demonstrated that TRIM22 overexpression
inhibited the TRAF6-stimulated NF-κB pathway by facilitating TAB2 degradation

69

.

However, TRIM22 overexpression has also been shown to activate NF-κB signaling 70.
Since NF-κB activates the transcription of proinflammatory cytokines, and because the
APR is induced by proinflammatory cytokines, TRIM22 expression may inadvertently
alter the APR by regulating NF-κB signaling. In this scenario, nsSNP rs1063303:G>C
would either: 1) disrupt TRIM22-mediated NF-κB activation, or 2) amplify TRIM22mediated NF-κB inhibition. Both possibilities would theoretically lead to a decrease in
proinflammatory cytokine production and a less potent APR. Given the integral role
played by TRIM proteins in the antiviral response, and the link between the immune
system and the APR, other TRIM family members may have a similar effect on serum
lipoproteins. Future studies are needed to address these possibilities and others and to
determine the molecular details underlying TRIM22-mediated effects on serum TG and
HDL levels.
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Chapter 5
5

Discussion

5.1 Summary of results
5.1.1

Ancient and recent adaptive evolution in the antiviral TRIM22
gene: identification of a single nucleotide polymorphism that
impacts TRIM22 function

The evolution of TRIM22 in mammals was examined using 29 evolutionarily diverse
mammalian TRIM22 sequences. These sequences were aligned using COBALT and a
phylogenetic tree was generated using EvolView software. Site-specific evolutionary
analysis of TRIM22 with the Selecton program identified multiple amino acid sites in
TRIM22 that have evolved under strong positive selection. The majority of these sites
were located in the PRY/SPRY (B30.2) domain; however, there was also evidence for
positive selection in other TRIM22 domains. Many positively selected sites clustered
around putative functional motifs in TRIM22, such as the zinc-finger motif in the BB2
domain and the NLS in the SP2 domain. Moreover, a number of sites corresponded in
location and spacing to sites that have evolved under positive selection in the closelyrelated TRIM5α protein. For example, in both TRIM22 and TRIM5α, many positively
selected sites are located in one of four variable regions (v1-v4) in the B30.2 domain.
In addition to sites undergoing positive selection among mammals, nsSNPs in human
TRIM22 were investigated. A total of 64 nsSNPs and 2 indels were obtained from the
NCBI dbSNP database for the human TRIM22 gene, including 56 missense mutationinducing nsSNPs and 8 frameshift mutation-inducing nsSNPs. To identify nsSNPs in
TRIM22 that may be functionally relevant, an in silico prediction program (SIFT) was
used to analyze the 56 missense mutation-inducing nsSNPs. SIFT predicted that 23 of
these nsSNPs were deleterious to TRIM22 function and 33 were tolerated. Notably, 2
potentially deleterious nsSNPs were located at sites that evolved under strong positive
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selection in mammals. One of these nsSNPs, rs1063303:G>C, was selected for further
analysis because of its high prevalence in the human population.
Large frequency differences were observed for nsSNP rs1063303:G>C among distinct
ethnic populations, including AFR, AMR, ASN, and EUR 1000 Genomes cohorts. Of
interest, an excess of intermediate frequency rs1063303 alleles was identified in AFR,
AMR, and EUR populations, indicating a decrease in population size and/or balancing
selection. To assess potential functional consequences of nsSNP rs1063303:G>C, its
RNA and protein expression, sub-cellular localization pattern, and anti-HIV-1 activity
were determined and compared to the wild type TRIM22 protein. Surprisingly, nsSNP
rs1063303:G>C significantly increased both RNA and protein expression of TRIM22,
but disrupted its anti-HIV-1 activity. nsSNP rs1063303:G>C also obstructed TRIM22
sub-cellular localization (localized diffusely in both the cytoplasm and nucleus, not in
punctate NBs). Taken together, these results describe multiple sites that have evolved
under positive selection in TRIM22 and identify a highly prevalent functional nsSNP
(rs1063303:G>C) with a complex evolutionary history.

5.1.2

In silico analysis of functional single nucleotide
polymorphisms in the human TRIM22 gene

To identify additional nsSNPs that may alter TRIM22 function, and to examine amino
acid sites in TRIM22 that may be subject to post-translational modification (PTM), an
extensive in silico analysis was performed on the protein coding region of the TRIM22
gene. All missense mutation-inducing nsSNPs (56) in TRIM22 were analyzed using 6
different nsSNP prediction algorithms, including Polyphen-2, PhD-SNP, SIFT, nsSNP
Analyzer, PMUT, and SNPs&GO. Since these algorithms use different parameters to
evaluate and rank nsSNPs, multiple algorithms were used to increase the accuracy and
power of prediction. A total of 14 nsSNPs were predicted to be deleterious to TRIM22
function by ≥ 4 nsSNP prediction algorithms. These 14 nsSNPs (L68R, H73R, E135K,
I234K, S244L, G346S, K364N, P403T, L432W, R442C, F456I, T460I, C494F) were
classified as high-risk deleterious and selected for further in silico analysis.
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Highly conserved amino acids tend to be required for important protein functions. As
such, nsSNPs that are located at highly conserved sites are often deleterious to protein
function 1. ConSurf analysis revealed that 13 of the 14 sites occupied by the high-risk
nsSNPs were highly conserved (conservation score of 7-9). In addition, by combining
evolutionary conservation data and solvent accessibility predictions, the ConSurf web
server predicted that T460 was a key structural residue and that L68, K364, and P403
were key functional residues. Structural analysis of the 9 high-risk deleterious nsSNPs
located in the B30.2 domain, including K364N, P403T, and T460I, showed that all of
these nsSNPs markedly altered the putative 3D structure of TRIM22’s B30.2 domain,
particularly the surface-exposed v2 and v3 regions. These same regions are critical for
HIV-1 restriction in the closely-related TRIM5α protein 2,3.
A number of putative PTM sites were also identified in the TRIM22 protein, including
multiple ubiquitylation (3), sumoylation (1), and phosphorylation (21) sites that were
predicted to undergo PTM by two or more in silico programs. Moreover, 7 SIMs were
identified in TRIM22, 2 of which are also present in TRIM5α (ILGV and VIGL) and
were previously shown to be required for its antiviral activity

4,5

. These 2 SIMs, plus 3

additional SIMs (5/7), are highly conserved among TRIM22 orthologues. Of interest,
several PTM sites coincide with the location of nsSNPs, including 2 high-risk nsSNPs
(S244L and T460I, which are both predicted to undergo phosphorylation). This study
comprises the first systematic in silico analysis of functional sites in the TRIM22 gene
and will be a valuable resource for future studies.

5.1.3

The TRIM22 nsSNP rs1063303:G>C is not evolving under
balancing selection in the Inuit and is associated with low
serum TG and high serum HDL levels in the Canadian Inuit

To determine the frequency of TRIM22 nsSNP rs1063303:G>C in the Inuit and examine
the selective forces acting on this site, we genotyped TRIM22 rs1063303:G>C in two
different Inuit populations and one non-Inuit population (Canadian Inuit, Greenlandic
Inuit, and Canadian population of European Caucasian descent). Interestingly, we found
that the TRIM22 rs1063303:C allele is inordinately prevalent in both Inuit populations
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and that unlike in the AFR, AMR, and EUR cohorts from the 1000 Genomes project, the
Canadian and Greenlandic Inuit populations do not contain an excess of intermediate
frequency TRIM22 rs1063303:G>C alleles. The latter indicates that in these two Inuit
populations TRIM22 nsSNP rs1063303:G>C is not evolving under balancing selection.
We also found an unexpected, but interesting association between the TRIM22 nsSNP
rs1063303:G>C and serum lipoprotein levels. Specifically, the TRIM22 rs1063303:C
allele was associated with significantly lower serum TG levels and significantly higher
serum HDL levels in the Canadian Inuit population. The effect on TRIM22 on TG and
HDL levels is unprecedented in the TRIM family and may represent an exiting new
avenue of research for TRIM22 and other TRIM family members.

5.2 Multiple sites in TRIM22 have evolved under positive
and/or balancing selection
5.2.1

Positive selection

Genetic conflict between host and viral genomes often results in the accumulation of a
large number of non-synonymous (dN) relative to synonymous (dS) mutations in host
and/or viral genes. While the majority of host genes evolve under negative (purifying)
selection, which removes deleterious nsSNPs from genes to preserve protein function,
host restriction factors tend to evolve under positive (directional) selection (defined as
dN/dS > 1)

6–8

. This is largely due to the evolutionary ‘arms race’ that occurs between

host restriction factors and viruses as they attempt to gain evolutionary superiority over
each other. Host restriction factors, for example, are often targeted by viral antagonists
and/or interact directly with viral proteins as part of their antiviral mechanism. For this
reason, they tend to select for novel nsSNPs that allow them to evade viral antagonists
and/or enhance their antiviral capacity (e.g. nsSNPs that increase viral protein binding
affinity). However, since viruses mutate frequently and select for their own beneficial
nsSNPs (e.g. nsSNPs that help circumvent the immune response and/or augment viral
replication), both host restriction factors and viruses are under tremendous pressure to
evolve new, more effective ways to counteract each other 9. As a result, multiple host
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restriction factors contain genetic signatures of positive selection, particularly at amino
acid sites that interact with viral antagonists. It follows that a number of recent studies
have conducted evolutionary analyses on host restriction factors to pinpoint amino acid
sites that are important for their antiviral activity 10–12.
In this work, we used a similar approach to examine 29 evolutionarily diverse TRIM22
sequences spanning >100 million years of evolution in mammals. While we identified
codons evolving under positive selection in all TRIM22 protein domains, 11 of the 28
codons were located in the B30.2 domain (Table 2.3). Moreover, 10 of these 11 codons
were located within one of four variable loops (v1-v4) in the B30.2 (Fig 2.1d). v1-v4,
which are also found in the closely-related TRIM5α protein, are required for TRIM5αmediated retroviral restriction

2,13

. In the rhTRIM5α protein, v1-v4 form an extensive,

highly flexible, HIV-1 capsid binding interface 3. The v1-v4 interface, which includes
several positively selected codons in the v1 and v2 loops (324, 332, 385, and 389), are
critical TRIM5α-mediated inhibition of HIV and/or SIV in hominoids

2,14–16

. There are

also two positively selected codons in the v3 loop of huTRIM5α (409 and 410) that are
required for N-MLV restriction

17

. We identified 6 positively selected codons (K324,

R327, T330, K332, S334, and C337) in the v1 loop of TRIM22, 2 in the v2 loop (S377
and S395), and 2 in the v4 loop (i.e. L488 and V489). Many of these codons mirrored
both the location and spacing of positively selected codons in the TRIM5α protein (Fig
2.1c). Similar to TRIM5α, TRIM22 has been shown to interact with the HIV-1 Gag or
capsid protein; however, the binding site for capsid is unknown

18–20

. It is possible that

the v1-v4 loops also comprise an HIV-1 capsid binding interface in TRIM22 and that
some of the positively selected codons in v1, v2, and/or v4 are important for TRIM22mediated HIV-1 restriction. Codons K324 and K332 are particularly interesting given
their importance in TRIM5α-mediated retroviral restriction and because both sites have
also evolved under positive selection in TRIM5α. Some of the codons evolving under
positive selection in TRIM22’s v1-v4 loops may alternatively be required for TRIM22mediated inhibition of other viruses, such as HBV and/or IAV, or help form a binding
site for interacting with viral proteins other than Gag. Previous studies have shown that
TRIM22 interacts with the EMCV 3C protease and the IAV NP; however, the binding
sites for these viral proteins are unknown

21,22

. One interesting difference between the
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TRIM22 and TRIM5α proteins is not there are no positively selected codons in the v3
loop of TRIM22 (Fig 2.1d). In contrast, there are several positively selected codons in
TRIM5α’s v3 loop, some of which are required for inhibition of N-MLV

17

. Thus, it is

possible that TRIM22, which does not inhibit N-MLV replication, does not contain any
positively selected codons in its v3 loop because it has not been subject to evolutionary
pressure from N-MLV 18. Future studies are needed to address these possibilities and to
establish the functional implications of the positively selected sites found in TRIM22’s
B30.2 domain.
Outside of the B30.2 domain, we identified 5 positively selected codons in the RING
domain (D2, F3, S4, S50, and S54), 3 in the SP1 domain (T61, N76, and V96), 2 in the
BB2 domain (Q105, I106), 3 in the CC domain (A171, V192, and T220), and 4 in the
SP2 domain (L241, R242, K257, R279) (Table 2.3). Of interest, many of these codons
are located close to putative protein binding sites in the TRIM22 protein. For example,
codons V96, Q105, and I106 cluster around the zinc finger motif in the BB2 domain.
Codons L241, R242, K257, and R279 flank the bipartite NLS in the SP2 domain (Fig
2.1b, Fig 2.2). Consistent with this, previous studies have shown that codons evolving
under positive selection tend to be located near protein binding sites and are typically
solvent-exposed

23

. Although the zinc finger motif and bipartite NLS in TRIM22 have

never explicitly been shown to function as protein binding sites, these motifs are often
involved in protein-protein interactions in other proteins

24,25

. Further, the presence of

positively selected codons near these motifs suggests that they may indeed function as
protein binding sites in TRIM22. Interestingly, our ConSurf results (Chapter 3) showed
that 24 of the 28 positively selected codons are solvent-exposed (codons I106, V192,
L241, and S395 are predicted to be buried) (Fig 3.1).
Future studies should focus on determining the functional significance of the positively
selected codons that we identified in TRIM22. For example, it will be important to test
whether these codons are involved in TRIM22’s antiviral activity against HIV-1, HBV,
IAV, and/or EMCV. In addition, examining whether specific codons affect TRIM22’s
ability to interact with viral proteins, such as the HIV-1 Gag and/or capsid protein, the
IAV NP, and the EMCV 3C protease, will be of great interest and may provide further
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insight into TRIM22’s antiviral mechanism. Several codons within the B30.2 domain,
such as K324 and K332, may be particularly relevant in this regard. Other codons may
also be interesting to examine, including two codons (T61 and R242) that coincide in
location with the TRIM22 nsSNPs rs192306924:C>A and rs1063303:G>C. Curiously,
these nsSNPs were predicted to be deleterious by some of the prediction programs in
Chapter 3; however, they are located at amino acid sites that have evolved under strong
positive selection in mammals (Tables 2.3, 3.1). Due to its high prevalence in humans,
we examined the TRIM22 nsSNP rs1063303:G>C in more detail in Chapters 2 and 4
(discussed in sections below). Finally, some codons may be involved in protein-protein
interactions. For example, codons V96, Q105, and I106 surround a zinc finger motif in
the BB2 domain and are also located amongst 2 putative hydrophobic surface patches
(also in the BB2). Zinc finger motifs are often involved in protein-protein interactions
and the zinc finger motifs found in the BB2 domains of other TRIM proteins have been
shown to facilitate homo- and/or heterodimerization

24,26–28

. Notably, V96, Q105, and

I106 are located amongst 2 putative hydrophobic surface patches in TRIM22. Similar
patches were previously identified in the BB2 of TRIM5α and are required for proper
TRIM5α self-association, capsid binding, and HIV-1 restriction

29

. While TRIM22 has

been shown to undergo trimerization, the residues responsible for self-association are
unknown and it is unclear whether self-association is required for TRIM22 function or
antiviral activity

30

. For these reasons, it will be interesting to examine if V96, Q105,

and/or I106 are involved in TRIM22 self-association and if self-association influences
TRIM22 function and/or antiviral activity.

5.2.2

Balancing selection

In contrast to positive selection, which involves transient genetic diversity and drives
advantageous alleles to fixation in a population, balancing selection actively maintains
polymorphism (multiple alleles) at selected loci in a population

31,32

. While it is rare in

other host genes, balancing selection has been identified in a number of immune genes
and may be beneficial in specific pathogenic environments

33

. For example, one well-

known nsSNP in the β-globin gene induces sickle-cell disease in homozygotes (sickle-
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cell mutation), but affords protection from malaria in heterozygotes. Even though this
mutation is deleterious in homozygous individuals, it is inordinately prevalent in highmalaria environments because it lowers mortality in the overall population

34

. In other

words, balancing selection selects for heterozygosity in the population because in this
environment it leads to fewer deaths. Heterozygosity may also be beneficial when, for
example, different alleles are effective against different pathogens. In addition, having
multiple alleles at specific loci in immune genes may make it harder for pathogens to
evolve suitable escape mutants and evade immune surveillance 6.
Several host restriction factors, including huTRIM5α and OAS1, have been shown to
undergo balancing selection in primates

35–37

. In Chapters 2 and 4, we found that there

was an excess of intermediate frequency TRIM22 rs1063303:G>C alleles in the AFN,
AMR, and EUR cohorts from the 1000 Genomes project, but not in the ASN cohort or
two different Inuit populations (Tables 2.4, 4.3). An excess of intermediate frequency
alleles is typically indicative of balancing selection. Interestingly, the frequency of the
TRIM22 nsSNP rs1063303:G>C varied markedly among different ethnic groups. The
Canadian and Greenlandic Inuit populations had the highest rs1063303:C frequencies,
whereas the ASN population had the lowest (Fig 2.3, Table 4.2). While the reasons for
these differences in frequency are currently unknown, it is possible that they are due to
differential prevalence of specific diseases in distinct geographic locations. Indeed, we
have shown in this work that the TRIM22 nsSNP rs1063303:G>C influences both the
antiviral activity of TRIM22 and its novel effects on serum TG and HDL levels in the
Canadian Inuit. Given the excess of intermediate frequency TRIM22 rs1063303:G>C
alleles in AFR, AMR, and EUR cohorts, and its disease-related functional effects, it is
possible that TRIM22 rs1063303:C confers some selective advantage in heterozygotes
and that the nsSNP is being maintained by balancing selection in these populations. In
contrast, the lack of balancing selection at the TRIM22 rs1063303:G>C site in the two
Inuit populations (Canadian and Greenlandic Inuit), may be due to lack of exposure to
certain pathogens. These populations have lived in isolation for many years with little
exposure to modern infectious diseases 38.
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In the future, it will be important to establish which pathogens (if any) are targeting the
TRIM22 rs1063303:G>C site in AFN, AMR, and EUR populations and to investigate
why these pathogenic pressures are not present in ASN and Inuit populations. This will
likely provide insight into the antiviral mechanism of TRIM22 and help elucidate why
the TRIM22 rs1063303:G>C site has been targeted by multiple evolutionary forces. Of
interest, a recent genome-wide scan of two ethnic populations (African Americans and
European Americans) identified TRIM22 as one of 60 ‘extreme’ genes evolving under
balancing selection in humans

39

. While we have identified one site in TRIM22 that is

likely targeted by balancing selection, additional sites may also be targeted. As such, it
would be interesting to perform a more thorough analysis of the entire TRIM22 gene
(coding and non-coding regions) to search for additional sites that may be undergoing
balancing selection.

5.3 TRIM22 contains 14 high-risk deleterious nsSNPs and
numerous putative PTM sites
5.3.1

High-risk deleterious nsSNPs

Studies have shown that genes that evolve under positive selection during interspecies
evolution also tend to be highly polymorphic in humans

40

. In Chapter 3, we found that

the human TRIM22 gene is highly polymorphic and contains multiple nsSNPs that are
likely deleterious to TRIM22 structure and/or function (Table 3.1). Using 6 different in
silico prediction programs, we analyzed all of the missense mutation-inducing nsSNPs
(56) in TRIM22 and identified 14 high-risk deleterious nsSNPs (L68R, H73R, E135K,
I234K, S244L, G346S, K364N, P403T, L432W, R442C, F456I, T460I, C494F) (Table
3.3). These nsSNPs were predicted to be deleterious by ≥ 4 of the prediction programs
and were located at highly conserved amino acid sites (Fig 3.1). Conserved sites are often
involved in important biological processes and thus, nsSNPs located at these sites are
often deleterious 1,41.
Of interest, our ConSurf analysis, which combines evolutionary conservation data with
solvent accessibility predictions, identified codon T460 as a critical structural site and
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codons L68, K364, and P403 as critical functional sites in the TRIM22 protein (Table
4.3). These sites coincide in location with 4 high-risk deleterious nsSNPs (i.e. L68R,
K364N, P403T, and T460I). While it is currently unknown why these sites are critical,
one possibility is that they are involved in key protein-protein interactions. Sites K364
and P403, for example, are located in the B30.2 domain just upstream of the v2 and v3
loops, respectively. These loops are essential for the antiviral activity of the rhTRIM5α
protein and help form an extensive HIV-1 capsid binding interface that is required for
HIV-1 restriction

3,20

. Since TRIM22 also interacts with the HIV-1 Gag and/or capsid

protein, its v2 and v3 loops may help form a similar interface in the B30.2 domain for
binding to capsid or other host and/or viral proteins

18

. K364N and P403T may disrupt

this interface and impair these interactions. Indeed, our molecular modeling results in
Chapter 3 showed that K364N and P403T significantly altered the putative structure of
the v1-v4 loops (Fig 3.2). Molecular modeling of the 7 additional high-risk deleterious
nsSNPs located in the B30.2 domain also altered the putative structure of these loops,
particularly within the v2 and v3 loops. Importantly, these 9 nsSNPs may decrease the
flexibility of v2 and v3 (and/or v1 and v4 for some nsSNPs) by introducing more rigid
secondary structures, such as alpha helices and/or beta strands, into these regions (Fig
3.2). In rhTRIM5α, v1-v4 flexibility is thought to facilitate the restriction of divergent
retroviruses and increase resistance to mutations in the HIV-1 capsid protein 3. nsSNPs
that interfere with v1-v4 flexibility in TRIM22 may be equally important to restriction
and may impair the antiviral activity and/or breath of TRIM22. Further studies, such as
the resolution of TRIM22’s tertiary structure, will be critical for addressing these and
other possibilities.
In Chapter 3, we analyzed and prioritized all 56 missense mutation-inducing nsSNPs in
TRIM22 and identified 14 high-risk deleterious nsSNPs that likely disrupt its structure
and/or function. Future in-depth studies on these 14 nsSNPs are required to establish if
they alter, for example, TRIM22 stability, localization, and/or antiviral activity. It will
also be important to investigate the clinical implications (if any) of these nsSNPs. This
will be essential for further prioritizing the 14 nsSNPs and elucidating their functional
consequences.
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5.3.2

Putative PTM sites

Although TRIM22 is involved in a variety of important biological processes, very few
studies have investigated the molecular determinants of its function. In Chapter 3, we
performed an extensive in silico analysis of TRIM22 and identified numerous putative
PTM sites (sites predicted to undergo ubiquitylation, sumoylation, or phosphorylation,
and several SIMs) that likely influence its function. PTMs are involved in a number of
biological processes, including many immune pathways, and are often essential for the
regulation of protein structure and function 42–45.
Previous studies have shown that TRIM22 can mediate both its own polyubiquitylation
and monoubiquitylation. These modifications are dependent on its RING-mediated E3
ligase activity; however, the specific sites within TRIM22 that undergo ubiquitylation
have not been identified

21,46

. One study demonstrated that a TRIM22 mutant lacking

residues 201-498 (comprises approximately one-third of the CC domain and the entire
B30.2 domain), but not a TRIM22 mutant lacking residues 1-200 (entire RING domain
and BB2 domain plus approximately two-thirds of the CC domain), was susceptible to
self-mediated TRIM22 polyubiquitylation

21

. Our results in Chapter 3, which revealed

that K93, K160, and K173 were the only TRIM22 lysine residues predicted to undergo
ubiquitylation by both UbPred and BDM-PUB, are consistent with this finding (Table
3.5). In addition, K173 was predicted to be an important functional residue by ConSurf
(Fig 3.1). Further studies on K93, K160, and K173 are required to establish how they
may influence TRIM22 turnover and/or function.
Our work also identified a number of putative sumoylation sites in TRIM22, as well as
several highly conserved SIM domains. K153 was the only lysine residue predicted to
undergo sumoylation by both SUMOplot and SUMOsp 2.0 (Table 3.6). While TRIM22
has been shown to function as a E3 sumo ligase for Mdm2, it has never been shown to
undergo sumoylation itself

47

. Notably, sumoylation is often associated with nuclear or

sub-nuclear targeting. For example, TRIM19/PML contains 8 sumoylation sites plus 1
SIM domain that are required for proper formation, maintenance, and function of sub-
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nuclear structures called PML nuclear bodies (NB). PML NBs recruit diverse proteins
involved in many cellular processes, including transcriptional regulation, DNA damage
repair, cell cycle control, apoptosis, and the host antiviral response. Thus, it is perhaps
not surprising that these sumoylation and SIM sites are also required for TRIM19/PML
stability and protein-protein interactions

48,49

. Of interest, the number and size of PML

NBs increases in response to IFN treatment and PML NBs contribute to innate defense
against a number of viruses. It follows that following entry into host cells many viruses
induce the modification and/or disassembly of PML NBs 50–52.
Although TRIM22 does not co-localize with TRIM19/PML in PML NBs, it does form
NBs and partially co-localizes with p80-coilin in Cajal bodies (CB)

53,54

. Interestingly,

several recent studies have implicated sumoylation in CB biogenesis and function. For
example, survival motor neuron protein (SMN), one of the major components found in
CBs, is targeted by sumoylation and contains a SIM-like domain that is integral to CB
assembly and SMN’s interaction with p80-coilin

55

. In addition, the sumo isopeptidase

UPL1 co-localizes with p80-coilin in CBs and its depletion leads to striking p80-coilin
mislocalization and defects in cell proliferation

56

. Given these studies, and the critical

role of sumoylation in PML NB assembly and function, it would be interesting to test
whether K153 and the SIMs in TRIM22 are necessary for its co-localization with p80coilin in CBs. Indeed, previous studies have shown that the B30.2 domain of TRIM22,
which contains 3 of the putative SIMs we identified in Chapter 3, is required for proper
TRIM22 localization in NBs

53

. Finally, because K153 is located in the CC domain of

TRIM22, which is typically required for self-association, it is possible that SIMs in one
TRIM22 monomer interact with sumoylated K153 in another TRIM22 monomer

57,58

.

This may help facilitate TRIM22 trimerization and/or its localization in CBs. It will be
interesting to investigate these possibilities in future studies.
Interestingly, 3 of the SIMs we identified in TRIM22 are also present in TRIM5α (Fig
3.3). Previous studies have demonstrated that 2 of these 3 SIMs (i.e. ILGV and VIGL)
are required TRIM5α-mediated antiviral activity. Mutating these SIMs in huTRIM5α
abolished its ability to interact with the sumoylated N-MLV capsid protein. As a result,
SIM mutation prevented N-MLV restriction 4. Similarly, SIM mutation in rhTRIM5α
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abrogated its ability to inhibit HIV-1 replication 5. Although the role of these SIMs in
TRIM22 is currently unknown, it is tempting to speculate that they are involved in its
antiviral activities. Further studies are necessary to determine whether these 2 SIMs (or
any of the other SIMs in TRIM22) are important for its antiviral activity against HIV-1
and/or other viruses.
Our in silico analyses in Chapter 3 also identified multiple phosphorylation sites in the
TRIM22 protein (Table 3.6). A total of 21 sites were predicted to undergo serine (16),
threonine (3), or tyrosine (2) phosphorylation by both GPS 2.1 and NetPhos 2.0. Many
sites were also predicted to be important structural or functional residues by ConSurf
(Table 3.6, Fig 3.1). TRIM22 phosphorylation has never been demonstrated; however,
several other TRIM proteins have been shown to undergo phosphorylation, including
TRIM19/PML and TRIM21

59–63

. A few particularly interesting sites exist in TRIM22,

such as S244, S259, S271, and T460. S259 and S271, both of which were identified as
key functional sites by ConSurf, are located within the NLS in TRIM22’s SP2 domain
(Table 3.6, Fig 3.1). Importantly, phosphorylation sites within or adjacent to NLSs are
often found in key regulatory proteins (e.g. transcription factors) and typically regulate
nuclear import, which directly affects gene expression

64,65

. Sites S244 and T460 both

coincide with the location of high-risk deleterious nsSNPs (S244L and T460I) (Tables
3.2, 3.3). In the future, it will be important to determine whether S259 and/or S271 are
required for the nuclear localization of TRIM22 and if the nsSNPs S244L and/or T460I
disrupt functionally relevant phosphorylation sites.
Collectively, this work comprises the first systematic in silico analysis of the TRIM22
gene and will be a valuable resource for many future studies. Although we identified a
number of putative PTM sites in TRIM22, these PTMs must be verified experimentally
and it remains unknown how specific PTMs influence TRIM22 function. Future work
using a panel of PTM mutants (clones of wild-type TRIM22 mutated at specific PTM
sites) could be used to confirm our in silico results and to establish how (or if) verified
PTMs affect TRIM22 stability, localization, and/or antiviral activity. Moreover, it may
also be interesting to investigate if certain PTM sites in TRIM22 are required for the
recruitment of specific E3 ligase target proteins. For example, sumo-targeted ubiquitin
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ligases (STUb), a novel class of E3 ubiquitin ligases, only recognize sumoylated target
proteins. STUbs that have been identified thus far are characterized by the presence of
multiple SIMs (facilitate the recruitment of the sumoylated target protein) and a RING
domain (mediates ubiquitylation of the sumoylated target protein) 66.

5.4 The TRIM22 nsSNP rs1063303:G>C influences diverse
TRIM22-mediated biological functions
5.4.1

The TRIM22 nsSNP rs1063303:G>C increases TRIM22
expression levels

Several interesting functional consequences of the TRIM22 nsSNP rs1063303:C were
identified in this work. In Chapter 2, we found that exogenous expression of TRIM22
rs1063303:C significantly increased TRIM22 mRNA and protein levels in human cells
(Fig 2.4a,b). nsSNPs often alter protein function, expression, conformation, or stability
and there are multiple examples of this in the literature 67–71. Fewer studies have reported
nsSNP-induced changes in mRNA expression; however, there are a number of notable
examples

72–75

. In these studies, the nsSNPs altered the secondary structure of the RNA

transcript, which led to changes in mRNA expression. Changes in RNA structure have
been shown to alter mRNA stability, splicing and/or the rate of translation

76,77

. While

TRIM22 rs1063303:C may alter the secondary structure of the RNA transcript, further
studies are needed to determine whether this is the case. Since TRIM22 has previously
been shown to inhibit gene expression from the HIV-1 and HBV promoters, it is also
possible that TRIM22 targets the promoter controlling its own expression

78–80

. In this

scenario, the resultant TRIM22 rs1063303:C protein may exhibit reduced or enhanced
activity, thereby increasing its own mRNA expression. It will be important to address
these possibilities in future research.
Given its effect on TRIM22 mRNA expression, it is likely that TRIM22 rs1063303:C
increases TRIM22 protein expression by increasing TRIM22 mRNA levels. However,
other possibilities for increased TRIM22 protein levels also exist. For example, since
TRIM22 undergoes self-ubiquitylation and proteasomal degradation, it is possible that
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TRIM22 rs1063303:C impairs TRIM22’s ability to regulate its own turnover

46

. Other

possible explanations include changes in TRIM22 protein stability and/or structure. Of
interest, one recent study demonstrated that α-helices in the SP2 domain of rhTRIM5α
govern cytoplasmic body formation and HIV-1 restriction. Specific residues in the SP2
domain, including residues 240-242 (RLQ), were critical for the formation of these αhelices

81

. Notably, the study showed that rhTRIM5α forms antiparallel dimers that are

stabilized by interactions between three α-helices (H1, H2, H3) found in the CC/SP2
domains of each monomer. H1, which contains the CC domain and the N-terminus of
SP2, makes contacts with H2 and together they form a hairpin structure that allows the
monomer to double back along the dimer. Residues surrounding the hairpin structure,
including residues 240-242, interact with each other and with other residues in the Nterminus of H1' in the second monomer

81

. Because TRIM22 and TRIM5α are closely-

related, it is tempting to speculate that TRIM22 also forms antiparallel dimers that are
linked via the CC and SP2 domains. Since TRIM22 rs1063303:C induces a ‘R’ to ‘T’
amino acid change at site 242 in the TRIM22 protein, it is also possible that this nsSNP
disrupts critical intra- and/or intermolecular interactions that are needed for antiparallel
dimer formation. While the tertiary structure of TRIM22 has not been resolved, other
TRIM proteins (e.g. TRIM25) have been shown to form antiparallel dimers and studies
have noted that this structure may be a common feature among all TRIM proteins 82.

5.3.2

The TRIM22 nsSNP rs1063303:G>C decreases TRIM22mediated antiviral activity against HIV-1

In addition to its effects on mRNA and protein expression, TRIM22 rs1063303:C also
altered the sub-cellular localization of TRIM22 and abrogated its anti-HIV-1 activity in
human cells. Other host restriction factors, such as APOBEC3G and TRIM5α, contain
nsSNPs that have been shown to decrease their ability to inhibit HIV-1. For example,
several nsSNPs in TRIM5α, including H43Y, R136Q, and G249D are associated with
marked changes in HIV-1 acquisition and disease progression in vivo

83,84

. In addition,

+

nsSNP H186R in APOBEC3G is strongly associated with reduced CD4 T-cell counts
and accelerated disease progression in African American individuals. Interestingly, this
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effect is not present in European Caucasian individuals

85–87

. In Chapter 2, we showed

that a TRIM22 clone containing the ancestral allele rs1063303:G (wild-type TRIM22)
potently inhibited HIV-1 replication, whereas a TRIM22 clone containing the derived
allele rs1063303:C (nsSNP TRIM22) failed to restrict HIV-1 replication (Fig 2.4d). In
contrast, a previous report by Ghezzi and colleagues

88

showed that a TRIM22 clone

containing the derived allele rs1063303:C inhibited HIV-1 LTR-driven expression of a
luciferase reporter gene. This discrepancy is likely due to differences between the two
systems where we used full-length HIV-1 and they used a reporter construct controlled
by the HIV-1 LTR. Of interest, these differences imply that other HIV-1 proteins (e.g.
antagonists) may influence TRIM22’s antiviral activity. Ghezzi and colleagues

88

also

found that TRIM22 rs1063303:C alone was not associated with disease progression in
HIV-1 infected individuals; however, a TRIM22 haplotype including nsSNP alleles of
rs1063303 and rs7935564 was found more often in advanced progressors compared to
long-term non-progressors.
It is interesting to note that two previous studies have shown that TRIM22 expression
levels influence HIV-1 infection in vivo. One study examined the Centre for the AIDS
Programme of Research in South Africa (CAPRISA) study cohort and found that the
expression of TRIM22 mRNA was positively correlated with CD4+ T-cell counts and
negatively correlated with viral load

89

. In contrast, the other study examined the Swiss

HIV study cohort and found that TRIM22 mRNA expression was positively correlated
with HIV-1 RNA levels at the viral set point

90

. In Chapters 2 and 4, we found striking

differences in TRIM22 rs1063303:G>C allele frequency among different ethnic groups
(Fig 2.3b, Table 4.2). Along these lines, it is worth noting that the CAPRISA cohort is
comprised entirely of African females, while the Swiss cohort is comprised entirely of
Caucasian individuals. It is possible that the high prevalence of TRIM22 rs1063303:C
found in Caucasian individuals is at least partially responsible for the increased HIV-1
RNA levels in the Swiss cohort. More studies that include populations from different
geographic regions are required to establish how TRIM22 rs1063303:C impacts HIV-1
infection and if other nsSNPs are involved.
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5.3.3

The TRIM22 nsSNP rs1063303:G>C is associated with low
serum TG and high serum HDL levels in the Canadian Inuit

In Chapter 4, we demonstrated that the TRIM22 rs1063303:C allele is associated with
significantly lower serum TG levels and significantly higher serum HDL levels in the
Canadian Inuit. Notably, these associations were not found in the Greenlandic Inuit or
European Caucasian populations (Table 4.4). Our results showed that homozygotes for
the TRIM22 rs1063303:C allele (Canadian Inuit population) had lower levels of serum
TG and higher levels of serum HDL than heterozygotes, while the TRIM22 rs1063303:G
allele homozygotes had higher serum TG levels and lower serum HDL levels (Table 4.5).
It remains unclear how the TRIM22 nsSNP rs1063303:C alters serum lipoprotein levels;
however, one possible explanation is that it alters them indirectly by regulating innate
immune signaling pathways. Recent studies have identified many TRIM proteins that
modulate key innate immune pathways, including NF-κB signaling, the IFN response,
and cytokine production following PRR activation

91–93

. Although TRIM22 has never

been explicitly shown to regulate these pathways, there is some evidence that it affects
NF-κB signaling. For example, one study showed that exogenous TRIM22 expression
inhibited the TRAF6-stimulated NF-κB pathway by degrading TAB2

94

. However, a

serparte study showed that TRIM22 activated NF-κB signaling 70. Because activation of
the NF-κB signaling pathway leads to proinflammatory cytokine production, and since
proinflammatory cytokines induce the APR, it is possible that TRIM22 influences TG
and HDL levels by modulating NF-κB signaling. Future studies are needed to address
these possibilities and others.

5.5 Concluding remarks
In this body of work, we have identified a number of pertinent sites in the TRIM22
protein the likely contribute to its overall biological and/or antiviral functions. Further,
we have shown that specific amino acid sites in TRIM22 have been subjected to strong
positive and/or balancing selection. One particular site, which coincides in location with
the TRIM22 nsSNP rs1063303:G>C, has evolved under positive selection during the
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evolution of mammals and has a disparate evolutionary footprint among distinct ethnic
populations. Moreover, TRIM22 nsSNP rs1063303:G>C increased TRIM22 expression
levels, altered its subcellular localization, decreased its antiviral activity against HIV, and
was associated with significantly lower serum TG levels and significantly higher serum
HDL levels in the Canadian Inuit population. Collectively, this research has paved the
way for multiple follow-up studies to further characterize highly relevant sites in the
TRIM22 protein and help identify novel factors that may regulate TRIM22 expression,
subcellular localization, and antiviral activity.
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Appendix A

A.1 Overview of serum lipoproteins
A.1.1

Introduction to serum lipoproteins

Serum lipoproteins are complex aggregates of lipids and proteins that are formed in the
liver and intestine, secreted into the circulation, and then taken up by peripheral tissues
for energy and storage 1. The formation of lipoproteins is necessary because it enables
lipid transport in the aqueous plasma environment. There are 4 major groups of serum
lipoproteins: 1) chylomicrons (CM), 2) very-low-density lipoproteins (VLDL), 3) lowdensity lipoproteins (LDL), and 4) high-density lipoproteins (HDL). These groups each
contain different ratios of specific lipid constituents, namely triacylglycerols (TG), free
cholesterol, cholesterol esters, and phospholipids (Table A.1). The groups also contain
several lipid-binding proteins called apolipoproteins that surround the lipids and create
soluble lipoprotein particles (Fig A.1). All lipoproteins are involved in lipid transport;
however, CM and VLDL function primarily to transport TG, whereas LDL and HDL
function primarily to transport cholesterol 2.

A.1.2

Triacylglycerol transport

Serum TG levels are often measured clinically, in which case they are defined as all of
the TGs present in one deciliter of plasma (mg/dL). This definition includes both CMs
and VLDLs; however, because CMs are very short-lived (half-life of ~1 hour) most of
the TGs transported in plasma are associated with VLDLs. CMs are synthesized in the
small intestine after meals and function primarily to transport dietary (exogenous) TGs
from the intestine to other tissues in the periphery 3. VLDLs, which are synthesized by
the liver, transport endogenous TGs to peripheral tissues following their excretion into
the bloodstream. VLDLs are carried into tissue capillaries via the bloodstream, where
they encounter an enzyme called lipoprotein lipase (LpL). LpL hydrolyzes some of the
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Table A.1
Table A.1: Physical properties and lipid composition of serum lipoproteins

Density (g/ml)
Total lipids (wt. %) *
Triacylglycerols
Cholesterol esters
Cholesterol
Phospholipids

CM
< 0.94
99
85
3
2
8

VLDL
0.94-1.006
91
55
18
7
20

* The remaining material is mainly composed of apolipoproteins

LDL
1.006-1.063
80
10
50
11
29

HDL
1.063-1.210
44
6
40
7
46
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Figure A.1: General structure of serum lipoprotein.
Schematic showing the general structure of serum lipoproteins (CM, VLDL, LDL, and
HDL). Lipoproteins are spherical in shape with a hydrophobic core comprised of both
triacylglycerols (TG) and cholesterol esters. This core is surrounded by a monolayer of
phospholipids, free cholesterol, and apolipoproteins.
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Figure A.1

Figure A.1 General structure of serum lipoprotein.
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TGs from VLDL into their core components (TGs consist of 1 glycerol molecule and 3
fatty acid molecules) so that they can be taken up by adjacent cells. For example, they
may be taken up by muscle cells for energy or fat cells for storage. VLDLs continue to
lose TGs as they travel through the blood and decrease in size, eventually turning into
intermediate density lipoproteins (IDL). Some IDLs are subjected to further lipolysis to
become LDL particles; however, most are reabsorbed by the liver (Fig A.2) 4.

A.1.3

Cholesterol transport

As mentioned above, LDLs are formed from VLDLs as they lose TGs to surrounding
tissues. As such, LDLs contain very few TGs compared to VLDLs, but have the same
protein shell and amount of cholesterol (Table A.1). Cells internalize LDL particles via
receptor-mediated endocytosis and hydrolyze LDL-bound cholesterol esters to release
free cholesterol. Cholesterol can be used for a variety of cellular functions, such as in
cellular membranes or for the synthesis of steroid hormones. Although LDL is integral
for cholesterol transport and cholesterol is necessary for proper cellular functions, too
much LDL can be harmful. Multiple studies have shown that higher levels of LDL are
associated with an increased risk of cardiovascular disease 5,6.
In contrast to LDLs, nascent HDL particles are formed in the liver and small intestine.
HDLs interact with multiple apolipoproteins (Apo) to facilitate cholesterol efflux from
cells; however, ApoA1 is particularly important in the initial stages of HDL assembly.
ApoA1 forms the scaffold for HDL assembly and is also required for activation of the
lecithin:cholesterol acyltransferase (LCAT) enzyme. LCAT, which is essential for the
formation of cholesterol esters, allows HDL to extract free cholesterol from LDLs and
IDLs. Cholesterol is also removed by HDL from cell surface membranes via a specific
transporter molecule (ABCG1) and delivered back to the liver for excretion (Fig A.2).
This process, whereby HDL extracts excess cellular cholesterol and transports it to the
liver, is called reverse cholesterol transport 7. A large number of epidemiological and
clinical studies have demonstrated that low HDL levels are a major risk factor for the
development of cardiovascular disease 8.
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Figure A.2: Serum lipoprotein synthesis and transport.
CMs are synthesized in the small intestine and enter the bloodstream to deliver dietary
(exogenous) TGs to various peripheral tissues. VLDLs are synthesized in the liver and
deliver endogenous TGs to the periphery. LpL hydrolyzes TGs from both VLDLs and
CMs so they can be taken up by cells. IDLs are formed from VLDLs as they lose TGs.
IDLs continue to lose TGs to peripheral tissues and are eventually either reabsorbed by
the liver or turned into LDL particles. LDLs transport cholesterol to cells in peripheral
tissues. In contrast, HDL, which is synthesized in the liver, removes excess cholesterol
from cells in the periphery. This excess cholesterol is transported back to the liver to be
excreted in a process called reverse cholesterol transport. The path for CM, VLDL, and
IDL transport is outlined in red, LDL in blue, and HDL in green.
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Figure A.2

Figure A.2 Serum lipoprotein synthesis and transport.
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A.2 Serum lipoproteins during the APR
A.2.1

Overview of the APR

The acute phase response (APR) is an early, complex host reaction that is generated by
infection and inflammation. The APR in animals leads to significant changes in serum
lipoprotein metabolism. For example, in primates, serum TG levels increase and serum
HDL levels decrease during the APR 9. The increase in serum TGs is largely due to a
concomitant increase in serum VLDL levels. Multiple proinflammatory cytokines (e.g.
TNF, IL-1, IL-2, IL-6, and IFN) induce this increase in serum VLDL levels via one or
more of the following metabolic changes: 1) increase in hepatic fatty acid synthesis, 2)
decrease in hepatic fatty acid oxidation, 3) induction of adipose tissue lipolysis, and 4)
decrease in hepatic VLDL clearance. Changes 1-3 increase the overall production and
secretion of VLDL into the circulation by increasing the amount of fatty acid substrate
available for TG re-esterification. Change 4, which often only occurs at higher doses of
LPS, decreases TG catabolism by reducing the activity of the LpL enzyme.
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